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Abstract
In 2010 there were 60.5 million people with glaucoma worldwide and this number
is expected to increase to 79.6 million by 2020. In most glaucoma patients medical
therapy consists of topical eyedrops. However, administration and compliance are
often problematic. Surgical and laser treatment for glaucoma is traumatic for the
patients, involving high costs and might require repetition of the procedure.
Therefore the aim of the present work was the development of drug-eluting
biodegradable implants designed to provide a localized and long-term (6 months to
2 years) sustained release of the drug that can be used in the treatment of glaucoma.
The implant should degrade within the site of implantation, eliminating the need
for further surgery. The implant should be introduced in the ophthalmologist office,
under local anaesthesia, with high implications in patient recovery and costs. By
delivering controlled amounts of drug the implant would be pharmacologically
efficient and increase patient compliance.
Several polymer processing and drug loading techniques were used in order to
prepare controlled drug delivery systems (CDDS) for intraocular application. The
chosen materials were poly(ε-caprolactone), PCL, because of its slow degradation,
which makes it useful for long term delivery and poly(oxyethylene-b-oxypropylene-
b-oxyethylene), Lu, because of its release modulation capacity. Moreover, they
are both commercially available, inexpensive and well characterised polymers.
Three drugs were incorporated: timolol maleate, acetazolamide and dorzolamide
hydrochloride. They are all agents that can decrease intraocular pressure (IOP) in
open-angle glaucoma. Two types of devices were prepared: monolithic (sponges,
fibers, disks) and hybrid (disks), using supercritical solvent impregnation (SSI),
electrospinning, melt compression and solvent casting.
PCL blends were successfully impregnated with timolol maleate using a SSI
technique. SSI efficiency results suggested that the best impregnating conditions
were obtained when a cosolvent was used and when specific drug-polymer interac-
tions occurred as a consequence of different chemical structures due to polymer
blending. Pressure can be either a favourable factor, when there was enough drug
affinity for the polymers, or an unfavourable factor, when weaker bonding was
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involved. Drug loading, heterogeneous/homogeneous dispersion of drug inside the
matrix, hydrophilicity and crystallinity all influenced the drug release. The in vitro
release results suggested that a sustained drug release rate can be obtained by
changing the SSI operational conditions and by modulating the composition of
blends, as a mean to control crystallinity, hydrophilicity and drug affinity for the
polymer matrix.
Bicomponent fibers of PCL and Lu were obtained by electrospinning. Acetazo-
lamide and timolol maleate were loaded in the fibers in different concentrations
(below and above the drug solubility limit in polymer) in order to determine the
effect of drug solubility in polymer, drug state, drug loading and fiber composition
on fiber morphology, drug distribution and drug release kinetics. High loadings
fibers (with drug in crystalline form) showed higher burst and faster release than
low drug content fibers, indicating that the release was more sustained when the
drug was encapsulated inside the fibers in an amorphous form. Moreover, timolol
maleate was released faster than acetazolamide, indicating that drug solubility in
polymer influences the partition of drug between polymer and elution medium,
while fiber composition also controlled drug release. At low loadings total release
was not achieved, suggesting that drug remained trapped in the fibers. The mod-
elling of release data implied a three stage release mechanism: a dissolution stage, a
desorption and subsequent diffusion through water filled pores, followed by polymer
degradation control.
Dorzolamide loaded disks (hybrid device) were prepared by solvent-casting of
PCL/Lu and subsequent coating with PCL solution. By blending, crystallinity,
water uptake and mass loss were modified relative to the pure polymers. Burst
was diminished by coating the disks with a PCL shell. All samples presented
burst release except PCL-coated samples that showed controlled release during 18
days. For PCL-coated samples, barrier-control of diffusion coupled with partition
control from the core slowed down the release, while for 50/50 Lu/PCL-coated
samples, the enhancement in porosity of the core diminished partition-control of
drug release. Non-linear regression analysis suggested that a degradation model
fully described the release curve considering a triphasic release mechanism: the
instantaneous diffusion (burst), diffusion and polymer degradation stages. MTT
test indicated that the materials were not cytotoxic for corneal endothelial cells.
A good in vitro–in vivo correlation was obtained, with similar amounts of drug
released in vitro and in vivo. The decrease in IOP was similar to that obtained by
dorzolamide eyedrop instillation.
Implantable monolithic disks for glaucoma treatment were prepared by blending
PCL, Lu and dorzolamide. Their in vivo performance was assessed by their capacity
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to decrease IOP in normotensive and hypertensive eyes. Drug mapping showed that
release was complete from blend disks and the low molecular weight (MW) PCL
after 1 month in vivo. The high MW PCL showed non-cumulative release rates
above the therapeutic level during 3 months in vitro. In vivo, the fibrous capsule
formation around the implant controlled the drug release, working as a barrier
membrane. Histologic analysis showed normal foreign body reaction response to
the implants. In hypertensive eyes, the most sustained decrease was shown by the
high MW PCL. The blending offers the possibility to manipulate the release rate
and the amount of released drug in order to prepare devices tailored to the patients
needs.
The long term degradation of all the prepared constructs (films, fibers, sponges
and disks) was studied. The influence on degradation rate of several factors
(construct type, crystallinity, MW, drug presence, blending) was assessed through
water uptake, mass loss, crystallinity and MW evaluation. The degradation rate
was higher for blends than for PCL and it was similar between different types
of blends. The low MW disks had a degradation rate that was lower by one
order of magnitude than high MW constructs. Porosity was shown to be a very
important factor because at initial stage (or initial porosity), it will enhance water
uptake and degradation, while at a later stage (or developed porosity), it will
decrease degradation rate because of diminished autocatalytic effects. High initial
porosity produced an acceleration of degradation for sponges, fibers and films when
compared to disks, while developed porosity reduced degradation for drug-loaded
disks when compared to disks without drug. Modelling of the experimental data
suggested that the contribution of surface effects was as significant as autocatalytic
effects in overall bulk degradation.
This work has revealed some insights into possible polymer processing and
drug loading techniques for the preparation of CDDS for intraocular delivery. It
also presented some results regarding the preliminary pre-clinical evaluation of
PCL-based implants. In vivo, the drug-eluting implants were able to reduce IOP in
an animal model of glaucoma. Nevertheless, another extremely important issue has
to be addressed: patient compliance. Patience compliance is of extreme importance
especially in the therapy of chronic diseases because patients have to keep up
constantly with their pharmacological regimen. The superiority of CDDS relative
to conventional therapy has to be proven in long term compliance studies because
this is one of the main reasons of developing CDDS therapy in the first place.
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Resumo
Em 2010 existiam cerca de 60,5 milho˜es de pessoas com glaucoma no mundo,
devendo este nu´mero aumentar para 79,6 milho˜es em 2020. Na maioria dos
pacientes com glaucoma o tratamento me´dico consiste na aplicac¸a˜o de col´ırios
to´picos. No entanto a administrac¸a˜o e a adesa˜o do paciente ao tratamento sa˜o
muitas vezes problema´ticas. No caso do glaucoma a cirurgia e o tratamento a laser
sa˜o frequentemente trauma´ticos para os pacientes. Ale´m disso, estes tratamentos
envolvem custos elevados e podem exigir a repetic¸a˜o do procedimento.
O objectivo do presente trabalho foi desenvolver implantes biodegrada´veis desti-
nados a fornecer uma libertac¸a˜o controlada e localizada de fa´rmaco a longo prazo (6
meses a 2 anos) e que possam ser usados no tratamento do glaucoma. O implante
deve-se degradar dentro do local de implantac¸a˜o, eliminando a necessidade de uma
nova cirurgia. O implante pode ser colocado no consulto´rio do oftalmologista, sob
anestesia local, o que favorece a recuperac¸a˜o do paciente. Ao libertar quantidades
controladas de fa´rmacos o implante e´ farmacologicamente eficiente, aumentando
assim a adesa˜o do paciente a` terapia.
Este trabalho descreve va´rias te´cnicas de processamento de pol´ımeros e de imo-
bilizac¸a˜o de fa´rmacos que podem ser utilizados para a preparac¸a˜o de sistemas de
libertac¸a˜o controlada de fa´rmacos (SLCF) para aplicac¸a˜o intraocular. Os materiais
escolhidos foram a poli(ε-caprolactona), PCL devido a` sua lenta degradac¸a˜o, o que
a torna u´til para a libertac¸a˜o de longa durac¸a˜o e o poli(oxietileno-b-oxipropileno-
b-oxietileno), Lu, devido a` sua capacidade de modulac¸a˜o da libertac¸a˜o. Ale´m
disso, ambos os pol´ımeros esta˜o dispon´ıveis comercialmente, sa˜o baratos e esta˜o
bem caracterizados. Treˆs fa´rmacos foram incorporados: maleato de timolol, ac-
etazolamida e cloridrato de dorzolamida. Sa˜o todos agentes que podem diminuir
a pressa˜o intra-ocular (PIO) em pacientes com glaucoma de aˆngulo aberto. Dois
tipos de dispositivos foram preparados: monol´ıtico (esponjas, fibras e discos) e
h´ıbrido (discos), usando te´cnicas de impregnac¸a˜o com solvente supercr´ıtico (ISS),
de “electrospinning”, de compressa˜o e de evaporac¸a˜o de solvente.
As misturas de PCL foram impregnadas com maleato de timolol usando uma
te´cnica ISS. Os resultados de eficieˆncia da impregnac¸a˜o indicaram que as melhores
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condic¸o˜es de impregnac¸a˜o foram obtidas quando um co-solvente foi usado e quando
ocorreu um aumento das interac¸o˜es pol´ımero-fa´rmaco devido a` mistura de pol´ımeros.
A pressa˜o pode ser um factor favora´vel, quando existe suficiente afinidade entre
o fa´rmaco e os pol´ımeros, ou um factor desfavora´vel quando as interac¸o˜es sa˜o
mais fracas. A percentagem de impregnac¸a˜o, a distribuic¸a˜o de fa´rmaco dentro de
matriz pol´ımerica, a cristalinidade e a hidrofilicidade influenciaram a libertac¸a˜o de
fa´rmaco. Os resultados de libertac¸a˜o in vitro sugerem que a libertac¸a˜o controlada
de fa´rmacos pode ser obtida atrave´s da variac¸a˜o das condic¸o˜es operacionais de SSI,
atrave´s da composic¸a˜o das misturas, como um meio para controlar a cristalinidade,
hidrofilicidade e afinidade do fa´rmaco para a matriz polime´rica.
Fibras bicomponentes de PCL e Lu foram obtidas por “electrospinning”. Ac-
etazolamida e maleato de timolol foram imobilizados nas fibras em diferentes
concentrac¸o˜es (abaixo e acima do limite de solubilidade do fa´rmaco no pol´ımero),
a fim de determinar o efeito da solubilidade do fa´rmaco no pol´ımero, o estado
de agregac¸a˜o do fa´rmaco, a oclusa˜o do fa´rmaco e a composic¸a˜o das fibras na
distribuic¸a˜o de fa´rmaco, na cine´tica de libertac¸a˜o e na morfologia das fibras. As
fibras contendo maior quantidade de fa´rmaco (com fa´rmaco na forma cristalina)
apresentaram maior “burst” e libertac¸a˜o mais ra´pida do que as fibras contendo
menor quantidade de fa´rmaco, indicando que a libertac¸a˜o foi mais constante quando
o fa´rmaco foi encapsulado dentro das fibras na forma amorfa. Ale´m disso, o maleato
de timolol foi libertado mais rapidamente do que a acetazolamida, indicando que a
solubilidade no pol´ımero influencia a partic¸a˜o do fa´rmaco entre o pol´ımero e o meio
de eluic¸a˜o, enquanto que a composic¸a˜o das fibras tambe´m controlou a libertac¸a˜o.
Em fibras contendo baixa quantidade de fa´rmacos, na˜o se obteve a libertac¸a˜o total,
sugerindo que o fa´rmaco permaneceu imobilizado nas fibras. A modelac¸a˜o dos
dados de libertac¸a˜o indica um mecanismo de libertac¸a˜o com treˆs fases: a fase de
dissoluc¸a˜o, uma de dessorc¸a˜o e difusa˜o, seguida de controle por degradac¸a˜o de
pol´ımeros.
Discos carregados com dorzolamida (dispositivo h´ıbrido) foram preparados por
“solvent-casting” de PCL/Lu e por revestimento posterior com uma soluc¸a˜o de PCL.
As misturas apresentaram propriedades diferentes (em termos de cristalinidade, de
absorc¸a˜o de a´gua e de perda de massa) em relac¸a˜o aos pol´ımeros puros. Todas as
amostras apresentaram libertac¸a˜o “burst”, excepto as amostras de PCL-revestidas,
as quais apresentaram libertac¸a˜o controlada durante 18 dias. Para as amostras de
revestidas com PCL, o controlo por difusa˜o na barreira e por partic¸a˜o desacelerou
a libertac¸a˜o, enquanto que para as amostras 50/50 PCL/Lu-revestido, o aumento
da porosidade do nu´cleo diminuiu o controlo de partic¸a˜o de liberac¸a˜o de fa´rmaco.
Um modelo de degradac¸a˜o da curva de libertac¸a˜o, sugeriu que ha´ que considerar
vii
um mecanismo de libertac¸a˜o trifa´sico: a difusa˜o instantaˆnea (“burst”), a difusa˜o
e a degradac¸a˜o de pol´ımero. O teste de MTT mostrou que os materiais na˜o sa˜o
citoto´xicos para ce´lulas endoteliais da co´rnea. Obteve-se uma boa correlac¸a˜o in
vitro–in vivo, observando-se quantidades similares de fa´rmaco libertado in vitro e
in vivo. A diminuic¸a˜o da PIO foi similar a` obtida por aplicac¸a˜o de um col´ırio de
dorzolamida.
Discos monol´ıticos implanta´veis foram preparados atrave´s da mistura de PCL,
Lu e dorzolamida. O desempenho in vivo foi avaliado atrave´s a capacidade de
diminuir a PIO em olhos normotensos e hipertensos. O mapeamento do fa´rmaco
mostrou que a libertac¸a˜o foi completa nas misturas e no pol´ımero de baixo peso
molecular (PM) PCL apo´s um meˆs in vivo. O pol´ımero de alto PM apresentou
taxas de libertac¸a˜o na˜o-cumulativa acima do n´ıvel terapeˆutico, durante treˆs meses
in vitro. Verificou-se a formac¸a˜o de uma ca´psula fibrosa em redor do implante que
controlou a libertac¸a˜o da fa´rmaco, funcionando como uma membrana de barreira.
A ana´lise histolo´gica sugeriu que havia uma resposta normal de reacc¸a˜o de corpo
estranho aos implantes. Nos olhos hipertensos, a queda mais sustentada de PIO
foi demonstrada pelo pol´ımero de alto PM. A mistura oferece a possibilidade de
manipular a taxa de libertac¸a˜o e a quantidade de fa´rmaco libertado a fim de
preparar dispositivos adaptados a`s necessidades dos pacientes.
Estudou-se tambe´m a degradac¸a˜o a longo prazo de todas as amostras preparadas
(filmes, fibras, esponjas e discos). A influeˆncia na taxa de degradac¸a˜o de va´rios
factores (morfologia, cristalinidade, presenc¸a de fa´rmaco, PM, composic¸a˜o) foi
avaliada atrave´s de estudos de absorc¸a˜o de a´gua, de perda de massa, de evoluc¸a˜o
da cristalinidade e de PM. A taxa de degradac¸a˜o foi maior para as misturas do
que para os sistemas so´ de PCL e foi similar para os diferentes tipos de misturas.
Os discos de baixo PM tiveram uma taxa de degradac¸a˜o uma ordem de grandeza
menor do que os discos de alto PM. Verificou-se que a porosidade e´ um factor muito
importante, visto que na fase inicial houve um aumento de absorc¸a˜o de a´gua e de
degradac¸a˜o, enquanto que numa fase posterior (ou porosidade desenvolvida), houve
uma diminuic¸ao˜ da taxa de degradac¸a˜o devido a` diminuic¸a˜o de efeitos autocatal´ıticos.
A alta porosidade inicial produziu uma acelerac¸a˜o da degradac¸a˜o de esponjas, fibras
e filmes, quando comparada aos discos, enquanto que a porosidade desenvolvida
reduziu a degradac¸a˜o dos discos com fa´rmaco, quando comparada com discos
sem fa´rmaco. A modelac¸a˜o dos dados experimentais sugere que a contribuic¸a˜o
dos efeitos de superf´ıcie era ta˜o importante quanto os efeitos autocatal´ıticos na
degradac¸a˜o em massa.
Este trabalho descreveu va´rias te´cnicas de processamento de pol´ımeros e de
imobilizac¸a˜o de fa´rmacos para a preparac¸a˜o de SLCF para aplicac¸a˜o intraocular.
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Sugeriu tambe´m alguns resultados sobre a avaliac¸a˜o pre´-cl´ınica de implantes a` base
de PCL. In vivo, os implantes foram capazes de reduzir a PIO num modelo animal
de glaucoma. No entanto, ha´ que realc¸ar uma outra questa˜o muito importante
que deve ser abordada: a adesa˜o do paciente. A adesa˜o do paciente e´ de extrema
importaˆncia, especialmente no tratamento de doenc¸as cro´nicas, pois os pacientes
teˆm de manter constantemente o seu regime medicamentoso. A superioridade da
SLCF em relac¸a˜o a` terapia convencional, tem de ser comprovada em estudos a
longo prazo porque o aumento da adesa˜o do paciente foi uma das principais razo˜es
do desenvolvimento de terapias SLCF.
Rezumat
Existau 60,5 milioane de oameni cu glaucom ıˆn 2010 la nivel mondial s¸i acest
numa˘r este de as¸teptat sa˘ creasca˘ la 79,6 milioane paˆna˘ ıˆn 2020. La pacient¸ii cu
glaucom, tratamentul medical convent¸ional consta˘ ıˆn administrarea de pica˘turi.
Din pa˘cate, administrarea s¸i aderent¸a la tratament sunt adesea problematice.
Tratamentul chirurgical sau cu laser pentru glaucom este adesea traumatizant
pentru pacient¸i, implicaˆnd costuri ridicate s¸i de cele mai multe ori, repetarea
procedurii.
Scopul prezentei lucra˘ri a fost dezvoltarea de sisteme de eliberare controlata˘
de medicamente, biodegradabile, concepute pentru a oferi eliberare localizata˘, pe
termen lung (de la 6 luni la 2 ani) s¸i care pot fi utilizate ıˆn tratamentul glaucomului.
Implantul se degradeaza˘ la locul de implantare, eliminaˆnd necesitatea de chirurgie
pentru extragere. Implantul poate fi introdus ıˆn cabinetul oftalmologistului, sub
anestezie locala, cu implicatii mari ıˆn recuperarea pacient¸ilor s¸i a costului procedurii.
Prin eliberarea controlata˘ de medicament, implantul are o eficient¸a˘ farmacologica˘
sporita˘ s¸i cres¸te aderent¸a la tratament.
Diverse tehnici de ıˆncorporare de medicamente s¸i de procesare de polimeri
au fost utilizate pentru a obt¸ine sisteme de eliberare controlata˘ de medicamente
(SECM) pentru aplicat¸ii intraoculare. Materialele alese au fost poli(ε-caprolactona˘),
PCL, din cauza degrada˘rii sale lente, fiind astfel utila˘ pentru eliberarea pe termen
lung s¸i poli(oxietilena˘-b-oxipropilena˘-b-oxietilena˘), Lu, din cauza capacita˘t¸ii de
reglare a elibera˘rii. Iˆn plus, ambii polimeri sunt disponibili ıˆn comert¸, ieftini
s¸i bine caracterizat¸i. Trei medicamente au fost ıˆncorporate: maleat de timolol,
acetazolamida˘ s¸i clorhidrat de dorzolamida˘. Aces¸tia sunt rpincipii active care
pot sca˘dea tensiunea intraoculara˘ (TIO) ıˆn glaucom cu unghi deschis. Trei tipuri
de dispozitive au fost obt¸inute: de tip matrice (buret¸i, fibre, discuri) s¸i de tip
hibrid (discuri), folosind impregnarea cu solvent supercritic (ISS), “electrospinning”,
formarea prin compresie s¸i formarea prin ıˆntindere-suflare.
Sisteme pe baza˘ de PCL au fost cu succes impregnate cu maleat de timolol,
folosind o tehnica˘ ISS. Rezultatele privind eficient¸a ıˆncorpora˘rii de medicament
au sugerat ca˘ cele mai bune condit¸ii de impregnare s-au obt¸inut atunci caˆnd
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xun cosolvent a fost folosit s¸i atunci caˆnd interact¸iuni specifice ıˆntre medicament
s¸i polimer au apa˘rut din cauza modifica˘rii caracterului chimic datorita˘ forma˘rii
amestecurilor de polimeri. Presiunea poate fi un factor favorabil, atunci caˆnd exista˘
afinitate ıˆntre medicament s¸i polimer, sau un factor nefavorabil caˆnd interact¸iunile
sunt mai slabe. Gradul de ıˆncorporare, distribut¸ia medicamentului ıˆn matrice,
caracterul hidrofilic, gradul de cristalinitate, toate influent¸eaza˘ eliberarea controlata˘
a medicamentului. Rezultatele testelor de eliberare in vitro au sugerat ca˘ o viteza˘
de eliberare sust¸inuta˘ poate fi obt¸inuta˘ prin optimizarea condit¸iilor de tehnicii SSI
s¸i prin relarea compozit¸iei amestecurilor de polimeri, ca un mijloc de a controla
cristalinitatea, caracterul hidrofilic s¸i afinitatea ıˆntre medicament s¸i matricea
polimerica˘.
Fibre bicomponente de PCL s¸i Lu au fost obt¸inute prin “electrospinning”. Ac-
etazolamida s¸i maleatul de timolol au fost ıˆncorporate ıˆn fibre ıˆn concentrat¸ii diferite
(sub limita s¸i peste limita de solubilitate a medicamentului ıˆn polimer), pentru a
determina efectul solubilitat¸ii, starea de agregare a medicamentului, a gradului
de ıˆncorporare s¸i a compozit¸iei asupra morfologiei, distribut¸iei de medicament s¸i
a cineticii de eliberare. Fibrele cu grad de ıˆnca˘rcare ridicat de medicament (cu
medicament ıˆn stare cristalina˘) au eliberat medicamentul mai repede decaˆt fibrele
cu grad de ıˆnca˘rcare sca˘zut, fapt ce sugereaza˘ ca˘ eliberarea este mai sust¸inuta˘ atunci
caˆnd medicamentul este ıˆncorporat ıˆn interiorul fibrelor, ıˆn stare amorfa˘. Iˆn plus,
maleatul de timolol a fost eliberat mai repede decat acetazolamida, indicaˆnd faptul
ca˘ solubilitatea medicamentului ıˆn polimer influent¸eaza˘ fenomenul de partit¸ie a
medicamentului ıˆntre matricea polimerica˘ s¸i mediul de elut¸ie, ıˆn timp ce compozit¸ia
fibrelor influent¸eaza˘, de asemenea, eliberarea medicamentului. La grad de ıˆnca˘rcare
sca˘zut, eliberarea totala˘ a medicamentului nu a fost realizata˘, sugeraˆnd ca˘ o parte
din medicament a ra˘mas imobilizata˘ ıˆn fibre. Modelarea datelor de eliberare a
indicat un mecanism de eliberare ıˆn trei etape: etapa “burst”, etapa controlata˘
de desorbt¸ie s¸i de difuzie, ultima etapa˘ fiind controlata˘ de viteza de degradare a
polimerului.
Discuri cu dorzolamida˘ (dispozitiv hibrid) au fost obt¸inute prin formare de filme
PCL/Lu s¸i acoperirea ulterioara˘ cu solut¸ie PCL. Prin amestecare, cristalinitatea,
capacitatea de gonflare s¸i eroziunea au fost modificate ıˆn raport cu polimerii puri.
Efectul “burst” a fost diminuat prin aplicarea membranei de PCL. Toate probele
au prezentat etapa “burst”, cu except¸ia probelor PCL cu membrana˘, care au
produs eliberare controlata˘ timp de 18 de zile. Pentru probele PCL cu membrana˘,
eliberarea a fost controlata˘ de difuzia prin membrana˘ s¸i de partit¸ia medicamentului,
ıˆn timp ce pentru probele 50/50 Lu/PCL cu membrana˘, porozitatea ridicata˘ a
rezervorului a diminuat controlul elibera˘rii prin difuzie s¸i partit¸ie. Un model de
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degradare a polimerului a descris pe deplin cinetica de eliberare, consideraˆnd un
mecanism trifazic: difuzie instantanee (“burst”), difuzie s¸i degradarea polimerului.
Testul MTT a indicat faptul ca˘ materialele nu au fost citotoxice pentru celule
endoteliale prevalate din cornee de iepure. S-a obt¸inut o corelare buna˘ in vitro–in
vivo. Dispozitivele au produs o sca˘dere a TIO similara˘ cu cea obt¸inuta˘ prin aplicare
de pica˘turi cu dorzolamida˘.
Discuri implantabile de tip matrice au fost preparate prin amestecare de PCL,
Lu s¸i dorzolamida˘. Performant¸a˘ in vivo a fost evaluata˘ prin capacitatea de a reduce
TIO ıˆn ochi normotensivi s¸i hipertensivi. Testele de distribut¸ie a medicamentului
au ara˘tat ca˘ eliberarea a fost completa˘ din discuri de amestec s¸i din polimerul cu
masa moleculara˘ (MM) joasa˘ , PCL10, dupa 1 luna˘ in vivo. Polimerul cu MM
ridicata˘, PCL40 a prezentat viteze de eliberare peste nivelul terapeutic timp de 3
luni in vitro. In vivo, formarea capsulei fibroase ıˆn jurul implantului a controlat
eliberarea de medicament, ıˆntr-o maniera˘ similara˘ cu membrana-bariera˘ dintr-un
sistem de tip rezervor. Analiza histologica˘ a ara˘tat ra˘spuns normal la corp stra˘in.
Iˆn ochi hipertensivi, sca˘derea TIO cea mai sust¸inuta˘ a fost obt¸inuta˘ de polimerul
cu MM ridicata˘, PCL40. Amestecare ofera˘ posibilitatea de a manipula viteza
de eliberare s¸i cantitatea de medicament eliberata˘ pentru a prega˘ti dispozitive
adaptate la nevoile pacient¸ilor.
Degradarea pe termen lung a tuturor probelor (filme, fibre, buret¸i s¸i discuri)
a fost studiata˘. Influent¸a asupra vitezei de degradare a mai multor factori (tipul
probei, cristalinitatea, MM, ıˆncorporare de medicament, compozit¸ia amestecului)
a fost evaluata˘ prin teste de gonflare, eroziune, evolut¸ie de cristalinitate s¸i MM.
Viteza de degradare a fost mai mare pentru amestecuri decaˆt pentru PCL s¸i a
fost similara˘ ıˆntre diferite tipuri de amestecuri. Discurile cu MM joasa˘ au avut o
viteza˘ de degradare cu un ordin de ma˘rime mai mic decaˆt discurile cu MM ridicata˘.
Porozitatea s-a dovedit a fi un factor foarte important, deoarece, ıˆn etapa init¸iala˘
va produce cres¸terea capacita˘t¸ii de gonflare s¸i ıˆn consecint¸a˘ degradarea, ıˆn timp ce
ıˆntr-o etapa˘ ulterioara˘, va reduce viteza de degradare din cauza diminua˘rii efectelor
autocatalitice. Porozitatea ridicata˘ init¸iala˘ a produs o accelerare a degrada˘rii pentru
buret¸i, fibre s¸i filme ıˆn comparat¸ie cu discurile, ıˆn timp ce porozitate “produsa˘”
a redus degradarea pentru discuri cu medicament ıˆn comparat¸ie cu discuri fa˘ra˘
medicament. Modelarea datelor experimentale a sugerat ca˘ prevalent¸a efectelor de
suprafat¸a˘ a fost la fel de importanta˘ ca efectele autocatalitice pentru degradarea ıˆn
masa˘.
Acest studiu a descris diverse metode de procesare de polimeri s¸i tehnici de
ıˆncorporare de medicamente pentru a obt¸ine SECM pentru aplicat¸ii intraoculare.
Au fost prezentate, de asemenea, rezultate cu privire la evaluarea precilinica˘ a
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implanturilor bazate pe PCL. In vivo, implanturile au redus TIO ıˆntr-un model
animal de glaucom. Cu toate acestea, un alt aspect extrem de important trebuie sa˘
fie abordat: evaluarea aderent¸ei pacientului la tratament. Aderent¸a la tratament
este extrem de importanta˘ ıˆn special ıˆn tratamentul bolilor cronice, deoarece
pacient¸ii trebuie sa˘ respecte tratamentul medicamentos prescris. Superioritatea
SECM ıˆn comparat¸ie cu terapia convent¸ionala˘ trebuie sa˘ fie dovedita˘ ıˆn studii de
aderent¸a˘ la tratament pe termen lung, deoarece acesta a fost unul dintre motivele
principale de dezvoltare a terapiei SECM.
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Outline
The current Thesis is a result of the Ph.D. research project (funded by FCT,
reference: SFRH/BD/30198/2006) with the title Drug loading strategies and pro-
cessing of polymer blends for intraocular controlled drug release application. The
Thesis is divided in eight Chapters.
In Chapter 1, an introduction to the main subject that is covered in the
Thesis is given. In this Chapter, an overview of glaucoma, its manifestation and
current treatment is given. Problems with current drug delivery routes to the
eye and benefits and drawbacks of controlled drug delivery systems (CDDS) for
ophthalmologic diseases are also presented. A very brief introduction on supercritical
fluids (SCF) technology and electrospinning is given in order to understand the
versatility of these techniques for the preparation and drug loading of CDDS.
Chapter 2 presents the results of the study on the supercritical solvent im-
pregnation of timolol maleate in poly(ε-caprolactone)-based blends. SCF-assisted
impregnation enables the production of drug-eluting implants because both drug
loading and porous polymer morphology is achieved in one step. This very porous
morphology allows further processing of the drug loaded matrix in order to obtain
implants with various dimensions and shapes. The effects of pressure, cosolvent
and blend composition on drug loading and release kinetics were evaluated.
Electrospinning of polymer and drug solutions was used in order to fabricate fiber
CDDS. Due to easy drug entrapment, high surface area, morphology control and
biomimetic characteristics, fibers can perform as CDDS. The effect of electrospinning
processing on crystallinity, hydrophilicity and degradation of bicomponent fibers as
well as the effect of drug solubility in polymer, drug state, drug loading and fiber
composition on morphology, drug distribution and release kinetics are described in
Chapter 3.
Chapter 4 presents the preparation of an implantable device for dorzolamide
delivery by solvent casting. Dip-coating was used as a strategy to decrease/eliminate
burst release. Preliminary in vivo results in normal tension rabbit eyes were also
reported.
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Chapter 5 describes the preparation of drug-eluting implants by melt compres-
sion so that high drug loading per implant mass is achieved. Results concerning the
in vivo performance (in terms of the effect on intraocular pressure) in an animal
model of glaucoma are also presented. Differences between in vitro and in vivo
drug release, offering insights into the mechanisms of drug release are considered.
Chapter 6 presents the results of long-term degradation tests for the various
constructs (films, fibers, sponges and disks) that were obtained during this research
project. The influence on degradation rate of several factors (construct type,
crystallinity, molecular weight (MW), drug presence, blending) was assessed through
water uptake, mass loss, crystallinity and MW evaluation.
A general discussion of all obtained results and final conclusions are presented
in Chapter 7.
Acronyms
CDDS controlled drug delivery system
IOP intraocular pressure
CAI carbonic anhydrase inhibitors
ACh acetylcholine
RGC retinal ganglion cells
TM trabecular meshwork
AH aqueous humor
SCF supercritical fluids
NTP normal temperature and pressure
scCO2 supercritical carbon dioxide
SSI supercritical solvent impregnation
PCL poly(ε-caprolactone)
Lu Lutrol F 127
Lw Luwax EVA 3
PBS phosphate buffer saline
DSC differential scanning calorimetry
PVAc poly(vinylacetate)
SEM scanning electron microscopy
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EPMA electron probe microanalysis
MTT 3-[4,5-dimethyl-thiazol-2-yl]-2,5-
diphenyltetrazolium bromide
DMA dynamic mechanical analysis
TGA thermogravimetric analysis
XRD X-ray diffraction
MW molecular weight
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Chapter 1
Introduction
1.1 Controlled drug delivery systems
A controlled drug delivery system (CDDS) is “a formulation or a device that
enables the introduction of a therapeutic substance in the body and improves its
efficacy and safety by controlling the rate, time, and place of release of drugs in
the body”. The release consists of the administration of the drug, the release of
the drug by the CDDS and the subsequent transport of the drug to the site of
action. The CDDS can be a drug formulation or a device (such as biosensors,
microfluidics, microchips, pumps and conduits) used to deliver the drug. Drugs
can be introduced in the body by systemic delivery (which includes oral, colorectal,
parenteral, transdermal, transmucosal, nasal, pulmonary, cardiovascular, central
nervous system and intraosseous routes) or local delivery, which is targeted to
various organs (Jain [2008]).
With standard drug delivery systems, the concentration of the drug reaches
a maximum level and then decreases rapidly to a low value. Thus, a new dose
has to be administered frequently. Sometimes, the obtained drug concentration
can be higher than the required therapeutic dose and can even be higher than
the toxic level. Standard delivery systems produce a pharmacologic profile that
gives rise to the alternation of doses that produce either over-dosage or lack of
efficiency. CDDS eliminate the variation in drug concentration, producing a more
efficient pharmacologic profile. With a CDDS, a drug is delivered in a predetermined,
predictable and reproducible manner. Thus, the drug concentration will be adjusted
so that it is below the toxic level and above the optimal therapeutic level. The
objective of a CDDS is to maintain a prolonged constant drug level in a carefully
controlled concentration range. The principle of action of a CDDS with respect to
standard drug delivery systems is shown in Fig 1.1.
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Figure 1.1: Comparison between CDDS and traditional delivery
A CDDS presents several advantages when compared to traditional delivery
(Jain [2008], Tiwari and Rajabi-Siahboomi [2008]):
• clinical advantages
– extend the duration of drug action
– improvement of drug safety and efficacy
– lower dosing frequency
– lower drug toxicity (local/systemic)
– chronopharmacological benefits
– lower fluctuations in drug blood/tissue level
– lower total drug usage when compared with conventional therapy
– improved patient compliance
• commercial/industrial advantages
– economical to the health care system and the patient
– lower cost of drug development
– product life-cycle extension
– product differentiation
– market expansion
– innovative/technological leadership
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Potential limitations of CDDS technology include (Jain [2008], Tiwari and
Rajabi-Siahboomi [2008]):
• delay in onset of drug action
• burst risk
• difficulty in dose adjustment in some cases
• higher cost when compared with conventional therapy
• not suitable for all drugs
• lower patient acceptance
• more difficult administration when compared with conventional therapy
The control of drug release from CDDS can be achieved by several mechanisms
(shown schematically in Fig. 1.2): diffusion, dissolution, swelling, osmosis, degrada-
tion (enzymatic/chemical) and external (magnetic, ultrasound) or self-regulation
(Heller [1996]). Release mechanisms will be discussed with more detail in section
1.5.3.
Drug release can be controlled by diffusion through the polymer matrix (in
the case of matrix system) or through the polymer membrane (in the case of
reservoir systems). Solvent diffusion into the system can also control the drug
release. In this case, either swelling or osmosis control the release phenomenon. The
drug is immobilized in a insoluble polymer matrix (usually hydrogels) that swells
when in contact with the solvent. The solvent will diffuse in the polymer matrix,
induce matrix swelling and trigger the diffusion of the solvated drug molecules from
the matrix. In osmotic systems, the drug is contained in a polymer reservoir (a
semi-permeable membrane) that allows water diffusion through the membrane, but
not drug diffusion. The membrane has a small orifice that will allow drug diffusion
when hydrostatic pressure in the system is modified. Other mechanisms include the
release due to polymer degradation and/or polymer dissolution. The disintegration
of the polymer matrix (either by physical or chemical mechanisms) will trigger the
release of the incorporated drug. In self-regulated or externally regulated systems,
certain stimuli regulate the drug release (such as temperature, pH, ultrasound,
electromagnetic fields). The self-regulated systems adjust the drug concentration
and the kinetic profile to the physiological needs. Thus, these systems try to imitate
biofeedback mechanisms.
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Figure 1.2: Drug release mechanisms
1.2 Drug delivery to the eye
The routes for ocular delivery include non-invasive methods such as topical
and systemic administration (oral ingestion or parenteral injection). Topical
administration of drugs (in the form of solutions, suspensions and ointments) is
usually preferred over other types of drug administration due to ease of application,
rapid onset of drug action and good patient acceptance (Amo and Urtti [2008],
Kaur and Kanwar [2002]). The local instillation of drugs can achieve therapeutic
concentrations in the anterior segment (cornea, anterior chamber, iris, crystalline
lens, and ciliary body), but less effectively to the posterior segment (vitreous humor,
retinal pigmented epithelium, retina and choroid) (Hughes et al. [2005]). Several
ocular diseases, such as inflammation, dry eye and glaucoma, can be treated by
topical application (Felt et al. [2002]).
Systemic administration can be used as an adjunct therapy when diseases
do not respond as desired to topical medication or in acute episodes of disease
manifestation (Gupta et al. [2008]). It is also more effective to treat diseases of the
posterior segment of the eye with systemic medication than with eyedrops (Amo
and Urtti [2008]). With systemic delivery, drug transport is achieved through the
blood-ocular barriers. Two main sites of the blood-ocular barrier exist in the eye:
the blood-aqueous barrier (transport through the cilliary body) and the blood-
retinal barrier (transport through the retina) (Velez and Whitcup [1999]). Some
posterior segment diseases treated by systemic administration include diabetic
retinopathy and endophthalmitis (Hughes et al. [2005]).
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Invasive methods of delivery can also be used, applied either to the intraocular
segments (injections in the intracameral, suprachoroidal, intravitreal, subretinal
regions and intracameral or intravitreal surgery), or to the periocular (subcon-
junctival and sub-Tenon injections) and scleral segments (intrascleral, episcleral,
subconjunctival surgery) (Amo and Urtti [2008]). A schematic representation of
the different segments of the eye is shown in Fig. 1.3. The periocular route is
often employed to treat severe infections of the anterior portion of the eye or to
administer drugs as an adjunctive treatment to glaucoma filtering surgery. The
intracameral injection may be used in intraocular antibiotic therapy in case of
severe infections of the eye. Injections within the posterior chamber can be used
after cataract surgery to prevent complications. Intravitreal injection of drugs
represents a direct way of attaining effective drug concentrations in the vitreous
cavity. Intracapsular administration route allows the treatment of diseases affecting
the capsular bag such as posterior capsular opacification, a frequent complication
of cataract surgery. Subretinal injections allow drug delivery directly to the retina,
or more precisely to the retinal pigment epithelium cells. Thus, diseases such as
glaucoma filtering surgery failure, proliferative vitreoretinopathy, cytomegalovirus
retinitis, endophthalmitis, posterior uveitis, posterior capsule opacification and
retinal degenerative diseases can be treated by intraocular injections (Urtti [2006],
Felt et al. [2002], Bourges et al. [2006]).
However, all the above mentioned drug delivery routes present several disad-
vantages. Drug solution drainage, lachrymation lead to drug loss into the systemic
circulation and reduce the bioavailability of the topically applied drugs. Thus,
topical therapy is based on frequent instillations, inducing poor patient compli-
ance and ocular and/or systemic toxicity. Through the systemic route most of
the drugs do not cross the blood-ocular barriers and the systemic exposure may
cause unwanted side effects. With periocular and intraocular administration, bolus
dosage and frequent delivery may be required to ensure therapeutic levels over
an extended period of time. Frequent injections may not be practical for chronic
diseases that sometimes require multiple weekly administrations over months or
years. In addition, multiple intraocular injections can lead to complications, such
as vitreous haemorrhage, retinal detachment, and endophthalmitis (Velez and
Whitcup [1999], Amo and Urtti [2008]).
To overcome these problems, research efforts focused in the development of
CDDS. Improved topical formulations, such as hydrogels, particulates and inserts
with higher precorneal residence time are already used in clinical practice or
under development. Though some of these systems provide an increase in drug
bioavailability, they present poor performance in the treatment of posterior segment
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pathologies or in the treatment of chronic diseases that require continuous drug
administration. Intraocular CDDS, capable of local delivery and extended drug
release for long periods of time, have been investigated (Felt et al. [2002]). These
CDDS will be described in the following sections.
1.2.1 Topical controlled drug delivery systems
Currently, in order to improve drug bioavalability, formulations of ocular drugs
for topical delivery are being developed. The challenge consists in increasing
bioavailability from less than 1-3% to at least 15-20%. Research is aimed at
increasing drug absorption in the ocular tissues either by maximizing corneal drug
penetration or by minimizing corneal drug loss (Kaur and Kanwar [2002]).
One possibility to improve drug residence time on the cornea and decrease
drug drainage rate is to increase solution viscosity. Polymeric hydrogels, used in
ophthalmology, are generally classified in two distinct groups: preformed gels (they
are administered to the eye as viscous preparations and do not undergo a liquid-gel
transition) and in situ-forming gels (they are applied as solutions/suspensions and
undergo a sol-gel transition in response to factors like pH, temperature or ion con-
centration). In situ-forming gels facilitate the administration, since they are applied
in liquid form. pH-responsive polymers (pseudolatexes, cellulose acetate phthalate
latex or carbomer) become viscous gels after instillation due to modification of
the pH. The existence of ionizable groups on the macromolecule, which can react
at a specific pH with the electrolytes of the lachrymal fluid or with mucin from
the tear film ensures adhesive properties (Ludwig [2005]). Temperature-sensitive
polymers (such as poloxamers, cellulose derivatives and xyloglucans), are liquid
at room temperature and undergo gelation at body temperature. Unfortunately,
these formulations present a major disadvantage: the risk of gelling before use due
to improper packing or storage conditions (Nanjawade et al. [2007]). Polymers
that undergo gelling in the presence of cations from tears include gellan gum,
carrageenans and alginates. The gelling is caused by the crosslinking of the charged
polysaccharide by mono/divalent ions. Timoptic®, a gellan gum based CDDS
formulation used in glaucoma treatment is available on the market (Nanjawade
et al. [2007]).
Another strategy to increase drug bioavailability is to promote binding between
polymers and mucus (present on the surface of the cornea). Mucoadhesive polymers
can be entrapped and/or bound in the mucus layer of the tear film or retained
in the conjunctival sac, thus withstanding drainage. Such polymers usually have
ionizable groups capable of hydrogen bonding or electrostatic interactions with
mucin, while thiolated polymers are capable of forming covalent bonds with mucin.
1.2 7
Such systems increase the contact time between the drug and the cornea and allow
a lower instillation frequency compared with the eyedrops, but they might produce
irritation, blurred vision and sticky eyelids (Ludwig [2005]).
Colloidal suspensions of particulate drug carriers were developed in order
to combine sustained release action with the ease of application of eyedrops.
Such polymers include polyacrylates, poly(ε-caprolactone), poly(D,L-lactic acid),
poly(D,L-lactide-co-glycolide), hyaluronan, chitosan, polysaccharides, albumin and
lipids. Upon instillation, the particles are retained in the cul-de-sac, where the drug
can be slowly released. However, the commercial development of these products
remains limited due to stability issues after sterilization, long manufacturing
process and only slight improvement of the pharmacological performance (Felt et al.
[2002]). Piloplex®is a colloidal CDDS, in which pilocarpine is ionically bound to
poly(methyl methacrylate-co-acrylic acid) nanoparticles used in glaucoma treatment
(Ludwig [2005]). The main advantages of nanoparticles relative to microparticles is
given by their smaller size which allows transport through the blood-retinal barrier
in the eye, making them useful in the treatment of diseases affecting the posterior
segment. Moreover, the smaller size might decrease the uncomfortable feeling of
foreign body sensation upon instillation of microparticle formulations (Nagarwal
et al. [2009]).
Liposomes and niosomes are vesicular systems in which the drug is encapsulated
in lipid structures. They can entrap both hydrophilic and hydrophobic drugs in
aqueous solutions and due to surface charge interaction with corneal surface, they
can increase ocular absorption for drugs with low partition coefficient, low solubility
or high molecular weight. Despite these advantages, liposomes present short shelf
life, low loadings and sterilization problems. Niosomes are also lipid bilayered
structures made of non-ionic surfactant polymers. They have all the advantages of
liposomes, but present higher stability (Kaur et al. [2004]).
Ophthalmic inserts are solid or semi-solid preparations and are usually intro-
duced in the lower fornix. They present several advantages such as accurate dosing,
increase in drug bioavailability, absence of preservatives and increased shelf life.
Ophthalmic inserts are generally classified according to their solubility. Soluble
inserts are made of erodible polymers (such as collagen, crosslinked gelatin deriva-
tives, polyesters, poly(vinyl alcohol) and cellulose derivatives), which do not need to
be removed from the eye in the end of therapy. Insoluble inserts can be of reservoir
or matrix type. The reservoir systems can release drug either by diffusion or by
an osmotic process. The matrix type is mainly represented by therapeutic contact
lenses. The main advantage of this system is the simultaneous vision correction
and drug release. However, the main problem associated with contact lenses is the
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difficult control of incorporated drug amount. Inserts are a promising alternative
to classical formulations. However, only a few of these formulations have been
commercialized. This can be attributed to difficult placement, discomfort (possible
movement around the eye, vision impairment), inadvertent loss, and lower patient
acceptance (Felt et al. [2002]).
1.2.2 Intraocular controlled drug delivery systems
Intraocular controlled drug release can be achieved by two means: injectable
solutions (semi-solid formulations and particulates) or implantable devices with
various geometries (see table 1.1) that can be either implanted through surgery or
injected.
Intraocular CDDS were developed in order to overcome some of the limitations
of topical and systemic routes of administration for ophthalmic drugs. These
implants can be placed in various sites to deliver drug to the eye (Fig. 1.3).
The purpose of the implant is to provide local, sustained controlled drug release
from the polymeric carrier. Local delivery of drugs to the eye using intraocular
implants offers several advantages over systemic therapy. Higher intraocular drug
levels can be achieved with local delivery when compared to systemic or topical
therapy because no drug is lost in the transport through the blood-ocular barriers.
Intraocular implants also provide control over the drug release rate, maintaining
it in the therapeutic window of the drug, avoiding thus the exposure to toxic
doses (bolus effect). This is particularly useful because most of the ocular drugs
have important side-effects. Moreover, sustained release of drugs over long periods
of time allows less frequent dosing than with conventional delivery or eliminate
the need of self-medication, when patient compliance is of concern. Finally, these
devices contain lower amounts of drug for similar treatment periods than traditional
formulations, which is especially important from the economic/commercial point
of view (Yasukawa et al. [2005], Amo and Urtti [2008]).
Another strategy for intraocular delivery is to encapsulate the drug in a
liquid/semi-solid formulation, that can be delivered by injection to the eye. Semi-
solid formulations (viscous polymers, sol-gel formulations) and particulates (mi-
cro/nanospheres, micro/nanocapsules, liposomes, micelles) can be administered
as intravitreal injection, a less invasive procedure than the surgical implantation.
They provide sustained drug delivery for weeks or months, allowing less frequent
injections than with conventional injectable drug solutions (Moshfeghi and Peyman
[2005], Amo and Urtti [2008]).
However, there are some disadvantages associated to CDDS implant/injections
therapy. Drugs that are used during a short time scale may produce toxicity, when
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Figure 1.3: Various intraocular implantation sites (adapted from Weiner [2008])
employed in long term therapy. The surgical placement or removal of intravitreal
implants can cause adverse effects due to the invasiveness of the procedure (such as
inflammation and infection) or due to the placement of the implant in the eye (such
as vitreous haemorrhage and retinal detachment). Biodegradable implants may
not require a surgery for their removal, which is an important advantage against
non-biodegradable implants. The intravitreal injections of the particulate systems
may cause vitreal clouding (Amo and Urtti [2008], Velez and Whitcup [1999]). As
mentioned in section 1.2, intravitreal route is only one of the available delivery
routes. Subconjunctival implantation/injection represents another route for the
delivery of drugs, especially to the anterior segment of the eye. When compared
with intravitreal procedures, this approach is less invasive (thus, it can be done
in the ophthalmologist office, under local anaesthesia, which is more economic
and less traumatic for the patient) and does not produce some of the adverse
effects associated with intravireal delivery such as vitreous haemorrhage and retinal
detachment (Hosoya et al. [2005]).
The ocular implants can be classified with respect to their degradability into
non-biodegradable and biodegradable devices. Non-biodegradable implants can
provide more accurate control of drug release and longer release periods than the
biodegradable implants. However, they require an additional surgery for implant
removal (Amo and Urtti [2008]). Implants can also be classified according to
the mechanism of drug release into: monolithic-type, which is composed of a
homogeneous/heterogeneous mixture of drugs and polymers, the binding-type,
in which the drug is chemically or physically bound to the polymer, and the
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reservoir-type, in which drugs are enclosed within a polymer shell (Yasukawa et al.
[2005]).
Various polymers, in terms of degradability and hydrophilic/hydrophobic charac-
ter, were used for manufacturing intraocular implants. Biodegradable polymers are
cleaved into mono/oligomeric soluble form in the body through enzymatic or non-
enzymatic reactions, while non-biodegradable polymers are not degraded/eroded
in the body. Biodegradable polymers belong to the classes of polyesters, poly-
orthoesters, polyanhydrides, polyhydroxyalkanoates. Non-biodegradable polymers
that were used for intraocular CDDS include cellulose derivatives, silicone, acrylates,
poly(vinyl alcohol) and poly(vinyl acetate). Hydrophilic polymers include albumin,
gelatin, collagen, chitosan, starch, dextran, fibrin, and hyaluronic acid. They
form a hydrogel when crosslinked and drugs/biomolecules can be loaded through
entrapment in the polymer network (in which case they are monolithic-type) or
through covalent bonding or polyion complexation (the binding-type) (Yasukawa
et al. [2005]).
The procedures for making implants involve powder compression, heat press,
melt compression, moulding, extrusion, and preparation as films. The choice of the
technique and selection of the technique parameters will be dictated by the type
of polymer to be processed, the type of drug to be loaded and the properties of
the final drug/polymer mixture. Polymer films can be produced by melt-pressing
or solvent-casting. Solvent-casting might involve using organic solvents in order
to dissolve the polymer, which might be problematic for loading biomolecules.
Moulding and extrusion are temperature aided processes in which the polymers are
heated/melted and then compacted/compressed into the final shape. Therefore,
these procedures might be inadequate for drugs that are thermolabile. Nevertheless,
extrusion methods allow for large-scale manufacture of implants and result in
homogeneous dispersion of the drug within the polymer matrix. Cold processes
are available for the loading of thermolabile drugs such as powder compression (by
means of a tablet press) or freeze-drying followed by cold compression. Hydrogels
are also suitable to deliver thermolabile drugs/biomolecules due to the mildness of
the preparation procedure (solvent casting or crosslinking are usually performed in
aqueous solutions, close to or at room temperature and under strict pH control)
(Breitenbach [2002], Choonara et al. [2007], Donello and Yang [2007], Yasukawa
et al. [2005]). For reservoir-type implants, the core of the implant can be prepared
using one of the already-mentioned techniques followed by deposition of the polymer
shell through coating processes such as spray coating, dip coating or melt coating
(Wong et al. [1999]).
In the monolithic-type implant, the drug is dissolved/dispersed in the polymer
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matrix and the drug release takes place either by diffusion, by polymer degradation
or by a combination of the two. When non-biodegradable polymers are used,
drug release occurs only by diffusion through the polymer matrix. In the case
of biodegradable polymer, we should distinguish between surface degrading and
bulk degrading polymers. In the first case, polymer degradation is as fast as drug
diffusion and release kinetics is usually of zero-type, while bulk degrading polymers
(where polymer degradation is much slower than drug diffusion) usually present a
t0.5 kinetics, characteristic to diffusion-controlled systems (Yasukawa et al. [2005],
Heller [1996]). In the reservoir system, the drug is surrounded by the polymer shell
which controls the drug release by diffusion across the shell (Fialho et al. [2003]).
A more detailed discussion on release mechanisms is presented in section 1.5.3.
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1.3 Glaucoma
Glaucoma is one of the leading causes of blindness in the developed world.
There were 60.5 million people with glaucoma in 2010, increasing to 79.6 million
by 2020 (Quigley and Broman [2006]). The annual direct treatment cost for
late-stage glaucoma ranges from 429 to 523 euro for each patient (Poulsen et al.
[2005]), producing high load on the health system. A high IOP, progressive
optic neuropathy, visual impairment or blindness are common characteristics of
this condition (Yudcovitch [2010]). The condition can be classified according to
a structural or to a etiological basis. Glaucoma is classified into closed angle
glaucoma or open angle glaucoma, based on the appearance of the angle of the
anterior chamber. Based on etiology, in primary glaucoma, no specific cause can
be identified, and in secondary glaucoma, optic neuropathy appears due to some
other ocular disease, such as inflammation or trauma (Titcomb [1999]).
1.3.1 Glaucoma damage theories
There are several theories that explain the relationship between elevated IOP
and glaucoma damage. Direct mechanical damage, ischemia, and apoptosis are
the most widely accepted theories. In the mechanical damage theory, IOP directly
damages the optic nerve by compression, which interferes with flow and cellular
function, producing the death of optic nerve fibers. According to ischemic theory,
increased IOP causes optic nerve fiber death by interfering with circulation of
blood to and from the optic nerve head. Apoptosis theory states that cells die
when their lifespan has been reached or when they have become damaged beyond
repair. Glaucomatous damage may result from a combination of these mechanisms
or by another mechanism. Moreover, different mechanisms may be involved in
different types of glaucoma. Acute angle closure glaucoma might be caused mainly
by mechanical damage of the optic nerve. On the other hand, normal tension
glaucoma might involve ischemic-based damage as indicated by the greater fre-
quency of haemorrhages associated with this type of glaucoma. Regardless of the
mechanism, current treatments have one primary goal: IOP decrease. Although
researchers are exploring new ways to slow down damage, such as neuroprotection
and neuroregeneration, the main treatment goal remains reducing IOP (Yudcovitch
[2010]).
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1.3.2 IOP reduction as target in glaucoma treatment
Clinical trials designed to assess the efficacy of glaucoma treatment have focused
on the role of lowering IOP in the prevention of optic field loss and optic nerve
damage. These studies demonstrated that lowering IOP can reduce the damage
caused by glaucoma. In order to reduce this damage, IOP should be lowered by
different percentages, considering risk factors for each patient. A reduction of 20%
is desired for patients with risk factors such as ethnicity, vascular compromise, a
reduction of 30% for early glaucoma patients, that present field loss, while 40 to
50% reduction in IOP is essential for patients with moderate to severe glaucoma,
that show both field loss and optic nerve damage. However, these reduction
percentages do not take into account individual variability and, as such, target
pressures reductions may deviate from these general IOP reduction percentages
(Yudcovitch [2010]).
1.3.3 Physiology of aqueous production and outflow
IOP is normally maintained by three mechanisms: aqueous fluid production
rate, outflow channel resistance and episcleral veins pressure level. Aqueous fluid
is produced by active secretion from the ciliary body, using the enzyme carbonic
anhydrase and provides about 80% of the aqueous production. Passive secretion via
ultra-filtration and diffusion from the ciliary body accounts for the other 20%. Most
of aqueous outflow involves the transport across the trabecular meshwork in the
anterior chamber of the eye. Aqueous enters the trabecular meshwork after flowing
through the pupil from the posterior chamber. From the trabecular meshwork,
aqueous flows through Schlemm’s canal and drains into a venous plexus, from where
it exits the eye through the episcleral veins. Another portion of aqueous outflow
involves the uveoscleral pathway. Following this pathway, aqueous passes in the
anterior chamber and is transported across the ciliary muscle into the supraciliary
and suprachoroidal spaces and exits the eye via the sclera (Yudcovitch [2010]).
1.3.4 Pharmaceutical treatment of glaucoma
IOP reduction can be achieved either by reducing aqueous humor production
and/or by increasing aqueous outflow (Felt et al. [2002]). The first approach
is attained by using beta-blockers, alpha-2 agonists, and carbonic anhydrase in-
hibitors, whereas the second approach is accomplished with the use of prostaglandin
analogs and cholinergics, while sympathomimetics act by both suppressing aqueous
production and increasing its outflow (Pang and Clark [2008]).
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• Beta-blockers (timolol, betaxolol, carteolol, levobunolol, metipranolol)
The ciliary epithelium contains beta-receptors which facilitate aqueous pro-
duction in the eye, when stimulated. Beta-blocking drugs are able to reduce
aqueous production by blocking beta-receptors. A typical IOP decrease with
topical beta-blocker instillation ranges from 10 to 25%. Beta-blockers are ad-
ditive in effect with other glaucoma drugs. An approximately 30% reduction
in IOP can be obtained with systemic beta-blockers (atenolol, metoprolol,
nadolol). Systemic side-effects include bronchial constriction/asthma, chronic
obstructive pulmonary disease, bradycardia, congestive heart failure, and
diabetes or hyperlipidemia (Yudcovitch [2010]).
• Prostaglandins (bimatoprost, latanoprost, travoprost, unoprostone)
Prostaglandin derivatives are very potent drugs for lowering IOP. The mech-
anism of IOP reduction involves increasing uveoscleral outflow by enlarging
the intercellular spaces on the ciliary body. The IOP reduction is typically
between 30 and 35%. Prostaglandins have various side-effects such as hyper-
trichosis (eyelash lengthening and thickening), subtle hyperpigmentation of
the iris, possible re-activation of herpes simplex virus in previously infected
individuals, conjunctivitis, iritis (Yudcovitch [2010]).
• Carbonic anhydrase inhibitors, (brinzolamide, dorzolamide)
CAI inhibit the carbonic anhydrase in the ciliary epithelium and reduce
the production of bicarbonate ion, which limits sodium and fluid transport
across the ciliary epithelium, and decreases aqueous production. Topical
treatment results in a 15 to 20% decrease in IOP. Topical CAI are useful
IOP-lowering compounds, have minimal systemic side effects and their action
is not influenced by the circadian rhythm. Topical CAI are not usually used
as a first-line medication because they are less efficient when compared to
other glaucoma drugs. They are indicated in adjunctive therapy when the
primary treatment (that consists of beta-blockers or prostaglandins) does not
control IOP adequately. Oral CAI (acetazolamide, methazolamide) are used
to treat acute angle closure glaucoma or other causes of extremely elevated
IOP because the present several side-effects (Pang and Clark [2008]).
• Alpha-2 agonists or selective sympathomimetics (apraclonidine and brimoni-
dine)
They stimulate alpha-2 receptors in the ciliary epithelium and cause both a
decrease in aqueous production and an increase in uveoscleral outflow. Bri-
monidine reduces IOP approximately by 25 to 30%. Tachyphylaxis (reduced
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medication effect) can develop with brimonidine use, but with lower frequency
of development than with apraclonidine, which makes the former more useful
for long-term treatment. Brimonidine also tends to produce fewer ocular
allergic reactions. It is additive with beta-blockers and CAI in lowering IOP.
Possible side-effects include ocular hyperemia, burning/stinging, blur, foreign
body sensation, and allergic reactions. Potential side-effects of apraclonidine
include eyelid retraction, mydriasis, conjunctival blanching, and/or ocular
allergy. Patients who have severe cardiovascular disease, low blood pressure,
or bradycardia should not take apraclonidine (Yudcovitch [2010]).
• Adrenergic agonists or non-selective sympathomimetics (epinephrine)
Epinephrine was the first sympathomimetic drug to be used in the treatment
of primary open angle glaucoma. The primary mechanism of epinephrine
action involves facilitating the uveoscleral outflow, and usually results in
a 15 to 20% decrease in IOP. It is no longer a commonly used glaucoma
medication because newer, more effective, and safer drugs are available. It is
contraindicated for patients with hypertension, heart or vascular disease, and
those who have had cataract surgery (Titcomb [1999]).
• Cholinergic agonists (carbachol, echothiophate iodide, physostigmine, pilo-
carpine)
They work by directly stimulating acetylcholine (ACh) receptors, present
on the ciliary muscles of the ciliary body. When stimulated, the ACh
receptors produce muscle contraction, enlarging the trabecular meshwork
spaces, thus increasing aqueous outflow. Pilocarpine is used in acute angle
closure glaucoma, when immediate action is required. It produces usaully a
20% reduction in IOP. Over time, tachyphylaxis can occur and this will require
higher concentrations of pilocarpine to maintain IOP reduction. Several ocular
and systemic side-effects can occur with pilocarpine such as ciliary muscle
spasm, retinal detachment and miosis, which reduces both the amount of
light entering the eye and the field of vision. Pilocarpine is contraindicated
in patients under 40 years of age, patients with cataracts, patients with
inflammatory or vascular glaucoma, and patients with a history or risk of
retinal detachments (Titcomb [1999]).
• Hyperosmotics (glycerol, isosorbide, mannitol, urea)
They are indicated in the treatment of acute angle closure glaucoma or other
causes of highly elevated IOP (with pressures over 40 mmHg). Hyperosmotics
cause increased blood serum osmolarity, extracting water from ocular tissues
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into the bloodstream. By increasing the osmotic gradient between plasma
and the eye, shrinkage of the vitreous occurs, reducing ocular volume and
lowering IOP. Hyperosmotics are either administered orally or by intra-venous
injection. Glycerol can cause hyperglycemia and should not be used with
diabetic patients. Isosorbide is not metabolized into sugar and it is safe to use
with diabetics. Mannitol can cause diuresis, headaches, chills, and chest pain.
Urea has numerous systemic side-effects and is rarely used. All hyperosmotics
cause nausea and vomiting as a common side-effect (Titcomb [1999]).
• Alcohol and marijuana
They can temporarily lower IOP, although with minimal and temporary effect
when compared to more effective drugs. Intoxication, central nervous system
depression, vomiting, nausea, and addiction are a few of the side-effects
of alcohol use. D-tetrahydrocannabinol is one of the active components in
marijuana and can be prescribed for treatment of chronic pain and IOP reduc-
tion. Inhaled marijuana smoke will lower IOP only slightly and temporarily.
The most promising formulation involve a topical ocular drop, which is still
under development. However, systemic side-effects (and legislation) currently
contraindicate the widespread use of cannabinoids in glaucoma treatment.
1.3.5 Neuroprotection, gene therapy, neuroregeneration
Pharmaceutical treatment of glaucoma involves the protection of the optic nerve
indirectly through lowering of the IOP. Neuroprotection therapy uses pharmaceutical
agents that slow down or prevent death of retinal ganglion cells (RGC), which form
the optic nerve, and maintain their normal function. An important advantage of this
strategy is that it allows treatment of a disease whose etiology is unknown or varies
between patients (Weinreb and Levin [1999], Mozaffarieh and Flammer [2007]).
Gene therapy works by targeting specific tissues (such as trabecular meshwork,
ciliary epithelium, ciliary muscle or RGC) in order to correct aqueous production
and outflow and prevent RGC death. Studies designed to determine whether gene
therapy can be applied to glaucomatous damage in the trabecular meshwork and
the optic nerve are currently underway (Borras et al. [2002]). Neuroregeneration
and repopulation with RGC involves directed axon growth and manipulation of
stem and progenitor cells towards transformation into retinal cells. Optic nerve
regeneration strategies involve peripheral nerve grafts, differentiation of stem or
precursor cells into RGC and integration of transplanted cells into the retina or
promotion of axon regrowth (Dahlmann-Noor et al. [2010], Levin [2005]).
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1.3.6 Laser and surgical treatments for glaucoma
Alternative therapies for glaucoma include laser and surgical treatments. These
are indicated in cases of poor IOP control by medication, or for patients that
can not be prescribed glaucoma drugs because of adverse reactions, or in cases
of advanced glaucoma that requires additional treatment to the pharmaceutical.
However, medications are required after surgical treatment to maintain IOP control,
but the dosages and types of medications might differ after surgery.
The purpose of surgical treatment is to either mechanically open a channel for
aqueous outflow between the anterior chamber and the subscleral or subconjunctival
spaces (as in trabeculectomy, sclerostomy, valve or tube implantation), or to partially
destroy the cells involved in aqueous humor production (cyclocryodestruction).
Laser treatment consists of directing a laser beam to the trabecular meshwork
or iris so that openings are created. it can also be applied to destroy the cilliary
processes and significantly decrease aqueous humor production. Advantages of
laser treatment when compared to surgery include less risk of bleeding and/or
infection, less dependence on patient compliance required to control IOP following
laser surgery and less diurnal variation in IOP following laser treatment. The most
commonly used laser treatments for glaucoma include trabeculoplasty (treatment
of the trabecular meshwork), peripheral iridotomy (treatment of the iris) and
cyclophotocoagulation (treatment of the ciliary processes). Laser treatment can
reduce IOP by 20 to 30 %, although a new treatment might be required within 5
years for 50% of the patients (Titcomb [1999]).
1.3.7 Animal models of glaucoma
The development of animal models for glaucoma are essential in providing
understanding of the mechanisms of aqueous humor production and outflow as
well as homeostasis control of IOP. A model of glaucoma is useful for studying
the effects of elevated IOP in the eye and for developing new treatment strategies.
Since high IOP is a major risk factor in glaucoma, one common approach consists
in increasing IOP to a level that preferentially kills RGC without damaging the
retina and other ocular structures (Levkovitch-Verbin [2004], Vecino [2008]). A
good animal model should reproduce human disease as closely as possible, be
reproducible, easy to induce, with few tissue damage and side effects (such as
pro-inflammatory reactions) and should have a low cost, so that enough animals can
be used to obtain statistically significant results. Besides these characteristics, a
glaucoma model should present a sustained chronic increase in IOP, allow frequent
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IOP measurements and permit assessment of retinal neuronal damage (Rudzinski
and Saragovi [2005]).
Spontaneous glaucoma models have been described in different animal species
(rabbits, dogs, monkeys, mice). These animal models are suitable for studying
the causes of the disease. Unfortunately, animals with spontaneous glaucoma are
difficult to obtain and even more difficult to obtain in a similar stage of the pathology
(with the exception of genetically engineered animals). Therefore, experimental
models of induced glaucoma had to be developed (Vecino [2008]).
There are several animal species that can be used as suitable models for glaucoma.
Primates are a clear choice due to the close phylogeny and homology with humans.
However, primates are very expensive, difficult to handle, require special housing
facilities and highly experienced teams (Levkovitch-Verbin [2004]). Consequently,
rodent models of glaucoma were developed because these animals are inexpensive,
easy to house and handle, and produce fewer ethical issues (Vecino [2008]). There
is high similarity between rodents and human genomes, which allows them to be
used in studies of human optic nerve disease. Moreover, their eyes and optic nerves
are easily accessible. And, in the case of rabbits, the comparable size of the eyes
to those of humans and the extensive information available about rabbit ocular
biochemistry and physiology makes it more appropriate for the testing of new drug
delivery systems (Diepold et al. [1989]). In addition, rodents have a much shorter
life span than humans and this allows the study of diseases that take decades to
develop in humans (Levkovitch-Verbin [2004]). However, their eyes also present a
number of differences such as the absence of the macula and the fovea.
Chronic increase in IOP can be achieved mainly by three mechanisms: block-
ing the trabecular network (pre-trabecular mechanism), reducing aqueous humor
outflow (trabecular mechanism) and blocking the limbal plexus (post-trabecular
mechanism). In the first case, the introduction of viscous substances at the TM,
blocks normal AH outflow and consequently raises IOP, while in the other two cases,
the decrease in AH outflow is produced by modifying the TM and post-trabecular
anatomy, respectively (Rudzinski and Saragovi [2005]).
Blockage of AH drainage at the level of the TM can be achieved by injection into
the anterior chamber of ghost red blood cells, latex microspheres or other viscoelastic
substances such as hyaluronate (Urcola et al. [2006], Diepold et al. [1989]). A
single injection of hyaluronate maintains elevated levels of IOP for 8 days, while an
injection performed once a week induces a sustained and significant hypertension
that lasts all along the duration of the study (50 % increase, during 10 weeks)
(Moreno et al. [2005]). Feasibility and reproducibility are the main advantages of
this experimental model. However, it also presents several disadvantages such as
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transient IOP increase (viscoelastic substances are cleared rapidly from the eye)
and spikes in IOP (very high IOP values can produce retinal ischemia). Thus, to
maintain high IOP weekly injections are necessary (Rudzinski and Saragovi [2005]).
Reduction of AH outflow in the TM can be produced by laser photocoagulation.
The treated eyes develop sustained, high IOP with decreased outflow and optic
nerve cupping like in human glaucoma. This is a simple, reliable and reproducible
method to produce experimental glaucoma. Treatment is very fast (approximately
3 min per eye), which allows many animals to be treated in 1 day. The laser burns
close the intertrabecular spaces and light microscopic examination shows only loss of
RGC and their nerve fibres (Levkovitch-Verbin [2004]). Nevertheless, this method
presents some disadvantages, such as the need for specialized equipment, multiple
laser treatments needed in order to maintain high IOP values for several months
and anterior chamber complications (hyphema and corneal opacities) (Rudzinski
and Saragovi [2005]).
Cortisteroid induced ocular hypertension is another way to simulate glaucoma
in which topically applied or subconjunctivally injected steroids cause a gradual
increase in IOP, within 2 weeks from the beginning of treatment. Accumulation of
cellular debris at the TM decreases AH outflow. This is a very simple model, that
was extensively used in the past, but it presents some drawbacks: not all rodents
are responsive to the treatment and secondary effects such as cataracts can be
produced (Diepold et al. [1989], Rudzinski and Saragovi [2005]).
Drainage form the limbal plexus can be interrupted by injection or cauterization
of the episcleral veins. Injections of hypertonic saline solutions in the episcleral
veins increases the outflow resistance. This technique is less invasive than laser TM
photocoagulation and has less anterior chamber complications. However, repeated
injections are needed to maintain chronic high IOP and it was shown to produce
high inter-animal variability in IOP. Cauterization of episcleral veins is easy to
perform and causes long-term, high increase in IOP. This model has advantages
over other in vivo models because it does not require sophisticated equipment, with
rare complications of surgery. Moreover, inter-animal variability of IOP is lower
than with episcleral saline injections (Rudzinski and Saragovi [2005]).
1.3.8 Concluding remarks
Glaucoma is a complex condition, whose etiology is still not yet fully understood.
Thus, it is very difficult to design agents that can act upon optic nerve damage, the
real cause of vision loss. Glaucoma can not be cured, so the treatment involving
IOP reduction in order to preserve vision is “at best a race with the patient’s life
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expectancy”. Hopefully, in the future, glaucoma cure will be possible (Titcomb
[1999]).
1.4 Supercritical fluids solvent impregnation
Supercritical fluids (SCF) technology is a versatile process that allows the
synthesis and the processing of high performance materials, including biomateri-
als. Industrial products obtained with SCF technology include powder coatings,
polymers, polymer additives and pigments. SCF processing can produce special
morphologies and properties in materials due to the interactions in the supercritical
environment, where different types of interactions from the the traditional organic
solvent/water medium can occur (Kazarian [2004]).
A substance is in its supercritical state when its pressure and temperature
are higher than its critical pressure and critical temperature, respectively. Some
properties of a SCF are intermediate to those of liquids and gases. The density is
higher than that of a gas, while the diffusivity is higher than that of a liquid. Due
to these properties, a SCF can be a good solvent for some compounds/materials.
Moreover, some applications of SCF processing were developed due to the non-
interaction with certain materials (see Fig. 1.4) (Knox [2005]). Solvents are
frequently chosen according to the temperatures and pressures corresponding to
the supercritical region where processing is desired. However, other factors such as
toxicity, cost and environmental issues are important as well. For pharmaceutical
applications, supercritical carbon dioxide (scCO2) is an ideal processing medium.
It is chemically inert and has relatively low critical temperature and pressure (304
K and 7.4 MPa, respectively), which allows processing of thermolabile and/or
biologically-active compounds. Furthermore, carbon dioxide is non-toxic, relatively
inexpensive, recyclable, and environmentally-friendly (Subramaniam et al. [1997]).
1.4.1 CDDS preparation in supercritical medium
The impregnation of polymers with drugs/biomolecules using scCO2 technology
(supercritical solvent impregnation, SSI) is a suitable process for CDDS preparation
because there is no residual solvent present in the processed materials, unless a
cosolvent is used. ScCO2 is a gas at ambient conditions and even in the case
of solvent contamination, scCO2 is not toxic. Organic solvent contamination is
undesirable for materials with biomedical application. The traditional methods of
drug loading involve the use of water or organic solvents as carriers for the drug into
the polymer matrix (Domingo et al. [2002]). Moreover, using SCF technology, low
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temperatures can be used for processing, impurities (such as residual monomers)
can be extracted and process parameters such as pressure and temperature can be
easily manipulated in order to obtain improved polymer properties and specific
drug deposition and release (Kazarian [2004]).
Impregnation of a polymer matrix by a drug dissolved in a SCF is a supercritical
adsorption or absorption process (depending on whether the polymer goes below
glass transition temperature), governed by three phenomena (see Fig. 1.5): the
drug solubility in SCF, that controls the amount of drug that can be carried by
the SCF, the polymer swelling that determines the ease of impregnation and the
adsorption isotherms and/or partition coefficients of the drug in the polymer phase,
that will determine the amount of drug that can be loaded in the matrix (Kikic
and Vecchione [2003]). As such, the impregnation process is feasible when the
solute is soluble in the SCF, the polymer is swollen by the supercritical solution
and the partition coefficient is favourable enough to allow the matrix to be charged
with enough solute. A characteristic feature of SSI process, that makes it suitable
for the preparation of CDDS are the low competition between the solvent and
the solute for the substrate adsorption sites, since, at supercritical conditions, the
solute will be transported and adsorbed preferentially. The gas-like viscosity and
diffusivity of SCF allows rapid penetration and drug deposition into the polymer
and compensates the relatively low solvent strength of scCO2 (Domingo et al.
[2002]).
Impregnation processes can be classified with regard to solute solubility in SCF
and affinity for polymer into processes in which the deposition takes place due to
the good solubility in the SCF (in this case, even a solute that has low affinity for
the polymer matrix can be impregnated) or processes in which loading occurs due
to a high affinity of the solute for the polymer matrix. In the first case, the polymer
matrix is subjected to the SCF-solute medium; when the cell is depressurized, the
SCF leaves the polymer matrix, leaving the solute trapped inside the polymer
matrix. In the second case, a different mechanism applies to the impregnation of
compounds with low solubility in SCF. In such cases, the high affinity of these
solutes for certain polymer matrices can result in the preferential partitioning of a
solute in favour of polymer over SCF (Kikic and Vecchione [2003]). The partitioning
mechanism has an advantage over the deposition mechanism because it does not
result in solute recrystallization and produce materials with homogeneous drug
distribution (Kazarian [2004]).
SCF processes can also be classified with respect to the solute modification
inside the polymer matrix into processes in which the solutes are not modified such
as the impregnation of drugs and dyes, and processes in which the solutes undergo
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Figure 1.4: SCF processing effect on polymers and applications (adapted from
Shieh et al. [1996b])
modification such as the impregnation of monomers and initiators for polymer
blends preparation or the impregnation of organometallic complexes (Kikic and
Vecchione [2003]).
1.4.2 SCF effect on polymers
Several effects of the SCF upon the polymer can be considered: polymer
dissolution in SCF, polymer swelling (or the dissolution of the SCF in the polymer)
and polymer plasticization. SCF can swell and plasticize glassy and rubbery
polymers, reducing the glass transition temperature. Moreover, SCF can interact
with crystalline polymers and reduce the melting temperature. The swelling
and plasticizing effects are important for many polymer processing operations:
viscosity reduction for polymer extrusion and blending, drug diffusion enhancement
for impregnation and extraction, enhancement of monomer diffusion for polymer
synthesis, foaming of polymers, and changes in polymer morphology due to induced
crystallization (Kikic and Vecchione [2003], Kazarian [2000]).
The swelling/plasticization of polymers is characterized by increased segmental
and chain mobility, allowing easier polymer processing and faster solute diffusion.
The plasticizing effect of scCO2 is the result of the ability of scCO2 molecules to
interact with polymer containing basic functional groups (such as carbonyl and
phenyl). It has been shown that such interactions between scCO2 and polymer
functional groups reduce chain-chain interactions and increase the mobility of
polymer segments (Kazarian [2000]). Swelling is a very important step in the
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SSI process: the greater the swelling, the faster the diffusion of the solute. The
solubility of carbon dioxide in many polymers is as high as that of typical organic
solvents, ranging from 10% to more than 30% by weight. As already mentioned,
the high diffusivity of scCO2 in polymers allows an efficient impregnation process
(Guney and Akgerman [2002]). It is possible to change the extent of polymer
swelling by changing the density of the SCF. In this way, diffusion of solute within
the SCF-swollen polymer matrix and the amount of solute incorporated in the
polymer can be controlled.
In amorphous polymers, SCF interactions with the polymers are much more pro-
nounced, while in crystalline polymers, SCF swelling and plasticization are lower in
extent. Moreover, due to plasticization, SCF processing may induce crystallization
in amorphous polymers or increase crystallinity in semi-crystalline polymers. As
such, SCF treatment will generally be more suitable for crystalline materials than
amorphous materials in precision cleaning, surface modification/coating or particle
removal applications. On the other hand, amorphous materials are more suitable
for applications such as polymer foaming, SSI, extraction, polymer crystallization
or formation of microcellular structures (Shieh et al. [1996b,a]).
1.4.3 Cosolvents
While scCO2 is a good solvent for many non-polar (and some polar) molecules
with low molecular weights, it is a poor solvent for most polymers and other polar
molecules. A common approach is to include a small amount of a cosolvent to
increase the solubility of the solute. The cosolvent will be a substance that has
a greater affinity for the solute than does carbon dioxide (Knox [2005]). The
presence of the cosolvent in the SCF mixture will increase the complexity of the
system and the interactions between components. Specific interactions (see Fig.
1.5) cause the formation of clusters with molecules of solute, solvent and cosolvent,
and thus the region around the solute molecule is enriched with cosolvent. This
local composition can be several times greater than that of the bulk composition
(Sauceau et al. [2004]). Thus, the effect of cosolvent on SSI is due both to different
solvent power of the mobile phase (and solute solubility) and also to a change in
drug partition in the polymer phase. The cosolvent may affect the polymer phase
through the adsorption of the cosolvent in the polymer phase that may alter its
chemical nature, thus affecting the partition of the solute. Moreover, polymer
swelling can be different in the presence of the cosolvent when compared with pure
SCF (Kazarian et al. [1998]).
Cosolvent effect on the solubility enhancement of solid solutes in SCF was
investigated through the choice of cosolvents of different polarity/functionality
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Figure 1.5: SCF medium interactions (adapted from Kikic and Vecchione [2003])
and in different concentration. Solvent self-association and Lewis character are
important because they will diminish or enhance the interactions between the
functional groups of the cosolvent and the solute or the polymer (Kazarian et al.
[1998], Sauceau et al. [2004]). As already discussed, solubility enhancement in the
presence of cosolvent is due to the interactions between the solute and cosolvent.
Thus, it is expected that the largest cosolvent effect on polar solute is from the
polar cosolvent, while for the non-polar solute the largest cosolvent effect comes
from the non-polar solvent (Li et al. [2003]).
The interactions between the cosolvent and the solute, and thus the cosolvent
effect (in terms of solubility enhancement) can also be manipulated by SSI pressure.
The importance of the cosolvent effect decreases with increasing pressure because
at very high pressures, the local concentration of the cosolvent approaches the bulk
concentration. While the local concentration decreases, the bulk concentration of
cosolvent (and thus solubility) always increases with increasing pressure, due to an
increase in density. Thus, it has been observed that, at low cosolvent concentration,
the cosolvent effect depends predominantly on the bulk concentration of cosolvent
around the solute, and as the cosolvent concentration is increased, the effect of local
concentration enhancement becomes significant. This result show the importance
of specific interactions between the cosolvents and the solute in comparison with
density effect (Sauceau et al. [2004]).
With respect to the other manifestation of the cosolvent effect, it was observed
that the partition coefficient of the cosolvent between the SCF and the polymer
phase decreases rapidly with an increase in SCF density near critical region and
flattens at higher density in the supercritical region (the density effect). This
may be due to increased solvent power of SCF and consequntly an increase of
cosolvent solubility in SCF at first, followed by weakening of interaction between
the cosolvent and the polymer due to higher polymer swelling. Such intermolecular
interactions are very important in the partitioning process. The preponderance of
the two effects can vary according to the system. Although, the bulk concentration
of cosolvent (and consequently cosolvent-solute interactions) increases at higher
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pressure, cosolvent interactions with the polymer (and consequently partitioning)
decreases due to higher polymer swelling (Sauceau et al. [2004]).
In conclusion, careful selection of cosolvents could improve SCF processing,
particularly for solutes with extremely limited solubility in pure SCF. As discussed
above, it is expected that a multicomponent SCF mixture can be highly selective
for particular solutes due to specific interactions.
1.4.4 Drug release from SCF impregnated matrices
The good performance of a CDDS is dependent on drug distribution in the
matrix as well as on the physical state of the drug. In general, crystallization of
drugs in a polymer matrix can result in unpredictable dissolution rates (Lo´pez-
Periago et al. [2009]). With SSI it is possible to obtain amorphous drug dispersions
even at relatively high loadings, due to the poor solvent properties of SCF for
most drugs and the high drug partition in the polymer phase. With traditional
methods, crystallization of the drug can occur in the solvent-rich areas (that are
good solvents for the drug) of the polymer matrix during the solvent evaporation
process (Wang et al. [2002]).
One problem with SSI is the surface precipitation of the drug that results
from the characteristics of the impregnation process. During the depressurization
procedure, the drug dissolved in the SCF will precipitate from the solution on the
polymer surface. The depressurization stage is of critical importance with respect to
this issue. If the depressurization is fast, then the polymer will be very porous and
will result in a heterogeneous drug distribution, with higher concentrations close
to the surface, resulting in burst effect. If the depressurization is slow, the initial
polymer morphology will be preserved and present homogeneous drug distribution
(Guney and Akgerman [2002]).
The release profiles typically present a biphasic release pattern: a diffusional
period of rapid release of drug precipitated on the surface of the polymer rather than
being impregnated within the polymer matrix (usually within the first day), followed
by a swelling/diffusional phase of linear release of the drug that has been impreg-
nated within the polymer matrix, that occurs before the dissolution/degradation
of the polymers, if biodegradable (Braga et al. [2008], Natu et al. [2008]).
The pharmacological activity of a drug can be determined by the release kinetics
in terms of released drug mass and release drug rate. Several phenomena that can
influence SSI (Fig. 1.6) have to be considered when parameters that can control
drug loading and drug release from SCF impregnated matrices are studied:
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• Pressure and temperature
One major advantage of SCF technology is the possibility to adjust solvent
power by simply changing the pressure or temperature of the system. The
solvent power increases with pressure at constant temperature because density
rises with increasing pressure. The intermolecular distance between molecules
decreases and consequently the interaction between the solute and the solvent
increase, leading to higher solubility (Duarte et al. [2004]). Nevertheless,
selecting the best process parameters is not straight forward and an increase
in pressure does not necessarily lead to better impregnation. When drug has
good solubility in SCF and/or low affinity for the polymer, lower pressures
and densities favour impregnation (Duarte et al. [2007]). At higher densities,
the interactions between the solute and the SCF increase and are detrimental
to the interactions between the solute and the polymeric matrix, thus leading
to lower impregnation yields (Braga et al. [2008]).
The effect of the temperature on the solute solubility depends on the pressure
range. Under a certain range of pressure, the solubility decreases when the tem-
perature increases and above a certain pressure, the solubility increases when
the temperature increases (retrosolubility phenomenon) (Belhadj-Ahmed
et al. [2009]). Usually, the higher the temperature, the higher the solute
concentration in the SCF. Additionally, higher temperatures will increase
polymer swelling, creating more free volume within the polymer matrix which
enhances solute diffusion (Bush et al. [2007]).
• Operation type (batch or continuous process), contact time and SCF flow
rate
The SSI can be carried out either in batch or continuous mode. The de-
termination of the best operating conditions requires a knowledge of phase
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equilibria and drug solubility in a SCF (Duarte et al. [2004]). When selecting
a contact time in the batch mode, one has to consider the equilibrium solute
solubility in SCF at the process pressure and temperature. In a continuous
operation, the flow rate of SCF has to be carefully selected so that it ensures
good mass transfer and allows the solute concentration in the fluid phase
approach the equilibrium value, otherwise it will lead to poorer impregnation
than in batch mode Duarte et al. [2007]. In dynamic mode, the solute concen-
tration in SCF phase can be significantly lower than the solute solubility (in
static mode), when the equilibrium is not reached for the operating conditions
(Belhadj-Ahmed et al. [2009]).
Usually, an increase in contact time will produce a better impregnation
yield due to increased solute concentration and enhanced polymer swelling,
allowing increased diffusion of drug into the polymer and ensuring solute
impregnation in the polymer bulk. Nevertheless, a higher contact time can
lead to heterogeneous drug distribution and solute crystallization on polymer
surface (Wang et al. [2002]). Concerning the effect of flow rate, the solute
concentration increases when the flow rate increases. For a range of flow rate,
the solute concentration will stabilize and above a certain value (threshold)
of flow rate it will decrease. After the threshold value of flow rate, the higher
the flow rate, the smaller the dissolved amount of solute in SCF due to an
increase of the dilution effect (Belhadj-Ahmed et al. [2009]).
• Sample geometry and dimensions
The geometry and the dimensions of the samples used in SSI process can
have a significant effect on the amount of the impregnated drug and the drug
distribution. Under similar experimental conditions, impregnation was more
efficient for polymer beads than for polymer rods. The effect of dimensions was
demonstrated by the rod samples where drug loading decreased significantly
with increasing rod diameter. The cross-section analysis of the rods indicated
that polymer swelling was not complete during the selected processing time
for the rods with higher diameter. Moreover, the rods presented gradient
drug deposition, with higher amounts of drug at the surface that subsequently
caused burst release (Argemı´ et al. [2008]). This suggests that SCF diffusion
in the polymer is of extreme importance for the success of the impregnation.
When selecting a sample geometry, one has to consider the SCF sorption
and diffusion kinetics in the polymer and allow sufficient contact time for
the impregnation of bigger/thicker samples (Duarte et al. [2006]). If shorter
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processing times are desired, then smaller/thinner samples, such as films,
should be used.
• Polymer swelling
The chemistry of the polymer is very important in SSI because it will determine
SCF sorption and diffusion in the polymer, as already mentioned. For the
preparation of CCDS, polymer-SCF interactions are extremely important for
the diffusion of drugs inside the polymer matrix. If the polymer does not
interact with the SCF, then there is no possibility to load the drug in the
polymeric matrix. As such, a polymer that contains certain functional groups
(like carbonyl) will interact with the SCF and swell, allowing more drug to
diffuse inside the polymer and higher amounts of drug to be impregnated
(Braga et al. [2008]).
Amorphous polymers are easily processed with SCF, while crystalline polymers
are not, since the SCF sorption occurs mainly in the amorphous regions. This
allows easy drug impregnation in the core and throughout the amorphous
polymer. For semi-crystalline polymers, the induced crystallization in the
amorphous fractions prevents the dispersion of the drug in the matrix, leading
to heterogeneous drug loading, mainly at the surface Lo´pez-Periago et al.
[2008]. A heterogeneous medium might be responsible for heterogeneous
impregnation of glassy polymers, where glassy and rubbery parts coexist
within the polymer, each inducing different uptakes of solute. This effect is
more significant at shorter processing times (Diankov et al. [2007]), that does
not allow complete SCF diffusion in the polymer. Moreover, the presence
of the drug in polymeric matrix might accelerate the SCF diffusion-front
propagation (Uzer et al. [2006]).
Sorption diffusion coefficients are relatively insensitive to pressure or tempera-
ture. The desorption diffusion coefficients (determined at ambient conditions)
are higher than sorption diffusion coefficients. The plasticizing effect of the
SCF might be responsible for this result. Even though sorption takes place
under supercritical conditions and desorption proceeds at ambient conditions,
the release of carbon dioxide from the polymeric matrix during desorption is
faster, due to the higher chain mobility of the plasticized polymer (Duarte
et al. [2006]). This might be particularly useful to consider when select-
ing a depressurization rate in order to ensure maximum drug loading and
homogeneous deposition.
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• Drug solubility in SCF (or SCF and cosolvent) and drug concentration
Solutes with good solubility in SCF will be easily impregnated in a polymer,
although with a heterogeneous distribution (Kikic and Vecchione [2003]). The
solute loading depends on the solute concentration in the fluid phase: there
is an increase in the amount of impregnated drug with an increase in solute
concentration (that ranged from 10 to 100% of the solubility value). It was
suggested that, rather than adsorption, partition of the solute between the
fluid phase and the swelled polymer network could explain the behaviour
(Diankov et al. [2007]).
As already discussed, a cosolvent can enhance the solute solubility in SCF by
several orders of magnitude due to the interaction with the solute molecules.
Moreover, the cosolvent can also modify the interactions between the high
pressure phase (that contains the drug) and the polymeric matrix, by im-
proving the compatibility, swelling and plasticizing power of this phase with
the polymer (Braga et al. [2008]).
• Drug chemistry (drug solubility, compatibility in polymer)
Drug chemistry will determine drug-polymer interactions and allow the
impregnation of drugs that have low solubility in SCF, but high affinity for
the polymer. Thus, smaller amounts of drug (with high partition in polymer)
are required to achieve similar loadings with traditional methods, even if SCF
is a poorer solvent for the drug than organic solvents. Usually, there is an
increase in drug loading with an increase of drug solubility in polymer (which
estimates drug-polymer compatibility) (Liu et al. [2005]). Such interactions
allow the incorporation of drug in amorphous form because they prevent
drug self-association and crystallization even at higher loadings (Lo´pez-
Periago et al. [2009]). The affinity based method of CDDS preparation is
especially suitable for molecular dispersions of drugs with low water solubility,
since dissolution is improved for drugs in amorphous state (Kazarian and
Martirosyan [2002]). When drug is not compatible with the polymer, SSI will
lead to drug crystallization on polymer surface even if care is taken against
drug precipitation during depressurization (Wang et al. [2002]).
1.4.5 Concluding remarks
SCF technology can be used for loading of drugs in polymers. The most
attractive aspects of this technology are the easy manipulation of several parameters
(such as pressure, temperature, cosolvent choice) in order to control drug loading,
34 CHAPTER 1. INTRODUCTION
drug distribution and polymeric material properties (such as morphology and
crystallinity), with great effect on the performance of the CDDS. SSI is particularly
useful for the production of drug-eluting implants because in only one step both
drug loading and a foam-like polymer structure is achieved. This very porous
morphology allows further processing (by cold compression, for example) of the
drug loaded matrix in order to obtain implants with various dimensions and shapes.
1.5 Electrospun fibers as controlled drug deliv-
ery systems
This section was published as a book chapter in Active Implants and Scaffolds
for Tissue Regeneration, part of the series Studies of Mechanobiology, Tissue
Engineering and Biomaterials (Springer).
Electrospinning is a method of producing fibers with diameters ranging from
micrometer to nanometer scale by accelerating a jet of charged polymer solu-
tion/melt in an electric field. Recently, this technology has been expanding due to
the simplicity of the process and the various materials that can be used. Fibers
can be produced from either natural or synthetic polymers. Such fibers have
diverse applications including filtration, catalysis, textiles, composite materials,
biomedicine (wound dressings, drug delivery, tissue engineering, cosmetics), sensors,
electronic devices, liquid crystals, photovoltaic cells and much more (Fridrikh et al.
[2003], Huang et al. [2003]).
Usually, the experimental set-up consists of a high voltage power supply con-
necting an electrode with needle-like geometry (through which the polymer solution
is ejected) to the collector electrode. The polymer solution is pumped at the
desired flow rate using a syringe pump. A diagram presenting the most common
electrospinning set-up is shown in Fig. 1.7.
Recent works suggest that the most important mechanism of electrospinning is
a rapidly whipping/bending fluid jet (Hohman et al. [2001]). The jet instability
is produced by the competition between surface tension and charge repulsion, in
which the destabilizing effect of charge repulsion is responsible for the stretching of
the fluid jet and simultaneous decrease in the jet diameter. Surface tension has
a stabilizing effect leading to the cessation of stretching and attaining a limiting
terminal jet diameter. The process can be decomposed into five components:
fluid charging, formation of the cone-jet, thinning of the steady jet, onset and
growth of jet instabilities and fiber collection (Rutledge and Fridrikh [2007]). Several
process parameters (voltage, nozzle to collector distance, polymer flow rate, spinning
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Figure 1.7: Basic electrospining set-up
environment) and solution parameters (concentration-viscosity, conductivity, surface
tension, solvent volatility) can be manipulated in order to obtain the desired
properties of the fibers such as fiber diameter and morphology. Moreover, the fibers
can be collected with a multitude of collectors producing fiber mats that contain
either aligned or unoriented fibers (McClure et al. [2009]).
Electrospun fibers have been shown to function as drug delivery systems be-
cause of high surface area (which enhances mass transfer), similar topography
and porosity to the extracellular matrix making them ideal candidates as active
implants/scaffolds. The easy control of the macrostructure (oriented or arranged
randomly, fiber mat porosity) and the microstructure (individual fiber porosity) will
determine both the bulk physico-chemical properties and the biological response to
the implant/scaffold. Variuos drugs ranging from low molecular agents to proteins
and even cells (Lo´pez-Rubio et al. [2009]) can be easily encapsulated inside or on
the surface of the fibers depending on the application. Some disadvantages include
drug loading that is limited by the drug solubility in the electrospining solution or
burst effect due to surface deposited drug.
CDDS can be classified according to different criteria (Heller [1996], Cussler
[1997]). The most common one is to classify with respect to the rate control
mechanism. These classifications may also be applied to drug-containing polymeric
fibers:
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• Drug diffusion controlled systems
Diffusion can take place either through the bulk polymer as in bicomponent
mixed fibers or through a barrier as in core-shell fibers
• Solvent diffusion controlled systems
Drug release is determined by the rate of polymer swelling
• Chemically controlled systems
Either polymer erosion or enzymatic/hydrolytic polymer degradation control
the drug release rate
• Regulated systems
The application of a magnetic field or another external stimulus can trigger
the release (as in composite fibers containing magnetic particles)
The active ingredient can be loaded either during electrospinning or during
post-processing of the electrospun fibers. In the former case, the drug is either
co-dissolved with the polymers in the electrospinning solution or the drug is loaded
in particles that will be co-electrospun with the polymers (Qi et al. [2006], Liang
et al. [2005], Wang et al. [2010]). The later case includes various modalities of drug
loading: fiber soaking in the drug solution, drug impregnation using supercritical
fluids technology (Ayodeji et al. [2007]), loading in previously molecular imprinted
fibers (Chronakis et al. [2006b,a]), functionalization of the fiber surface through
grafting copolymerization (Ma et al. [2006]) and subsequent drug/protein binding
(Casper et al. [2007, 2005]).
By electrospinning, the drug is usually entrapped as solid particles inside or
on the surface of the fibers. According to the type of solid-solid or polymer-drug
mixture, the drug loaded fibers can be classified as:
• Solid solutions
The drug is dissolved at molecular level in the polymer
• Solid dispersions
The drug is distributed in the polymer as either crystalline or amorphous
aggregates
• Phase-separated systems or reservoir systems
The drug is contained inside the core of the fiber or encapsulated in particles,
that are surrounded by a polymer shell (as in core-shell constructs or composite
fibers, see section 1.5.1)
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Figure 1.8: Preparation methods for multicomponent fibers
1.5.1 Multicomponent fibers
Multicomponent fibers have attracted special attention because new proper-
ties can be obtained through the combination of different materials. Synthetic
polymers with good processability and good mechanical properties can be mixed
with natural hydrophilic polymers producing an increase in cellular attachment
and biocompatibility (McClure et al. [2009]). Unfortunately, sometimes the solvent
that is used to dissolve both polymers can damage the structure of the natural
polymer or phase separation can worsen the mechanical properties. One possible
solution is to incorporate function-regulating biomolecules in synthetic polymers to
increase bioactivity (Casper et al. [2005]) or to modify the structure of the polymer
before electrospinning (Skotak et al. [2008]).
Multicomponent fibers can be obtained mainly by two techniques (Sawicka
and Gouma [2006], Liang et al. [2007]) as shown in Fig. 1.8: electrospinning of
polymers solution in a single-needle configuration (if a mixture of polymers is
co-dissolved in the electrospinning solution) or a multi-needle configuration (in
which the polymer solutions are separated in parallel or concentric syringes) and
post-treatment of the electrospun fibers (which can include either coating with
other inorganic/polymer layers (Casper et al. [2007], Lee et al. [2009]), grafting
(Ma et al. [2006]), crosslinking (Lee et al. [2007]), chemical vapour deposition (Zeng
et al. [2005a]) or functionalization with other (bio)polymers (Casper et al. [2005]).
In addition to the combination of physico-chemical properties that arise from
using various components, there can be obtained a variety of fiber morphologies as
presented in Fig. 1.9 such as core-shell fibers, micro/nanotubes, interpenetrating
phase morphologies (matrix dispersed or co-continuous fibers) Bogntizki et al. [2001],
Wei et al. [2006], nanoscale morphologies (spheres, rods, micelles, lamellae, vesicle
tubules, and cylinders) obtained by self-assembly of block copolymers (Kalra et al.
[2006]), multilayers (either with different composition or different fiber diameter)
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Figure 1.9: Various fiber constructs types
(Vaz et al. [2005], Pham et al. [2006]). Moreover, the fiber morphology can be
further controlled after electrospinning by selective removal of one component using
thermal treatment or dissolution (Hong et al. [2008], You et al. [2006]).
Many of the fiber constructs are supposed to work as implants/tissue scaffolds
besides functioning as drug delivery devices. Good mechanical properties are
required in order to preserve the structural integrity of the implant. Crosslinking
(Sisson et al. [2009]), thermal interfiber bonding (accomplished near the melting
temperature of the electrospun polymer and impregnated with a hydrogel that
maintains the structure of the scaffold against shrinkage) in order to improve
biomechanical properties (Lee et al. [2008]) or continuous alignment of electrospun
fiber yarn obtained by self-bundling electrospinning and further treated by drawing
and annealing to improve tensile strength (Wang et al. [2008]) are just some of the
available post-processing techniques.
1.5.2 Release control of drug loaded fibers
Fibers can be easily loaded with drug in a similar fashion as multicomponent
fibers (section 1.5.1), the drug being an extra component. By blend electrospinnning,
the drug or drug vehicle (such as microspheres (Qi et al. [2006]), nanoparticles
(Liang et al. [2005], Wang et al. [2010])) is mixed or phase-separated with the
polymer phase and by coaxial electrospinnning, the drug is contained either in
the core or in the shell. The advantage of encapsulating the drug in the core or
in a vehicle is that usually burst release is minimized/avoided since the drug has
longer diffusional paths (Wang et al. [2010]) and the protection of active agents
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(such as proteins) that are sensitive to organic solvents can be achieved. Moreover,
it does not require good interaction between the polymer and drug, but it must
show sufficient interfacial compatibility in order to prevent delamination (Tiwari
et al. [2010]). In contrast, for the cases of drugs loaded by blend electrospinning,
poor interaction between the drug and polymer affect the drug distribution in the
polymer matrix and consequently the release behavior (Chew et al. [2005], Zeng
et al. [2005b]). Incorporation of bioactive agents that are usually water soluble and
can not be dissolved in the same solvent as the polymer (usually organic solvents)
can be performed by emulsion electrospining (Chew et al. [2005], Xu et al. [2005]).
Various post-treatment modalities exist in order to further control the fiber
drug release. These can be grouped in two main categories: physical and chemical.
The first category includes functionalization of electrospun fibers with biomolecules
using coating (Casper et al. [2007]), subcritical carbon dioxide impregnation of
electrospun fibers with which it is possible to load drugs and obtain more sustained
release profiles in comparison to loading through soaking in drug solution (Ayodeji
et al. [2007]). The second category consists of coating electrospun fiber by chemical
vapour deposition in order to prolong the release and avoid burst effect (Zeng et al.
[2005a]), molecular imprinting of fibers (either by loading the template molecule
(Chronakis et al. [2006b]) or by loading molecularly imprinted particles (Chronakis
et al. [2006a]) inside the fibers during electrospinning) that can selectively rebind the
target molecule (biological receptor molecule) and produce targeted drug delivery.
Drug delivery systems are intended to deliver well controlled amounts of drug
between the minimum effective level and the toxic level during a predetermined
time interval (Heller [1996]). Control of burst effect is essential either to avoid
toxicity or to ensure immediate action at the targeted location (as in the case of
antibiotics (Kim et al. [2004])). These are the reasons why the factors that affect
the release rate should be considered when designing a new fiber drug delivery
system:
• Fiber construct geometry (fiber mats or multilayers) and thickness
The drug deposited in single layers is released faster than from multilayers
either because the drug layers are intercalated with non-drug layers that
function as barrier to drug release (Okuda et al. [2010]) or because the inner
layers are not equally exposed to the release medium (Ranganath and Wang
[2008])
• Fiber diameter and porosity
A thinner or more porous fiber implies a bigger surface and consequently
accelerates the release (Cui et al. [2006]). However, thicker, but more porous
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fibers release drug faster than thinner, less porous fibers (Buschle-Diller et al.
[2007])
• Fiber composition
The choice of a degradable polymer will allow release control through a
hydrolytic (Ranganath and Wang [2008]) or enzymatic mechanism (Zeng
et al. [2005b]). Besides, blending various components leads to modulating
release capacity (Buschle-Diller et al. [2007]) either by improving fiber wetting
properties (using hydrophilic polymers (Nie et al. [2008], Maretschek et al.
[2008])) or aiding incorporation of drug. In this case, it is possible to avoid
burst effect by blending polymers with amphiphilic copolymers which can be
compatible with both the drug and the initial incompatible polymer (Kim
et al. [2004])
• Fiber crystallinity
Initial polymer crystallinity influences the drug release (it blocks the release
of the drug from the crystalline domains due to limited water uptake). When
the release of drug from the amorphous domains or from the fiber surface
is finished, no more drug is released (Kenawy et al. [2002]). Moreover,
there is an increase in crystallinity during drug release (the drug works as
a plasticizer, the polymer chains gain more mobilility and as it is leached
out, they crystallize), which decreases the release of residual drug (Xu et al.
[2006])
• Fiber mat swelling
Water uptake by fibers or by the (macro)pores created between fibers will
speed up drug release (Buschle-Diller and Xie [2009]) as the dissolution of
drug molecules is the initial step in the release process (Chien [1992])
• Drug loading
Higher loadings will produce faster release (Cui et al. [2006], Xu et al. [2006],
Buschle-Diller and Xie [2009], Luong-Van et al. [2006], Zamani et al. [2010]);
on one hand, at high loadings, there is more surface segregated drug that
dissolves fast and on the other hand, there is an increase in porosity during
drug elution proportional to the initial amount of drug (Xu et al. [2006], Cui
et al. [2006])
• Drug state
In general, drug release was shown to be more sustained, when drug is
incorporated in amorphous state (Zamani et al. [2010], Xie and Wang [2006]),
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than when drug is loaded in crystalline state Thakur et al. [2008]. Moreover,
it was shown that, even when the drug is in amorphous state, the drug release
was faster from the solid solution than from the amorphous dispersion (Yu
et al. [2009])
• Drug molecular weight
Drugs with smaller volumes will be released faster since they diffuse faster
through the aqueous pores created by the water uptake in the fiber (Buschle-
Diller et al. [2007], Taepaiboon et al. [2006])
• Drug solubility in the release medium
Usually, the higher drug solubility, the faster the release (Buschle-Diller et al.
[2007])
• Drug-polymer-solvent interaction
Solubility and compatibility of drugs with the polymer and/or the electrospin-
ning solvent is essential since it ensures proper drug incorporation inside the
fibers and not on the fiber surface (Chew et al. [2005], Buschle-Diller and Xie
[2009], Zeng et al. [2005b]). Phase separation between the drug and polymer
will produce amorphous or crystalline drug at the fiber surface leading to
faster release (Verreck et al. [2003b]). Moreover, the interaction between
drug and the polymer can block the crystallization of the drug in the fibers,
if so desired (Yu et al. [2009]) and can even determine sustained release of
drugs that are present in crystalline state because of hydrogen bonding to
the polymer (Taepaiboon et al. [2006])
However, in order to predict the outcome of a drug from fibers, it is important
to consider the interaction among the various factors in such a complex system.
We have already discussed how the drug state controls drug release. However,
sometimes high drug loadings are needed for long term applications. Usually, at
high loads, the drug will crystallize and/or phase-separate from the polymer and
form conglomerates that will produce a heterogeneous distribution of the drug inside
the fibers (Chew et al. [2005], Huang et al. [2006]) or deposition on the fiber surface
(Verreck et al. [2003b]). Thus, in long term release applications where high amounts
of loaded drug are required, a compromise must be found between loading and
release rate that change in contrary directions. Careful consideration should also
be paid when selecting best pair of polymer and drug, although some applications
require material properties that may not match in terms of compatibility the drugs
used in the treatment of the targeted diseases.
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1.5.3 Release modeling in fiber CDDS
As summarized in Table 1.2, a multitude of drug/biomolecules loaded fibers
have already been produced. They have been produced either from polymers
(synthetic and natural) or inorganic compounds. Most of the release mechanisms
were attributed to drug diffusion (as it is the case for most non-biodegradable,
non-erodible polymers), solvent diffusion (as in the case of natural polymers that
are usually hydrophilic (Sikareepaisan et al. [2008])), polymer erosion (as in the
case of erodible (bio)polymers (Yu et al. [2009], Taepaiboon et al. [2006])), polymer
degradation (as for hydrolytic or enzymatic degradable polymers) or external
triggers (like a magnetic field). In the release system governed by drug diffusion,
one has to consider two cases, one in which the diffusion takes place through the
bulk of polymer (bulk diffusion) or through a membrane/layer (barrier diffusion,
similar to the reservoir devices as in the case of core-shell fibers, composite fibers
or multilayered constructs). There are cases in which several mass transport
mechanisms superpose. However, in most cases, there is only one that is the
“rate-limiting” step. For example, in the case in which diffusion is coupled with
chemical reaction (in most cases, hydrolysis), if diffusion is faster than the chemical
reaction, then mass transfer is controlled by the polymer degradation (Tzafriri
[2000]) and when diffusion is not much faster than reaction, then diffusion and
degradation superpose (Ranganath and Wang [2008]). In some systems, the release
process is composed of sequential stages, with each stage being controlled by a
different phenomenon. For example, in the first stage you can have the drug release
controlled by the polymer erosion and subsequent diffusion, followed by polymer
degradation control stage (Kim et al. [2007]).
Related to core-shell fibers, we can consider two controlling phenomena: diffusion
through the polymer shell (barrier diffusion) or partition of the drug from the core to
the shell. The diffusion through the shell polymer should not be too slow, otherwise
this diffusion will be rate-limiting step. In this instance, the system behaves as
monolith fibers and not core-shell fibers (reservoir system). Shell porosity must
also be carefully controlled since the drug from the core will be released through
water-filled channels rather than through the barrier/shell polymer (Tiwari et al.
[2010]). Composite fibers that contain drug vehicles such as microspheres and
nanoparticles (see section 1.5.2) are also a type of reservoir system (double barrier
system) in which the drug molecules have to diffuse through longer pathways: the
polymer comprising the vehicle and the “shell” polymer (Wang et al. [2010]).
Drug diffusion (more precisely solid state diffusion) was mentioned earlier as
one of the most common mechanisms of drug release. There are models that
consider diffusion of solutes in polymers insignificant in comparison with diffusion
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in water-filled spaces in between polymer chains, so they assume that water uptake
and subsequent solubilization of the drug is an important step in the release process
and it is the solvated molecule that is actually diffusing (Perale et al. [2009]). This
is the assumption behind biphasic diffusion that includes an initial diffusion phase
through the polymer (either amorphous or semi-crystalline) and a second diffusion
phase through water-filled pores formed in the fiber due to polymer swelling/chain
rearrangement or polymer recrystallization (Verreck et al. [2003b], Zong et al.
[2003]).
The power law equation, which was developed considering that the main
mechanism for drug release is drug diffusion through the polymer or solvent
diffusion inside the polymer that produces polymer relaxation/chain rearrangement
(Eq.1.1) is the most widely used equation in works concerning drug release:
mt
mtot
= a0 + k t
n (1.1)
where mt/mtot is the fractional release of the drug at time t, a0 is a constant,
representing the percentage of burst release, k is the kinetic constant and n is the
release exponent, indicating the mechanism of drug release (which can either be
Fickian drug diffusion or polymer relaxation and an intermediate case combining
the two (Peppas and Brannon-Peppas [1994])).
Other models consider different phenomena that control the release such as
desorption due to the fact that under the assumption of diffusion control, 100 %
release of the drug is expected, but this was not verified experimentally. In the
desorption model, the release is not controlled by diffusion, but by the desorption
of the drug from fiber pores or from the fiber surface. Thus, only the drug on the
fiber and pore surfaces can be released, whereas the drug from the bulk can only
be released when the polymer starts to degrade. These assumptions are similar to
the theory of mobile agent, that can be released by diffusion and the immobilized
agent, that can be released through degradation (Tzafriri [2000]).
The Eq.1.2 is based on a pore model, in which the effective drug diffusion
coefficient, Deff is considered and not the actual diffusion coefficient in water, D
(with Deff/D  1) because desorption from the pore is the rate limiting step and
not drug diffusion in water, which is relatively fast.
mt
mtot
= α
[
1− exp
(
− pi
2
8
t
τr
)]
(1.2)
where the porosity factor α = ms0/(ms0 +mb0) < 1, with ms0 and mb0 being the
initial amount of drug at the fiber surface and the initial amount of drug in the
fiber bulk, respectively; mt is the drug amount released at time t, while the total
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Figure 1.10: Types of release kinetics
initial amount of drug in the fiber is mtot = ms0 +mb0 and τr is the characteristic
time of the release process (Srikar et al. [2008]).
Various release kinetics exist and the most desirable one is the zero-order kinetics
in which the drug is released at constant rate, independent of time (see Fig. 1.10).
Usually, zero-order kinetics is achieved for reservoir systems such as core-shell
fibers or composite fibers in which the drug is properly encapsulated in the core
of the fiber or in other vehicles (micro/nanoparticles). Burst stage in this kind
of system is diminished (or non-existent) because there is no drug deposited on
the surface of the fibers. As the controlling release phenomena is drug partition
from one phase to another and not diffusion, there is no decrease in release rate
over time as expected in a diffusion-controlled system (the release rate depends on
the concentration gradient and on the length of diffusion path; as release proceeds,
the concentration gradient decreases and the diffusion length increases and both
contribute to slowing down the release rate).
Other strategies to attain zero-order release include polymer degradation con-
trolled release (either accompanied by erosion or not) because then drug is released
due to polymer chain cleavage (Zeng et al. [2005b], Ranganath and Wang [2008]).
The drug is released either because the diffusion paths are shortened as degradation
takes place (surface degradation) or because porosity is increased due to the leach-
ing of degradation products (bulk degradation) (Heller [1996]). Another strategy
to obtain constant release rate is the use of multilayered constructs (Okuda et al.
[2010]), in which sequential electrospinning is used to obtain drug loaded layers
surrounded by barrier layers.
Burst effect can be determined by fiber porosity (Tiwari et al. [2010]), poor
drug solublity in electrospinning solvent (Buschle-Diller and Xie [2009]), poor
drug solubility in polymer (Zeng et al. [2005b]), high drug solubility in release
medium (Buschle-Diller et al. [2007]), heterogeneous drug distribution (Chew et al.
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[2005]) or surface segregated drug (Kenawy et al. [2002]). Most of the times, the
polymer and drug selection depend on the properties of the implantation site that
need to be matched by the fiber mat and the targeted disease. Thus, the burst
stage can only be controlled in unicomponent/monolith fibers by manipulating the
process parameters and not by the material choice. Ensuring a homogeneous drug
distribution (Luong-Van et al. [2006]) (usually by encapsulating drug in amorphous
state (Zamani et al. [2010], Xu et al. [2006])), low drug loadings (Zamani et al.
[2010]), or coating the drug loaded fibers (Casper et al. [2007]) are some simple
techniques to diminish burst if so desired.
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1.5.4 Concluding remarks
Electrospinning is a simple and versatile method to produce fibers using charged
polymer solutions. As CDDS, electrospun fibers are an excellent choice because
of easy drug entrapment, high surface area, morphology control and biomimetic
characteristics. Various drugs and biomolecules can be easily encapsulated inside
or on fiber surface either during electrospinning or through post-processing of
the fibers. Multicomponent fibers have attracted special attention because new
properties and morphologies can be easily obtained through the combination of
different polymers. Several factors that affect the drug release such as construct
geometry and thickness, diameter and porosity, composition, crystallinity, swelling
capacity, drug loading, drug state, drug molecular weight, drug solubility in the
release medium, drug-polymer-electrospinning solvent interactions can be easily
manipulated in order to prepare a CDDS with the desired properties. For ocular
delivery, a fiber CDDS provides higher structural flexibility, more suitable for
use in a soft tissue environment, such as the ocular structures. Moreover, faster
integration at the implantation site (as evidenced by thin fibrous capsule formation
(Kashanian et al. [2010]) is expected due to the biomimetic features.
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Chapter 2
Supercritical solvent
impregnation of polymer matrices
for controlled release applications
The text that comprises this Chapter was published in the journal The Journal
of Supercritical Fluids (2008), volume 47, pages 93–102.
Abstract
Poly(ε-caprolactone) blends were successfully impregnated with timolol maleate,
an anti-glaucoma drug, using a supercritical solvent impregnation (SSI) tech-
nique. Supercritical fluid impregnation efficiency results suggested that the best
impregnating conditions were obtained when a cosolvent was used and when specific
drug-polymer interactions occurred as a consequence of different chemical structures
due to polymer blending. Pressure can be either a favourable factor, when there is
enough drug affinity for the polymers, or an unfavourable factor when weaker bond-
ing is involved. In order to determine the relative hydrophilicity/hydrophobicity
of the blends, contact angle analysis was performed, while crystallinity determi-
nation was also useful to understand the obtained release profiles. Drug loading,
heterogeneous/homogeneous dispersion of drug inside the matrix, hydrophilicity,
crystallinity, all seem to influence the obtained drug release rates. The “in vitro”
release results suggested that a sustained drug release rate can be obtained by
changing the SSI operational conditions and by modulating the composition of
blends, as a mean to control crystallinity, hydrophilicity and drug affinity for the
polymer matrix. After a first day burst release, all samples showed a sustained
release profile (1.2-4 µg/ml/day, corresponding to a mass of 3-10 µg/day) which
is between the therapeutic and toxic levels of timolol maleate, during a period
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of 1 month. These drug-loaded polymeric matrices can be a feasible alternative
treatment modality for the conventional repeated daily administration of eye drops.
2.1 Introduction
The two main causes of blindness in adult population are age related macular
degeneration and primary open angle glaucoma, two diseases that affect the pos-
terior segment of the eye (Kocur and Resnikoff [2002]). Glaucoma is frequently
asymptomatic at the time of diagnosis, but it can result in progressive visual
field loss and and, in extreme cases, eventual blindness. Timolol maleate (a beta
blocker) is considered as the “golden standard” against which other glaucoma
medications are compared in terms of efficacy, side effects and cost. Although
topically administered timolol maleate is frequently recommended as first-line
therapy, some systemic side effects of this drug may limit its use. For example,
timolol maleate and other topically applied beta blockers have been associated to
asthma exacerbation, worsening congestive heart failure, heart block and, rarely,
to sudden death (Lewis et al. [1999]).
Low drug bioavailability and systemic toxicity are usually caused by the relative
impermeability of the cornea, by tear dynamics and blinking and by nasolacrimal
drug drainage. In the case of eye drops medications, only around 5 % of the
applied drug actually penetrates through cornea (Urtti [2006]). The drug that is
not absorbed by the cornea will reach the bloodstream through the nasolacrimal
duct causing some of the above mentioned systemic side effects. To avoid low drug
bioavailability, topical eye formulations normally require high drug concentrations
and frequent dosing treatments which also may increase systemic side effects risks.
To overcome these issues, several efforts have been made in order to improve the
ocular delivery and bioavailability of topically applied ocular drugs and to reduce
their adverse effects. The most common approach is by developing ophthalmic
polymeric-based controlled drug delivery systems (CDDS) such as bioadhesives
and in situ forming hydrogels, colloidal systems, ocular inserts and implantable
devices (Ding [1998], Bourlais et al. [1998], Ludwig [2005], Bourges et al. [2006],
Yasukawa et al. [2004]).
Polymeric-based CDDS can be prepared in numerous different ways. Dispersing
a drug, or therapeutic agent, in biocompatible and/or biodegradable polymeric
matrices encompasses the majority of all research in this field and there are
several well-known methods to incorporate and disperse drugs into polymeric
matrices. However and in most cases, these conventional methods present several
disadvantages, like the potential use of toxic organic solvents (specially for water
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insoluble drugs), drug/solvent dissolution and compatibility issues, undesired drug
reactions, drug photochemical and thermal degradation, low incorporation yields
and heterogeneous drug dispersion.
Drugs may also be impregnated and dispersed in polymeric matrices by dissolv-
ing them in compressed high volatile fluids (like carbon dioxide) at temperatures
and pressures near or above their critical temperatures and pressures, and con-
tacting the resulting mixture with the polymeric matrices to be infused. In these
conditions, the compressed fluid can act also as a swelling and plasticizer agent for
polymers, dilating the matrices and helping drug diffusion into them. This recent
technique, known as Supercritical Solvent Impregnation (SSI), already proved its
advantages for the development of drug impregnated polymeric materials which can
be used as CDDS for many biomedical applications (Kikic and Vecchione [2003],
Subramaniam et al. [1997], Braga et al. [2008], Kazarian [2000]).
SSI allows the drug impregnation of most polymeric articles and, when prop-
erly employed, without altering and/or damaging their physical, chemical, and
mechanical properties and without degrading their constituent drugs, additives
and polymers. Furthermore, drug loading and depth penetration can be easily
controlled and drugs will be homogeneously dispersed, in short treatment times and
leaving no harmful solvent residues. Finally, SSI also permits to have previously
prepared polymeric articles and, later, impregnate them with the desired drugs,
according to the specific needs of the envisaged therapeutic application, and without
interfering with the established conventional method/procedure to produce/process
the original polymeric articles. This particular feature can lead to very attractive
and useful medical and commercial applications (de Sousa et al. [2006a,b]).
Although carbon dioxide is the most frequently employed supercritical fluid
(SCF), it also presents several limitations mainly due to its inability to dissolve high
molecular weight compounds and to its non-polarity and lack of several specific
solvent-solute and solvent-polymer interactions that would lead to high polymeric
drug loading. A frequent strategy to increase drug solubility in supercritical carbon
dioxide (scCO2) is the addition of small amounts of specific cosolvents which can
produce dramatic effects on its solvent power, sometimes up to several hundred
percent in terms of solubility enhancement (Knox [2005], Duarte et al. [2005]).
Our long-term goal is to prepare an implantable (subconjunctival) system for
sustained drug delivery, with controlled release and degradation that could deliver
timolol maleate for up to 4-6 months, in an attempt to overcome the problems
of low drug bioavailability and the potential occurrence of systemic toxicity. The
system would deliver only the therapeutic drug amount (Ahmed and Patton [1985])
and would eliminate the problem of frequent administration (timolol eye drops are
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applied twice daily), improving patient compliance.
For the present study, poly(ε-caprolactone) (PCL) was selected as the main
blend homopolymer for the preparation of the biodegradable CDDS due to its
good biocompatibility (Serrano et al. [2004], Tan and Teoh [2007], Pena et al.
[2006]) and its known swelling ability in scCO2 (Leeke et al. [2006]). Poly(ethylene-
co-vinyl acetate) and poly(oxyethylene-b-oxypropylene) are copolymers which
have numerous applications and recognised applications in the development of
CDDSs mainly because of biocompatibility, processability (e.g. extrusion) and
proved long-term release properties (Kumar et al. [2001], Scherlund et al. [2000],
Chutimaworapan et al. [2000], van Laarhoven et al. [2002], Costantini et al. [2004]).
The aim of this work is to evaluate the effects of operational pressure, of blend
chemical nature and composition, as well as of cosolvent effects, on the supercritical
solvent impregnation process of different poly(ε-caprolactone) blends, in order to
determine the best operating conditions to achieve maximum drug loading and
optimal drug release profiles.
2.2 Experimental section
2.2.1 Materials
Timolol maleate, (99,6 % purity) was purchased from Cambrex Profarmaco Cork
Ltd., Ireland. Poly(ε-caprolactone) pellets (PCL, average Mw 65000 g/mol) were
obtained from Sigma-Aldrich. Poly(ethylene-co-vinyl acetate), Luwax EVA 3 (Lw,
13-15 % vinylacetate content) and poly(oxyethylene-b-oxypropylene-b-oxyethylene),
Lutrol F 127 (Lu, 9000-14000 g/mol, 70 % by weight of polyoxyethylene) were
bought from BASF. It was not possible to obtain (from supplier) the average
molecular weight of Luwax EVA 3. The chemical formulae of the employed
copolymers are shown in Fig. 2.1. Tetrahydrofurane (THF, HPLC grade) was
obtained from Sigma-Aldrich. Phosphate buffer saline (PBS) tablets (pH 7.4, 10
mM phosphate, 137 mM sodium, 2.7 mM potassium) were used to prepare the
drug release medium and were bought from Sigma-Aldrich. Carbon dioxide (99.998
% purity) was obtained from Praxair. All products were used without further
purification.
2.2.2 Blends preparation
Several PCL-based blends were prepared by solvent casting and according to
the procedure described below. The blends (Lutrol F 127/PCL: 25/75, 50/50 and
Luwax EVA 3/PCL: 25/75, 50/50, 75/25, % w/w) were prepared by dissolution in
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Figure 2.1: Chemical structures of the employed polymers and copolymers
THF (10 % w/v total polymer solutions) at 40 ◦C and 60 ◦C, respectively. Blends
films were obtained by solvent casting at room temperature in glass Petri dishes.
Then, the films were vacuum-dried at 37 ◦C, for 24 h, to ensure the complete
removal of the solvent. After drying, the films were removed from the Petri dishes
and cut in rectangular pieces of approximately 0.5 cm×0.5 cm and used as such
subsequent impregnation and characterization experiments.
2.2.3 Supercritical fluid impregnation process
The supercritical impregnation equipment is schematically presented in Fig. 2.2.
The equipment consists of a cylindrical high-pressure stainless steel cell (21.57 cm3)
placed in a water bath that maintains the temperature within ± 1 ◦C. The water
bath temperature was measured by means of a thermocouple. A magnetic stirring
plate (750-800 rpm) was used to homogenise cell-containing high pressure mixtures
(CO2, timolol maleate and cosolvent). Carbon dioxide was liquefied through a
cooling unit and compressed to the operating pressure with a high-pressure liquid
pump. A one-way high-pressure valve (3) was introduced in the system. System
pressure was measured with a pressure transducer in-line with the impregnation
cell.
The drug or drug solution (in the cases when cosolvents were used), was loaded
in the bottom of the cell and the polymer films (with masses between 0.01-0.02 g)
were separated in a metallic grid, placed in the centre of the cell. The amount of
drug was established in order to obtain a saturated environment at the operational
conditions. A cosolvent concentration of 10 % (v/v), at NTP conditions, was
used in order to increase drug solubility in scCO2 (Coimbra [2004]). Then, carbon
dioxide was allowed to flow through the cell to remove all the air from the system.
Then, valves 11 and 12 were closed and the cell was loaded with CO2 until the
desired pressure and temperature conditions were attained. After this, valve 6 was
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Figure 2.2: Schematic diagram of the experimental supercritical solvent impregna-
tion apparatus: (1) CO2 reservoir, (2) high-pressure CO2 pump, (3) one-way valve,
(4, 5, 6, 11, 12) valves, (7) water bath heater/controller, (8) high-pressure stainless
steel impregnation cell, (9) digital thermometer, (10) pressure transducer, and (13)
glass trap
closed and the system was maintained static and under constant pressure during
the 2 h of impregnation experiments.
At the end of the impregnation period, the system was depressurized (depressur-
ization rate was 5 bar/min) in order not to alter or damage the polymeric samples.
For this, two consecutive valves (11 and 12) were used in order to have a greater
control over the depressurization rate. Impregnated samples were then recovered
in a dry or soaked state (when cosolvent was used). Wet samples were dried in a
vacuum oven at 37 ◦C for 2 h. Then, sample masses were registered in order to
calculate the impregnation efficiency (Section 2.2.4).
A pressure of 200 bar and a temperature of 40 ◦C were chosen because scCO2
has the highest solubility (3.2 g CO2/g of PCL) in poly(ε-caprolactone) at these
operating conditions (Leeke et al. [2006]). At these conditions, PCL presents a
maximum swelling degree which, supposedly, may help diffusion and increase drug
loading yields. A second operational pressure (110 bar) was chosen in order to
study the possible pressure effects on the resulting polymer blends on which we did
not have any previous data regarding the solubility of scCO2 in these polymeric
matrices. The operational parameters for each of the performed experiments are
summarised in Table 2.1.
2.2.4 Impregnation efficiency
The impregnated timolol maleate mass (md) was determined spectrophotomet-
rically by UV-vis analysis (Jasco V-530 Spectrophotometer), at 299.5 nm, after
dissolving the impregnated blends in tetrahydrofuran. The impregnation yield was
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Exp. P (bar) T (◦C) Time (h) Cosolvent con-
centration (v/v),
NTP
Depressurisation
rate (bar/min)
1 200 40 2 None 5
2 200 40 2 Water(10%) 5
3 200 40 2 Ethanol(10%) 5
4 110 40 2 None 5
5 110 40 2 Water(10%) 5
6 110 40 2 Ethanol(10%) 5
Table 2.1: Employed impregnation experiments operational conditions
calculated using Eq. 2.1. Triplicate assays were performed in order to obtain the
experimental standard deviation.
Impregnation efficiency (g drug/g blend) =
md
mp
(2.1)
In this equation, mp is the polymer mass after the impregnation process. For
each different blend composition, the operating conditions leading to the highest
impregnation were selected and only these impregnated samples were tested for
the in vitro kinetics drug release experiments.
2.2.5 Contact angle measurements
The contact angle formed between a water droplet placed on the surface of a
material and the kinetics of spreading is related to the hydrophilicity/hydrophobicity
of the material. Water contact angles of the prepared polymer blend films were
evaluated by static contact angle measurements using an OCA 20 from Dataphysics.
The tests were performed on the air-facing surfaces of the samples, using water
and employing the sessile drop method. Nine measurements on different sample
points were performed to calculate the mean static contact angle and its standard
deviation.
2.2.6 DSC - Crystallinity determination
Differential scanning calorimetry (DSC) was carried out using a SDT Q 600
calorimeter, from TA Instruments. Films were heated under a nitrogen gas flow
at a heating rate of 10 ◦C/min. DSC results were calibrated using indium as the
calibration standard. The melting temperature of the blends was considered as the
temperature at which the endothermic peak occurred. The fusion enthalpy, for each
blend, was determined integrating the peaks from the melting endotherm using
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TA Analysis software. The relative crystallinity, Xrel of the blends was calculated
using Eq. 2.2 (Kong and Hay [2002, 2003]):
Xrel (%) =
∆Hf
∆Hf,100%
× 100 (2.2)
In Eq. 2.2, ∆Hf is the experimental fusion enthalpy of the blends. The value of
∆Hf,100% was used considering the reported fusion enthalpy of 100 % crystalline
polycaprolactone (Tsuji and Ikada [1998]).
2.2.7 In vitro kinetics of drug release studies
The kinetics of timolol maleate release from the prepared materials was studied
in PBS medium at 37 ◦C. The impregnated blend samples were compressed in a
mould, using a press, into discs of 6 mm diameter and 1 mm thickness. These
discs were weighed and introduced in vials containing 4 ml of PBS and maintained
at 37 ◦C. At scheduled time intervals (every 15 min during the first hour, then
every hour during 6 h, twice a day during 2 days and finally once a day for the
remaining time), half of the the PBS/drug solution was removed from the vial and
a fresh PBS solution of identical volume was added to maintain sink conditions.
The timolol maleate concentration in each of the collected samples was measured at
299.5 nm using a Jasco V-530 Spectrophotometer. The amount of timolol maleate
released at time t (mt), was determined from a pre-determined standard curve
(with an absorption coefficient ε299.5 = 20.97± 1.51 ml/mg cm). The total amount
(mtotal) of impregnated timolol maleate was determined after the release test ended,
by dissolving the blends in THF and adding this residual mass to the accumulated
released mass. The percentage of released drug was calculated using Eq. 2.3.
Calculations of the amount of released drug took into account the drug removal
and the replacement with fresh medium at each sampling point:
Released drug (%) =
mt
mtotal
× 100 (2.3)
In order to study the drug release mechanism, the Korsmeyer-Peppas equation
(Eq. 2.4) was used (Korsmeyer et al. [1983]):
mt
mtotal
= k · tn (2.4)
In this equation, mt/mtotal is the fractional release of the drug, k is the kinetic
constant and n is the release exponent, which gives an indication of drug release type
of mechanism. Following the Korsmeyer-Peppas equation, only the experimental
drug release data that satisfied the relation mt/mtotal ≤ 0.6 were employed for the
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determination of the release exponent. Release exponents, n, were calculated as the
slopes of the straight lines fitted to the release data using a least squares method.
2.3 Results and discussion
2.3.1 Contact angle measurements
Contact angles are characteristic constants of liquid-solid systems and, when
water or aqueous solutions are used as the liquids, may provide valuable information
on the solid surface hydrophilicity or hydrophobicity. This information is of great
importance for the development of polymeric CDDS since water-promoted polymeric
swelling will strongly influence drug diffusion through the polymeric network as
well as polymeric erosion/dissolution and degradation (Heller [1996]). The obtained
water-polymeric blends contact angles are presented in Table 2.2. These results show
that all the prepared blends, as well as the individual polymers and copolymers,
are mainly hydrophilic (contact angles ≤ 90◦). But, and for the investigated
individual samples, we can assume that Lu is the more hydrophilic sample, PCL
has an intermediate hydrophilic character and Lw is the less hydrophilic sample.
Moreover, and as expected, obtained blend contact angles are intermediate values
of the constitutive polymers and copolymers. Thus, as PCL content is increased in
Lu/PCL blends, the resulting blend samples become less hydrophilic. The same
behaviour is observed when Lw content is increased in Lw/PCL blends: contact
angle increased because the overall hydrophobic content of the blend was also
increased. These results were confirmed by water swelling experiments, which will
be reported in due time, together with other blend characterization data. Due to the
specific interactions that may occur between polymers/copolymers, resulting blends
and the involved solvents, these different relative hydrophobicity/hydrophilicity
characters may have a strong influence on the obtained kinetics of drug release
results and on the impregnation efficiency results, as it will be discussed later.
2.3.2 DSC - Crystallinity determination
Polymer and copolymer crystallinity is known to play an important role in
determining degradability, erosion, water and drug permeability because the bulk
crystalline phases that may be present become more inaccessible to water diffusion.
Moreover, scCO2 induced crystallization of polymeric substrates can also influence
the overall supercritical solvent impregnation process as well as the final relative
crystallinity of the processed polymeric materials (Kikic and Vecchione [2003],
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Samples Contact angle (deg)
Lu 48.3 (0.8)
50/50 Lu/PCL 50.1 (1.2)
25/75 Lu/PCL 55.9 (1.3)
PCL 61.8 (1.8)
25/75 Lw/PCL 63.6 (1.0)
50/50 Lw/PCL 66.1 (0.9)
75/25 Lw/PCL 70.9 (1.3)
Lw 72.5 (1.4)
Table 2.2: Obtained contact angle for the employed homo- and copolymers and for
prepared blends
Kazarian [2000], Zhou et al. [2003], Berens et al. [1992], Xu and Chang [2004],
Condo et al. [1996]).
PCL, Lu and Lw are semi-crystalline polymers and copolymers and, in their
blends, the overall final crystallinity degree may be strongly influenced by blend
composition, by the relative crystallinity of each component in the blend and by
the specific interactions that may occur between blend components or between
specific blocks of the involved copolymers in the blend. As shown in Table 2.3, the
relative crystallinity, Xrel (%), calculated using Eq. 2.2 increases with the PCL
ratio in Lw/PCL blends and decreases with the PCL ratio in Lu/PCL blends.
We did not find any previously reported values for the fusion enthalpy of 100%
crystalline Lu and Lw, ∆Hf,100%, and thus it was not possible to calculate the
relative crystallinities for these pure copolymers. However, the measured fusion
enthalpies for both pure Lu and Lw are higher than the corresponding value for
PCL. Usually this is an indication that their relative crystallinity values should
also be higher than the corresponding value for PCL.
Therefore, it should be expected that blends with higher Lu and Lw contents
should also present higher relative crystallinities. This happens for Lu/PCL blends
and this behaviour was already found and discussed in other works involving, for
example, polyethylene oxide/PCL blends (Qiu et al. [2003]).
Despite this rule, some exceptions may occur especially when the
co-crystallization of blend components can take place with some crystallization
restrictions of one component due to the presence of the second one. For example,
in the case of Lw/PCL blends, as the proportion of Lw in the blend is increased,
the expected higher crystallization ability of Lw can be restricted and, as a
consequence, the final relative crystallinity decreases. Furthermore, and again in
the case of Lw/PCL blends, it has been proposed that the carbonyl groups from
polyesters can interact favourably with the α-hydrogens of the poly(vinylacetate)
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Samples ∆ Hf (J/g) Xrel (%)
Lu 109.6 -
50/50 Lu/PCL 85.7 60.4
25/75 Lu/PCL 80.9 57.0
PCL 72.8 51.3
25/75 Lw/PCL 70.4 49.6
50/50 Lw/PCL 62.1 43.7
75/25 Lw/PCL 57.4 40.4
Lw 116.8 -
Table 2.3: Fusion enthalpies and relative crystallinities
(PVAc) block due to their proton accepting and proton donating properties,
respectively. Such favourable interactions between PCL and the PVAc block
can be responsible for the commonly found miscibility of PCL/PVAc blends
(Sivalingam et al. [2004]). It is also accepted that the favourable interactions that
are often established between two constituents in miscible blends can contribute to
slowing down of the formation rate of crystallising species being drawn into (or
diffusing to) the crystals (Ajili and Ebrahimi [2007]). Therefore, these are other
possible explanations of why, in the Lw/PCL series, the addition of Lw causes a
decrease in relative crystallinity in comparison with pure PCL. The obtained
fusion enthalpies of these blends are also smaller than that obtained for PCL alone,
further sustaining these hypotheses.
2.3.3 Supercritical drug impregnation process
The 75/25 Lu/PCL blend was not studied because it was found that it dissolves
in PBS at 37 ◦C, and thus it is not a good material for the intended CDDs
application. The 25/75 Lu/PCL, 50/50 Lu/PCL blends, as well as PCL samples,
were not impregnated using 10% of ethanol as cosolvent because the samples would
dissolve completely at these operational conditions.
It is important to notice that the employed cosolvent compositions are expressed
in terms of volume fractions (v/v) and are referred to NTP conditions. In the case
of ethanol, at the experimental conditions (40 ◦C/110 bar and 40 ◦C/200 bar), these
compositions are slightly different from this value but all ethanol was dissolved
and the experiments were performed employing a homogeneous supercritical fluid
phase mixture (CO2+ethanol). However, in the case of water, and because an
excess of cosolvent was added to the cell, there are always two immiscible phases
inside the cell, with compositions determined by the high pressure vapour-liquid
equilibria of CO2+water mixtures, at those pressure and temperature conditions:
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(a) (b)
Figure 2.3: Cosolvent (water and ethanol) effects on the impregnated samples: (a)
110 bar and (b) 200 bar
a high pressure fluid mixture (CO2+water), in contact with the polymeric samples,
and a high pressure liquid phase (water+CO2), at the bottom of the cell.
In general terms, the obtained results indicate that not just timolol maleate
solubility (which is highly dependent on the presence or absence of the cosolvent)
in scCO2 plays an important role in the overall impregnation process efficiency,
but also all the other specific and complex interactions that may occur between
all the involved components of the system: scCO2-polymeric matrices-cosolvent
interactions (which determine cosolvent and scCO2 solubility in the polymeric
matrix and, consequently, swelling and plasticization effects) and drug-polymeric
matrices-cosolvent interactions (which control the entrapment/deposition of the
drug in the polymeric network).
In Fig. 2.3(a) and Fig. 2.3(b), the effect of cosolvent on impregnation efficiency
is illustrated for both employed impregnation pressures. It is clear that, for the
Lw/PCL blends, the highest impregnation yields (0.018-0.033 g/g) were obtained
when using ethanol (at both operational pressures) while for Lu/PCL blends,
highest impregnation yields (0.012-0.018 g/g) occurred in the presence of water as
cosolvent (also at both employed pressures). For pure PCL samples, best results
(0.009 g/g) were achieved when no cosolvent was used and, as observed, water
addition decreased the amount of impregnated drug. As already referred, ethanol
was not employed with pure PCL.
Therefore, the presence of the cosolvent and its inherent nature radically changed
the impregnation results for these blends: ethanol visibly promoted Lw/PCL blends
impregnation while water promoted Lu/PCL blends impregnation.
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These results can be explained by the favourable specific interactions drug-CO2-
cosolvent that may occur, i.e., by the timolol maleate (a water-soluble polar drug)
solubility enhancement in the high pressure fluid phase, which was caused by the
polarity increase of the mobile phase when the polar cosolvents (ethanol and water)
were added (Li et al. [2003]). As more drug can be dissolved, more drug can be
carried out into the polymeric network by the mobile high pressure phase. In the
case of timolol maleate, this ethanol induced solubility enhancement was already
measured in our group (Coimbra [2004]).
For water, and to the best of our knowledge, there is not any high pressure
timolol maleate-CO2-water solubility data in the literature. However, and because
timolol is a water soluble molecule and water is much more polar than ethanol, we
should expect the same (or even higher) solubility enhancement as the one observed
for ethanol. However, when water was employed as cosolvent, the impregnation
efficiencies increased for Lu/PCL blends but for Lw/PCL blends were drastically
reduced. This suggests that other different phenomena should also be involved in the
impregnation process. A possible explanation can be the occurrence of favourable
specific timolol-maleate-polymeric matrix-ethanol interactions for Lw/PCL blends
and of specific timolol-maleate-polymeric matrix-water interactions for Lu/PCL
blends. Ethanol/blends contact angle measurements were not performed but
water/blends contact angle experiments indicated that Lu/PCL blends were more
hydrophilic than pure PCL and than Lw/PCL blends. Therefore, a high pressure
mobile phase containing water may interact more efficiently with Lu/PCL blends
than with pure PCL and with Lw/PCL blends, thus promoting a higher swelling
degree and consequently favouring diffusion. This effect seems to be increased at
higher pressures (200 bar). Furthermore, and if there is some water absorption in
the hydrophilic portions of Lu/PCL blends (as expected), this will also create the
conditions for a water-soluble molecule, like timolol maleate, to be deposited in these
blends, instead of being removed with the mobile phase during depressurization.
A recognized advantage of SCF polymeric processing is that SCF can enhance
the diffusion of drugs+SCF mixtures into some polymeric matrices because, in
most cases, they can increase the polymeric free volume and the side groups chain
mobility. Furthermore, this diffusion enhancement can be controlled (“tuned”) just
by changing the operational pressure and temperature. When polymer-SCF phase
interactions are present and are favourable, high pressures usually facilitate the
diffusion process mostly because they will allow more fluid absorption which will
generate a higher swelling degree. This is the case when higher operational pressure
determines higher drug loading in the polymeric matrix. On the other hand, when
drug-SCF phase interactions are stronger than drug-polymer interactions, pressure
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(a) (b)
Figure 2.4: Pressure effect on impregnated samples: a) no cosolvent and b) 10%
water
usually will be an unfavourable factor because higher pressures will originate an
increase in SCF phase density, thus leading to an increased solvating power of the
mobile phase. At the same time, and if the polymer-SCF phase interactions are
still appreciable, this increased density will also originate an increase in polymer
swelling. As a result of these two combined factors, more drug will “choose” to
diffuse out the polymeric matrix and stay in the mobile phase, originating a low
polymeric loading (Kazarian et al. [1998]).
In Fig. 2.4(a), Fig. 2.4(b) and Fig. 2.5, we present the explicit effect of
pressure on the impregnation efficiencies. Pressure effects complement the previous
discussion about the cosolvent effects on impregnation efficiencies and can also help
to explain why impregnation efficiencies are higher at 200 bar for Lu/PCL blends,
while Lw/PCL blends and PCL have higher impregnation efficiencies at 110 bar.
More effective drug-polymer interactions are expected to take place for Lu/PCL
blends because of Lu/PCL blends higher hydrophilicities. Thus, higher pressures
will favour drug deposition. For Lw/PCL blends and for PCL samples, drug
diffusion into the polymeric samples also takes place but, during depressurization,
more drug comes out with the mobile phase, due to the weaker drug-polymer
interactions (when compared to the drug-SCF phase interactions). This is also in
agreement with other works in which the efficiency of the impregnation decreases
at higher pressures (Duarte et al. [2007]).
As already referred, copolymer/polymer chemical structures can strongly affect
drug-polymer and polymer-SCF phase interactions, thus controlling the overall
impregnation process. These complex interactions can be understood, for example,
through the supercritical surfactants theory. Generally, surfactants for use with
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Figure 2.5: Pressure effect on impregnated samples with 10% ethanol
carbon dioxide are amphiphilic molecules containing both a CO2-phobic and a
CO2-philic portion (Woods et al. [2004]). For Lutrol F 127 (which is a non-ionic
surfactant), the ethylene oxide segment is the hydrophilic portion of the block
copolymer but it also is less CO2-philic than the polypropylene oxide segment.
However, it still interacts with CO2 thus still having some swelling degree in
scCO2 media. The polypropylene oxide segment has superior CO2-philicity (when
compared to the polyethylene oxide block) mainly because of the pending methyl
groups along its backbone). Luwax is a copolymer containing a hydrophobic part
(polyethylene) and a slightly hydrophilic one (polyvinylacetate). In terms of CO2
interactions, we can assume than the polyethylene block will interact in a stronger
way with CO2 than the polyvinylacetate block, thus being more CO2-philic than
the PVAc segment. Finally, PCL is a homopolymer that is known to interact
strongly with CO2 (Leeke et al. [2006]). This happens because of the methylene
groups present on its backbone as well of the specific interactions that can occur
between CO2 and carbonyl groups.
Therefore, a hydrophilic drug (like timolol maleate) when is transported by a
SCF, or by a SCF-cosolvent mixture, will have a tendency to specifically interact
and deposit on the hydrophilic portions of the employed polymeric matrices. How-
ever, and because CO2 is also interacting in a strong way with the hydrophobic
(CO2-philic) portions of the polymeric matrix, a hydrophilic drug can also be
deposited (in a lower extent) in these hydrophobic portions. The use of a hy-
drophilic cosolvent (like water and ethanol, as already discussed), will yet increase
these interactions with the more hydrophilic parts of the polymeric matrices thus
increasing impregnation efficiency. If a hydrophobic drug is used, we should expect
that these effects will influence impregnation efficiency in an opposite way.
Consequently, we should expect that more timolol maleate would be impregnated
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(a) (b)
Figure 2.6: Effects of blends compositions: a) Lu/PCL blends and b) Lw/PCL
blends
in Lu/PCL blends as the composition, in terms of the more hydrophilic blend
compound (Lu), is increased. In Fig. 2.6(a), this is verified but only when water
is used as the cosolvent. For Lw/PCL blends, Fig. 2.6(b), the same effect is
observed and as the Lw content is increased (the more hydrophobic component),
the impregnation efficiency decreases, but only in the case when ethanol is employed.
In the case of Lw/PCL blends, and as already discussed in terms of water-samples
contact angles and relative hydrophilicity, water seems not to affect greatly the
impregnation efficiency.
Finally and as already mentioned, the scCO2 induced crystallization of some
polymeric substrates can occur during the impregnation experiments, decreasing
the overall chain mobility of the involved polymeric materials. This effect is
contrary to the favourable plasticization effect and can increase the final relative
crystallinity of the processed polymeric materials, thus influencing negatively the
overall impregnation efficiency (Kikic and Vecchione [2003], Kazarian [2000], Zhou
et al. [2003], Berens et al. [1992], Xu and Chang [2004], Condo et al. [1996]).
However, we did not measure the relative crystallinity of the employed materials
after scCO2 and scCO2+cosolvent processing and therefore we did not know if
crystallinity increased or decreased. This work is still being performed and results
will be presented in due time.
2.3.4 In vitro kinetics of drug release studies
In vitro kinetics of drug release studies were performed for selected impregnated
samples. This selection was made taking in consideration the best impregnation
2.3 83
(a) (b)
Figure 2.7: Kinetics of drug release studies: a) cumulative percentages of released
timolol maleate and b) cumulative concentrations of released timolol maleate and
(c) linear regressions to calculate kinetic constants and release exponents
conditions, in terms of impregnation efficiency, for each set of blends or sample: 200
bar/ 10 % water for Lu/PCL blends, 110 bar/ 10 % ethanol for Lw/PCL blends
and 110 bar/ 0 % cosolvent for PCL samples. Results are presented in Fig. 2.7(a)
and 2.7(b). The cumulative percentages of released timolol maleate are shown in
Fig. 2.7(a). A magnification of the initial 8 hour release period is also shown. After
32 days of release studies, the cumulative released percentages were found to be
higher for the Lw/PCL blends, followed by the Lu/PCL blends and, finally, by PCL
(84.6-92.3 %, 79.2-79.9 % and 77.2 %, respectively). All the impregnated samples
presented almost the same drug release profile, i.e., a biphasic release pattern: an
initial burst period exhibiting a very rapid release rate (probably caused by the
drug deposited on/near the polymeric surface), followed by a polymeric swelling
and/or erosion period, exhibiting an almost constant release rate (3-10 µg/day
after the first day). We must remember that Lutrol F 127 is soluble in water and
poly(ε-caprolactone) undergoes hydrolytic degradation.
The obtained results seem to indicate that the initial drug loading of the
supercritical impregnated samples somehow influenced drug release kinetics results:
the higher cumulative percentages of released drug were obtained for the samples
which were impregnated with higher drug amounts (Lw/PCL blends impregnated
with 10% ethanol). However this could not be the true reason for these observations
and a possible explanation may be that timolol maleate was released faster in
Lw/PCL blends because most part of impregnated drug was probably deposited
very close to the surface. This will be confirmed further on when the kinetics
modelling results will be discussed.
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Figure 2.8: Linear regressions to calculate kinetic constants and release exponents
Lu/PCL blends and PCL were impregnated in a lesser extent but show more
sustained drug release profiles. These results are probably due to the fact that
these lower impregnated amounts of drug (when compared to Lw/PCL blends)
were deposited more deeply in the polymeric structure (thus more homogeneously
dispersed throughout all the polymeric samples). And, this was the result of the
favourable specific interactions that were established between timolol maleate,
water (cosolvent) and the highly hydrophilic segments of the Lu/PCL blends (as
discussed in section 2.3.3). In addition, sample crystallinity may also control the
drug release rates (higher crystallinity degrees usually lead to slower release rates)
and Lu/PCL blends and PCL present the highest percentage of crystalline phases
(see Table 2.3).
Cumulative released drug concentration results are presented in Fig. 2.7(b).
It can be seen that, after the initial first day burst release, timolol maleate con-
centration becomes almost constant (1.2-4 µg/ml/day corresponding to a mass of
3-10 µg/day), which is located above the therapeutic limit of timolol maleate (5
µg/day) (Bartels [1988]) and below the maximum recommended human ophthalmic
dose (0.42 mg/day, considering a patient weight of 60 kg) (Ophthalmic dose). The
burst dose, released by the systems during the first day is below the maximum
recommended human ophthalmic dose, with two formulations surpassing this value
(0.53 mg for 50/50 Lw/PCL and 0.78 mg for 75/25 Lw/PCL). Even these values
are well below the maximum recommended daily oral dose, which is 60 mg/day
(considering a patient weight of 60 kg) (Oral dose). The knowledge of these values
is essential for the development of efficient and safe controlled drug release sys-
tems because the released drug concentrations must always be kept between the
therapeutic and toxic levels.
The Korsmeyer-Peppas model (Eq. 2.4) is usually employed to analyse kinetics
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Sample k (days−n) n R2
50/50 Lu/PCL 45.22 0.21 0.88
25/75 Lu/PCL 54.93 0.12 0.91
PCL 46.48 0.17 0.94
25/75 Lw/PCL 57.65 0.24 0.96
50/50 Lw/PCL 134.71 0.38 0.96
75/25 Lw/PCL 115.97 0.30 0.99
Table 2.4: Obtained kinetic parameters for kinetic drug release studies: release
exponents (n) and kinetic constants (k)
of drug release from systems where the release mechanism is not well-known or when
more than one type of release phenomena (diffusion-, swelling- or erosion-controlled)
are involved. For cylindrical systems, release profiles having a release exponent,
n, around 0.45, exhibit a drug release mechanism controlled by classical/Fickian
diffusion. When n ∼ 0.89, the drug release rate is controlled by a polymer relaxation
mechanism (or Case II transport). Systems having release exponents, n < 0.45,
account for pseudo-Fickian behaviour, while when 0.54 < n < 0.89 are an indication
of the superposition of both the above referred phenomena. In this case, the release
mechanism is termed anomalous transport (Peppas and Brannon-Peppas [1994],
Neogi [1996]).
The value of the release exponent, n, was calculated as the slope of the straight
lines fitted to the release data using the least squares method (Fig. 2.8). The
obtained values are presented in Table 2.4 and, for all systems, n < 0.45, accounting
for pseudo-Fickian release behaviour. Steeper slopes were obtained for Lw/PCL
blends which confirmed the already discussed higher initial burst release behaviour
observed for these systems. As expected, and in general terms, results suggest
that the release mechanism is quite complex, as drug diffusion, polymeric swelling,
crystallinity and polymer erosion are all likely to contribute to the overall release
phenomenon.
2.4 Conclusions
Lu/PCL, Lw/PCL blends and PCL samples were successfully impregnated with
timolol maleate, an anti-glaucoma drug, in order to, as a final objective, prepare
polymeric implantable (subconjunctival) systems for long-term timolol delivery,
with controlled release and degradation.
Different blends (with distinct blend components and compositions) were pre-
pared and characterized in terms of water-sample contact angle measurements and
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sample relative crystallinity. Several SSI experimental conditions were tested: blend
composition, impregnation pressure and different cosolvents (water and ethanol).
Impregnation efficiency was determined and the obtained showed indicated
that, and in general terms, the overall impregnation process and its efficiency is the
result of the relative specific interactions that may be established between all the
involved components of this complex system: scCO2-cosolvent-drug interactions
(which control drug solubility in the high pressure mobile phase and its overall
polar character), scCO2-polymeric matrices-cosolvent interactions (which deter-
mine cosolvent and scCO2 solubility in the polymeric matrix and, consequently,
swelling and plasticization effects) and drug-polymeric matrices-cosolvent inter-
actions (which control the entrapment/deposition of the drug in the polymeric
network). In addition, the employed polymeric samples, with the exception of PCL,
are copolymer blends and each one of these copolymers has blocks/segments with
different hydrophobic/hydrophilic characters, thus increasing even more the system
complexity.
However, in specific impregnation conditions, the addition of a cosolvent (water
and ethanol for Lu/PCL and Lw/PCL, respectively) promotes higher drug loading.
This happened because, in these conditions, drug solubility is increased and higher
drug amounts can be transported by the mobile phase. Moreover, the relative
hydrophilicity/hydrophobicity of prepared blends, together with the cosolvent
addition, also seemed to affect favourably the impregnation process (because of the
specific favourable interactions that are formed between the drug, cosolvent and
the more hydrophilic blend segments). Higher pressures were either a favourable
factor (for Lu/PCL blends) or an unfavourable factor (for Lw/PCL blends and for
PCL samples).
Selected impregnated samples (the ones that presented higher impregnation
efficiencies) were employed in kinetics of drug release studies and the obtained results
indicated that the higher cumulative percentages of released drug were obtained for
the samples which were impregnated with higher drug amounts (Lw/PCL blends
impregnated with 10% ethanol). However, these systems presented high initial drug
burst release profiles. Lu/PCL blends and PCL were impregnated in a lesser extent
but they showed more sustained/controlled drug release profiles. These results are
probably due to the fact that timolol maleate was more homogeneously dispersed
throughout all the polymeric samples, as the result of the favourable specific
interactions that were established between timolol maleate, water (cosolvent) and
the highly hydrophilic segments of Lu/PCL blends. In addition, and for these
blends, sample crystallinity may have also influenced drug release rates because of
the Lu/PCL blends and PCL higher percentages of crystalline phases. These results
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were confirmed by the application of Korsmeyer-Peppas model, that accounted
for pseudo-Fickian release behaviour for all the tested samples, which indicates
that the release mechanism is quite complex, as drug diffusion, polymeric swelling,
crystallinity and polymer erosion are all expected to contribute to the global release
phenomenon.
After the first release day, all samples showed a sustained release of 1.2-4
µg/ml/day, corresponding to a mass of 3-10 µg/day, during a period of 1 month.
These values are between the therapeutic and toxic levels of timolol maleate. The
obtained impregnation efficiencies and drug release results suggested that a desired
final sustained drug release rate can be achieved by changing several operational
impregnation conditions and by modulating blend compositions, i.e., as a way to
control crystallinity, hydrophilicity and drug affinity for the polymer matrix.
As final conclusions, the prepared timolol maleate-loaded polymeric matrices
can be a feasible and promising alternative to the conventional repeated daily
administration of timolol maleate eye drops for glaucoma treatment. Moreover, the
SSI method proved to be a good choice and a “tunable” method for the preparation
of these long-term controlled release systems.
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Chapter 3
Drug-eluting electrospun fibers
for controlled release applications
The text that comprises this Chapter was published in the journal International
Journal of Pharmaceutics (2010), volume 397, pages 50–58.
Abstract
Bicomponent fibers of two semi-crystalline (co)polymers, poly(ε-caprolactone),
PCL and poly(oxyethylene-b-oxypropylene-b-oxyethylene), Lu were obtained by
electrospinning. Acetazolamide and timolol maleate were loaded in the fibers in
different concentrations (below and above the drug solubility limit in polymer)
in order to determine the effect of drug solubility in polymer, drug state, drug
loading and fiber composition on fiber morphology, drug distribution and release
kinetics. The high loadings fibers (with drug in crystalline form) showed higher
burst and faster release than low drug content fibers, indicating the release was
more sustained when the drug was encapsulated inside the fibers, in amorphous
form. Moreover, timolol maleate was released faster than acetazolamide, indicating
that drug solubility in polymer influences the partition of drug between polymer
and elution medium, while fiber composition also controlled drug release. At low
loadings, total release was not achieved (cumulative release percentages smaller
than 100 %), suggesting that drug remained trapped in the fibers. The modeling
of release data implied a three stage release mechanism: a dissolution stage, a
desorption and subsequent diffusion through water filled pores, followed by polymer
degradation control.
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3.1 Introduction
Electrospinning is a versatile technique through which a variety of constructs
can be obtained with application in biomedicine (medical prosthesis, tissue scaffolds,
wound dressings, drug delivery, cosmetics), textiles, electricity and optics, sensors,
filtration, catalysis, unconventional energy sources and storage cells (Hunley and
Long [2008], Huang et al. [2003]). In the field of drug delivery and tissue engineer-
ing, electrospun polymer fibers have gained increasing importance because they
present several advantages: relatively easy drug entrapment during the electro-
spinning process, obtaining of high loadings if so desired, burst control, stability
and preservation of drug/growth factor activity, high surface area (which enhances
drug release) and specific morphology which can be easily controlled during the
electrospining process (Agarwal et al. [2008]). Multicomponent fibers have attracted
special attention because new properties can be obtained through the combination
of different materials. Synthetic polymers with good processability and good me-
chanical properties can be mixed with natural polymers producing an increase in
cellular attachment and biocompatibility (McClure et al. [2009]). Multicomponent
fibers can be obtained mainly by two techniques (Sawicka and Gouma [2006]):
direct electrospinning of polymers solution (in a single-needle configuration, if a
mixture of polymers is co-dissolved in the electrospinning solution or a multi-needle
configuration in which the polymer solutions are separated in parallel or concentric
syringes) and post-treatment of the single-component electrospun fibers (which
can include coating with other inorganic-polymer layers (Casper et al. [2007], Lee
et al. [2009]), grafting (Ma et al. [2006]), crosslinking (Lee et al. [2007], chemical
vapour deposition (Zeng et al. [2005a]), functionalization with other (bio)polymers
(Casper et al. [2005])). In addition to the new physico-chemical properties that
arise from using various components, a variety of fiber structures can be obtained
such as core-shell fibers, micro/nanotubes, interpenetrating phase morphologies
(matrix dispersed or co-continuous fibers) (Bogntizki et al. [2001], Wei et al. [2006]),
nanoscale morphologies (spheres, rods, micelles, lamellae, vesicle tubules, and
cylinders) (Kalra et al. [2006]) and multilayered constructs (either with different
composition or different fiber diameter) (Vaz et al. [2005], Pham et al. [2006]).
For drug delivery applications, several polymers (in terms of degradability and
crystallinity) have been studied as well as drug/growth factor loading in crystalline
or amorphous form in order to fulfill specific requirements of drug-eluting fiber mats
(usually, good mechanical properties and biocompatibility are required together
with control of drug release and burst effect in order to ensure physical integrity
of the construct, long term delivery or immediate action at the targeted location).
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There are several factors that can affect the drug release from electrospun fibers:
fiber construct geometry and thickness (Okuda et al. [2010]), fiber diameter and
porosity (Cui et al. [2006]), fiber composition (Buschle-Diller et al. [2007]), fiber
crystallinity (Kenawy et al. [2002]), fiber swelling (Buschle-Diller and Xie [2009]),
drug loading (Cui et al. [2006], Buschle-Diller and Xie [2009]), drug state (Zamani
et al. [2010], Xie and Wang [2006]), drug molecular weight (Buschle-Diller et al.
[2007], Taepaiboon et al. [2006]), drug solubility in the release medium (Buschle-
Diller and Xie [2009]), drug-polymer-electrospinning solvent interactions (Chew
et al. [2005], Zeng et al. [2005b]). The release characteristics of the fiber mat are
highly influenced by the state of the drug and the structure of the polymer that
forms the fiber. For example, the crystallinity of the polymer controls the rate
of drug release as semi-crystalline polymers showed in general a higher extent of
burst because of two reasons: on one hand, the instantaneous release of the drug
deposited at the fiber surface, and on the other hand, the hindered release of the
drug from the fiber bulk due to limited water uptake in the semi-crsytalline regions
(Kenawy et al. [2002]). The drug state in the fibers is also an important factor since
it was shown that a drug that is incorporated in crystalline form will mainly be
deposited outside the fibers and trigger burst release, while drug in amorphous state
will be loaded inside the fibers and be released in a sustained manner (Zamani et al.
[2010], Xie and Wang [2006], Thakur et al. [2008]). Drug loading is another factor
that can affect the drug release: higher loadings will produce faster release (Cui
et al. [2006], Buschle-Diller and Xie [2009], Zamani et al. [2010]); on one hand, at
high loadings, there is more surface segregated drug that dissolves fast and on the
other hand, there is an increase in porosity during drug elution proportional to the
initial amount of drug (Cui et al. [2006]). Drug compatibility with polymer solution
was also shown to be an important factor in controlling release, as lipophilic drugs
should be incorporated in lipophilic polymers and hydrophilic drugs in hydrophilic
polymers in order to avoid drug deposition outside fibers and subsequent burst
(Zeng et al. [2005b]). Moreover, the interaction between drug and the polymer can
block the crystallization of the drug in the fibers, if so desired (Yu et al. [2009])
and can even determine sustained release of drugs in crystalline state because of
chemical interaction with the polymer (Taepaiboon et al. [2006]).
In our study, bicomponent fibers were prepared using poly(ε-caprolactone), a
semi-crystalline, more hydrophobic polymer and Lutrol F127 (poly(oxyethylene-b-
oxypropylene-b-oxyethylene)), also semi-crystalline, hydrophilic block copolymer.
Poly(ε-caprolactone) was selected because it has been used in a variety of elec-
trospun fibers applications (Agarwal et al. [2008]), while Lutrol F127 was added
as hydrophilicity enhancer and release modulator (Natu et al. [2008]). The prop-
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erties of the bicomponent fibers were studied in order to determine the effect of
processing on crystallinity, water contact angle and mass loss. As both polymers
are semi-crystalline, we could test the influence of such organization on the loading
and release of drugs. Two drugs were selected for incorporation in the fibers in
different concentrations (below and above the drug solubility limit in polymers),
acetazolamide, a hydrophobic drug and timolol maleate, a hydrophilic drug in
order to determine the effect of drug solubility in polymer, drug state, drug loading
and fiber composition on fiber morphology, drug distribution and release kinetics.
Moreover, modeling of the release data using a semi-empirical model (power law
(Peppas and Brannon-Peppas [1994])) and a mechanistic model (desorption model
(Srikar et al. [2008])) was performed, determining the release mechanism, while the
models were compared in terms of goodness of fit.
3.2 Materials and methods
3.2.1 Materials
Timolol maleate, (lot no. 90191189, 99,6 % purity) was purchased from Cam-
brex Profarmaco Cork Ltd., while acetazolamide was obtained from Sigma-Aldrich.
Poly(ε-caprolactone) pellets (PCL, average Mw 65000 g/mol) were obtained from
Sigma-Aldrich. Lutrol F127 (Lu, 9000-14000 g/mol, 70 % by weight of polyoxyethy-
lene) was bought from BASF. Acetone and methanol, both spectrophotometric
grade were obtained from Sigma-Aldrich. Phosphate buffer saline (PBS) tablets
(pH 7.4, 10 mM phosphate, 137 mM sodium, 2.7 mM potassium), used to prepare
the release medium were bought from Sigma-Aldrich. All products were used
without further purification.
3.2.2 Electrospinning
Lutrol F127 and PCL mixtures (25/75, 50/50, w/w) or PCL alone were dissolved
in acetone/methanol (4/1, v/v) at 15 % (w/v) and at 40 ◦ C. The final volume
of each polymer solution was 3 ml. Acetazolamide and timolol maleate were co-
dissolved with the polymers (1 %, w/w). The electrospinning set-up consisted of a
high voltage power supply (SL 10W-300W, Spellman), delivery system (syringe,
teflon tubing, 30 gauge needle, syringe pump (NE-1000 Multiphaser, New Era
Pump Systems)) and a rectangular copper collector. A voltage of 20 kV was applied,
while the syringe pump was operated at a flow rate of 10 ml/min. Polymeric fibers
were deposited on aluminium paper covering the collector placed at a distance of 8
cm from the needle tip. All electrospinning experiments were carried out under
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ambient conditions (25 ◦ C, 50 % humidity in average). The films deposited on
the aluminium paper were peeled off and cut in rectangular pieces of 1 cm×1 cm.
They were used as such in drug release experiments.
3.2.3 Morphological analysis and drug mapping
The morphology of the electrospun fiber and drug distribution were examined
using scanning electron microscopy (SEM, Jeol JSM 5310) coupled to an X-ray
energy dispersion unit to determine the presence of elemental sulphur (present in
both drugs). The drug mapping for some of the samples was done using electron
probe microanalysis (Camebax SX50, Cameca) at 15 kV accelerated voltage and
40 nA probe current. SEM images were analyzed using an image analysis software
(ImageJ 1.42 (ImageJ)) and the average fiber diameter was calculated by measuring
the diameter of 40 fibers, selected from different areas of the samples.
3.2.4 Fiber mat crystallinity, drug solubilitity in polymer
and drug state
Films containing different drug percentages were prepared by solvent casting.
Differential scanning calorimetry was carried out on a DSC Q100 equipment (TA
Instruments). Samples with masses of approximately 4 mg were heated until 350
◦C, at a heating rate of 10 ◦C/min in a hermetic pan, under nitrogen atmosphere
(100 mL/min). Drug concentration in the film was plotted against drug melting
enthalpy (calculated using Universal Analysis 2000 software (TA Instruments)) and
the drug solubility in the polymer (as percentage) was determined as the intercept
of the linear regression curve. The relative crystallinity of the fibers was calculated
using Eq. 3.1.
Xrel (%) =
∆Hf
xLu∆Hf,100%Lu + xPCL∆Hf,100%PCL
× 100 (3.1)
where ∆Hf is the melting enthalpy determined in analysis by integrating the
peaks corresponding to polymer/blend melting, xLu and xPCL are Lu and PCL
mass fractions in the blend, while ∆Hf,100%Lu=181 J/g is the melting enthalpy of
100 % crystalline Lu and ∆Hf,100%PCL=142 J/g is the melting enthalpy of 100 %
crystalline PCL (Tsuji and Ikada [1998]). The melting enthalpy of 100 % crystalline
Lu was calculated using Eq. 3.2.
∆Hf,100%Lu = xPPO∆Hf,100%PPO + xPEO∆Hf,100%PEO (3.2)
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where xPPO and xPEO are polypropyleneoxide and polyethyleneoxide mass frac-
tions in Lutrol and ∆Hf,100%PPO and ∆Hf,100%PEO are the corresponding melting
enthalpies of 100 % crystalline polymer (ATHAS).
3.2.5 Swelling and mass loss
Fiber films were accurately weighed and immersed in 4 ml phosphate saline
buffer (PBS) in sealed vials at 37 ◦C. At scheduled time intervals, samples were
withdrawn from the vials, blotted with a tissue paper to remove the surface water
and weighed. The water content (∆w) was calculated using the Eq. 3.3.
∆w(%) =
mt −mi
mt
× 100 (3.3)
where mt denotes the mass of the wet sample at immersion time t and mi denotes
the initial mass of the sample.
For mass loss determination, at scheduled time intervals, samples were with-
drawn from the vials and vacuum dried until constant weight at 37 ◦C. The
percentage of mass loss (∆m) was calculated using Eq. 3.4.
∆m(%) =
mi −md
mi
× 100 (3.4)
where mi denotes the initial mass and md is the mass of the dried sample after a
certain immersion time.
3.2.6 Drug loading and release
The drug release from the fibers was studied in PBS medium (4 ml), using a
shaker (37 ◦C, 100 rpm). At scheduled time intervals (1, 2, 3, 4, 7, 8, 9, 10, 11,
15, 19, 36, 52 days), 2 ml of sample was taken and fresh PBS medium of identical
volume was added to maintain sink conditions. The mass of timolol maleate and
acetazolamide released at time t, mt, as well as the total drug amount (mtot) were
determined by UV spectroscopy (Jasco V-650 Spectrophotometer) at 299.5 nm
and 265 nm, in PBS and 4/1 (v/v) THF/methanol solution, respectively. The
drug loading was determined using Eq. 3.5. The percentage of released drug
was calculated using Eq. 3.6. Calculations of the amount of released drug took
into account replacement with fresh medium at each sampling point. Controls
(fibers without drug) were also tested and their contribution to the absorbance was
substracted.
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Loading (%) =
mtot
mfiber
× 100 (3.5)
in which mfiber is the mass of the fiber mat.
Released drug (%) =
mt
mtot
× 100 (3.6)
In order to study the drug release mechanism, different equations (Eq.3.7, 3.8)
were used to model the release data. The equations were fitted to the data using
non-linear regression and the results were compared in terms of goodness of the
fit. The power law equation (Eq.3.7) is one of them and was chosen because it
is the most widely used equation in works concerning drug release (Peppas and
Brannon-Peppas [1994]):
mt
mtot
= a0 + k t
n (3.7)
where mt/mtot is the fractional release of the drug at time t, a0 is a constant,
representing the percentage of burst release, k is the kinetic constant and n is the
release exponent, indicating the mechanism of drug release.
In most models, the release mechanism has been attributed to diffusion of
the drug from the polymers and under this assumption, a 100 % release of the
drug is expected in a certain time. In the desorption model, the authors suggest
that release is not controlled by solid-state diffusion, but by the desorption of the
drug from pores of the fibers or from the outer surface of the fibers. Thus, only
the drug on the fiber and pore surfaces can be released, whereas the drug from
the bulk can not be released within the time scales characteristic of the release
experiments. The Eq.3.8 is based on a pore model, in which the effective drug
diffusion coefficient, Deff is considered and not the actual diffusion coefficient in
water, D (with Deff/D  1) because desorption from the pore is the rate limiting
step and not drug diffusion in water, which is relatively fast.
mt
mtot
= α
[
1− exp
(
− pi
2
8
t
τr
)]
(3.8)
where the porosity factor α = ms0/(ms0 +mb0) < 1, with ms0 and mb0 being the
initial amount of drug at the fiber surface and the initial amount of drug in the
fiber bulk, respectively; mt is the drug amount released at time t, while the total
initial amount of drug in the fiber is mtot = ms0 +mb0 and τr is the characteristic
time of the release process (Srikar et al. [2008]).
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Figure 3.1: Chemical structures
3.2.7 Statistics
All values are presented as mean (n=3) and standard error of the mean (SEM).
Linear regression analysis was performed using OpenOffice.org Calc 3.1 (Openoffice),
while non-linear regression was done using the regression module of SigmaPlot
10 (SigmaPlot). Adjusted R2 (AdjR2) was calculated instead of R2 to evaluate
goodness of fit for the two equations that have different number of model parameters.
3.3 Results and discussion
3.3.1 Fiber mat crystallinity, drug solubilitity in polymer
and drug state
In this work, two drugs, timolol maleate (pka= 3.9, experimental logP= 1.2,
experimental water solubility= 2.74 mg/ml (Timolol)) and acetazolamide (pka=7.2,
experimental logP= -0.26, experimental water solubility= 0.98 mg/ml (Acetazo-
lamide)) with the chemical structures shown in Fig. 3.1 were chosen because of
different hydrophilic/hydrophobic character that would allow us to understand how
the interactions between the drug and polymers contribute to drug release. Thus,
as a measure of interaction, the drug solubility in polymers was determined and
the obtained results are presented in Table 3.1. Moreover, the drug solubility is
expected to influence the loading and the state of the drug in the fibers. Thus,
fibers with low and high drug loadings (see Table 3.4) were prepared corresponding
to drug percentages below and above the drug solubility limit, respectively.
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Sample Drug solubility (%) Rel. degree of crystallinity (%)
Timolol maleate Acetazolamide Timolol maleate Acetazolamide
PCL 4.48 (1.11) 16.53 (2.1) 54.39 54.59
25/75 Lu/PCL 5.14 (0.94) 15.94 (4.81) 54.71 59.55
50/50 Lu/PCL 6.97 (1.86) 14.81 (0.8) 64.01 59.89
Lu 8.34 (1.54) 11.25 (3.92)
Table 3.1: Drug solubility in polymer
(a) (b)
Figure 3.2: DSC curves of fiber mats. a) low timolol loading and b) low acetazo-
lamide loading
It was observed that acetazolamide had higher solubility in all fibers when
compared to timolol maleate probably because of enhanced interaction with the
hydroxyl/carboxyl groups of the polymers (the chemical structures are shown in
Fig. 3.1). Furthermore, a tendency of increase in solubility was noticed when
PCL ratio is increased. On the other hand, timolol is more hydrophilic, therefore
a higher solubility is expected in the fibers that contain more Lu and are more
hydrophilic, which is the case of 50/50 Lu/PCL (Natu et al. [2008]). An opposite
trend was observed for timolol maleate when an increase in solubility was obtained
with decrease in PCL content. We will discuss in section 3.3.4 how the solubility
affects the drug release.
Polymer crystallinity is known to play an important role in determining degrad-
ability, water and drug release because the bulk crystalline phases are more in-
accessible to water. The polymers used in this work are semi-crystalline and the
obtained fibers are expected to be semi-crystalline too. DSC analysis confirmed
this hypothesis showing a clear melting peak in all fibers (PCL melts at 65.1 ◦C
and Lu melts at 59.4 ◦C). The relative degree of crystallinity of drug loaded fibers
is presented in Table 3.1, where it can be seen that the fibers showed similar
crystallinity values regardless the type of loaded drug. Another important fact was
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Figure 3.3: DSC curves of fiber mats with high acetazolamide loading and pure
drug
that the drug appeared to be in amorphous state in fibers with low drug loadings
as proven by the absence of drug melting peak in Fig. 3.2(a) and Fig. 3.2(b)
(acetazolamide melts at 271.0 ◦C, while timolol maleate melts at 205.6 ◦C). In
fibers with high loadings, part of the drug was in crystalline form as confirmed by
morphological analysis (in the DSC scans of these sample (Fig. 3.3), there is a
broad peak possibly corresponding to drug melting, that is unfortunately masked
by fiber degradation process that starts at around 250 ◦C).
3.3.2 Morphological analysis and drug mapping
The morphology of the fibers with low drug loadings as function of composition
is presented in Fig. 3.4, while the calculated fiber diameters are shown in Table
3.2. There was a slight variation in fiber diameter as a function of loaded drug and
a more significant one with respect to fiber composition. Morphological differences
between samples loaded with the two drugs above or below the solubility limit
were also assesed by SEM analysis. In Fig.3.5(a) and Fig. 3.5(c) surface and
cross-section images of fibers that contain acetazolamide above solubility limit are
shown. As the loaded mass of drug was above the solubility limit in the polymer,
the drug was expected to be in crystalline form as confirmed by the images where
drug crystals were visible outside or inside the fibers. On the other hand, no
crystals were observed in the fibers that contain drug in low loadings (Fig.3.4)
suggesting that the drug was in amorphous state in the fibers in agreement with
DSC analysis results.
SEM coupled with elemental analysis was performed in order to assess the drug
distribution inside the fiber mats. It was seen that both surface and cross-section
showed relatively homogeneous drug distribution regardless of composition or type
of loaded drug (Fig. 3.5(b) to Fig. 3.6(d)).
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(a) (b)
(c)
Figure 3.4: SEM images of fibers with low drug loadings. a) PCL with timolol; b)
50/50 Lu/PCL with timolol; c) 25/75 Lu/PCL with acetazolamide
Sample Drug d (µm)
PCL timolol 1.59 (0.36)
PCL acetazolamide 0.71 (0.45)
25/75 Lu/PCL timolol 1.01 (0.20)
25/75 Lu/PCL acetazolamide 0.87 (0.45)
50/50 Lu/PCL timolol 0.56 (0.11)
50/50 Lu/PCL acetazolamide 0.55 (0.12)
Table 3.2: Fiber diameters
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(a) (b)
(c) (d)
Figure 3.5: SEM of high acetazolamide content 25/75 Lu/PCL fibers and sulphur
mapping. a) Surface view; b) Surface mapping; c) Cross-section view; d) Cross-
section mapping
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(a) (b)
(c) (d)
Figure 3.6: SEM of high timolol content fibers and sulphur mapping. a) PCL,
surface view; b) 25/75 Lu/PCL, surface view; c) PCL, surface mapping; d) 25/75
Lu/PCL, surface mapping
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Sample Contact angle (deg)
PCL 123.18 (0.98)
25/75 Lu/PCL 18.28 (4.07)
50/50 Lu/PCL 16.25 (2.16)
Table 3.3: Static contact angle with water
3.3.3 Swelling and mass loss
The fiber mats are supposed to function in an aqueous environment, so their
properties in the presence of water have to be known. In Table 3.3, the values
of the water contact angles are given for the different fibers. PCL fibers were
highly hydrophobic, while the bicomponent fibers were highly hydrophilic. These
results were surprising since in a previous work films with the same compositions
presented contact angles in the range 50-62 degrees (Natu et al. [2008]). Water
contact angle is determined by both chemical structure and surface morphology.
In general, fiber mats have a rougher surface morphology when compared to films
and as a result they present higher contact angle than the films made of the same
polymers (Kang et al. [2008]). It seems this is the case of PCL that showed an
increase in water contact angle from 62 for films to 123 for fibers. In contrast, the
bicomponent fibers presented much lower contact angles probably because of a
preferential arrangement of Lu (that is very hydrophilic) towards the margin of the
fibers. Lu has a lower molecular weight than PCL and higher molecular mobility
and consequently it migrates to the regions of highest shear rate (at the walls of
the needle). The higher viscosity component (PCL) occupies mostly the center of
the fiber (Wei et al. [2006]).
Consequently, PCL fibers absorbed water gradually (see Fig. 3.7(a)) because
the fibers were hydrophobic and semi-crystalline, hindering the water penetration
inside the fiber mat, while the bicomponent fibers presented a sudden increase in
water content during the first day (79.0 % for 50/50 Lu/PCL and 68.5 % for 25/75
Lu/PCL), followed by a constant value thereafter as Lu content in the fiber was
diminished due to dissolution.
As observed in the mass loss plot (Fig. 3.7(b)), there was an initial increase in
mass loss for bicomponent fibers (42.5 % for 50/50 Lu/PCL and 16.6 % for 25/75
Lu/PCL), while PCL fibers did not show almost any mass loss (0.45 %). Mass
loss of PCL is detectable only after the molecular weight reaches a value of 10000
g/mol (Hglund et al. [2007]) and thus the initial high mass loss of the bicomponent
fibers can only be attributed to the dissolution of Lu as the sample with higher Lu
content had the highest mass loss.
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(a) (b)
Figure 3.7: a) Fibers water uptake and b) mass loss, (•) PCL, (◦) 25/75 Lu/PCL,
(H) 50/50 Lu/PCL
The morphology of aged fibers (immersed in PBS during 3 days) was also
investigated in order to determine the change in fiber structure. In Fig. 3.8(a), it
can be noticed the smooth surface of the fibers, while in Fig. 3.8(b) pores were
observed that were formed due to the dissolution and leaching of Lu. A different
appearance was shown by 25/75 Lu/PCL fiber mat (Fig. 3.8(d)), where the fibers
appeared more wrinkled in comparison with the initial ones and no pores were
visible, probably because of lower Lu content.
3.3.4 Drug release
We previously showed how the fiber morphology and drug deposition were
affected by the drug state in the fibers: when drug was in amorphous state, it
was incorporated inside the fibers, while the drug present in amounts above the
solubility limit crystallized inside and on the fiber surface (as shown in Fig. 3.5(a)).
In Fig. 3.9(a) and Fig. 3.9(b), the cumulative percentage of released acetazolamide
and timolol maleate from fibers with low drug content is presented, while in Fig.
3.10, the released drug for fibers with high loadings is shown. It was noticed that
fibers with high drug loading presented burst release in contrast with low drug
content fibers that showed a more sustained release. The former contained drug
crystals at the fiber surface or inside the fibers that were not totally encapsulated
and were instantaneously “released”, implying that the predominant mechanism of
release was drug dissolution. On the other hand, in the low loadings fibers, the
drug was amorphous and dissolved in the fiber, decreasing burst. These findings
were in agreement with another study where bicomponent fibers loaded with 25%
drug (by weight) showed burst release as opposed to 5% drug fibers (Kenawy et al.
[2002]) that did not, suggesting that the drug state can control the burst extent.
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(a) (b)
(c) (d)
Figure 3.8: SEM images of fibers. a) initial 50/50 Lu/PCL, b) 50/50 Lu/PCL
aged, c) initial 25/75 Lu/PCL, d) 25/75 Lu/PCL aged
(a) (b)
Figure 3.9: Drug release a) low loadings fibers with acetazolamide, b) low loadings
fibers with timolol maleate (solid and dashed lines corresponding to non-linear fit
of Eq.3.8)
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Figure 3.10: Drug release from high loadings fibers
In Table 3.4, the results of non-linear regression are presented. The objective
behind fitting these equations to the release data was to understand the underlying
phenomena involved in the drug release mechanism. The parameters a0, α and k
define the burst stage and the bigger values they have, the higher extent of burst.
On the other hand, τ and n indicate the magnitude of the drug desorption/diffusion
stage and the higher values they have, more sustained is the release.
Drug solubility in polymer as well as drug solubility in solution are important
as they control the partitioning of the drug from the polymer toward the elution
medium. For the same type of fibers, higher percentages of timolol maleate were
released in comparison with acetazolamide (for example, in the case of PCL fibers,
α=45.96 (2.92) for timolol and α=35.14 (1.43) for acetazolamide). This can be
explained by the combined effect of lower polymer solubility and higher water
solubility of timolol maleate in contrast with acetazolamide that has higher polymer
solubility and lower water solubility. The compatibility between drug and polymer
is indeed important as it ensures sustained release during drug diffusion from
the polymer (Zeng et al. [2005b]), when the drug is completely encapsulated and
dissolved in the fiber.
Fiber composition influenced the release kinetics as drug was released in a more
sustained manner from PCL fibers (α=45.96 (2.92) and k=11.51 (3.23) for timolol)
than from bicomponent fibers regardless of the drug type (α=50.41 (2.95) and
k=12.58 (2.72) for 25/75 Lu/PCL with timolol, while α=64.60 (2.99) and k=25.97
(4.09) for 50/70 Lu/PCL with timolol). Certainly, as erosion was very fast (see
section 3.3.3), the drug was released faster from bicomponent fibers than from
the hydrophobic PCL fibers that released the drug at the pace dictated by water
uptake.
It was observed that a steady state was attained (after approximately 10 days for
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bicomponent fibers and after 20 days for PCL fibers) without total release of loaded
drug (cumulative release percentages significantly smaller than 100 %). There is a
fraction of the drug that is desorbed from the fiber and then diffuses out through
the water filled pores, while another portion of the drug encapsulated probably
in crystalline areas (and inaccessible to water) can only be released by polymer
degradation (which is insignificant during the time scale of release experiment)
(Srikar et al. [2008], Tzafriri [2000]). This was not the case for the high drug loading
fibers where release was almost complete in the time frame of the experiment. At
high loadings, when a significant amount of drug was in crystalline form, only a
small portion of drug was trapped (approximately 10 % in the case of PCL, see
Fig. 3.10). As drug was in crystalline state (with crystal dimensions between 1
to 6 µm), additional regions of macroporosity were created after drug dissolution
besides those created by water uptake and polymer erosion, increasing surface
area and enhancing drug release. Thus, the state of the drug in the fiber has an
important part in further controlling release kinetics.
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The release kinetics and regression analysis results implied a three stage release
mechanism, with different stages depending on fiber composition: the first stage was
drug dissolution (mainly because of crystalline drug that is not totally encapsulated
in the fibers), the second was drug desorption and subsequent diffusion through
water-filled pores (Miyajima et al. [1997]) (created either due to Lu leaching or
water uptake in the amorphous regions of PCL), while the last stage was controlled
by polymer degradation.
3.4 Conclusions
Fibers were obtained by electrospinning of two semi-crystalline (co)polymers,
PCL and Lu, and were loaded with two drugs, acetazolamide and timolol maleate,
in concentrations below and above the drug solubility limit in polymer. The PCL
fibers were semi-crystalline and hydrophobic, while the bicomponent fibers were
semi-crystalline and hydrophilic. Thus, the bicomponent fibers showed high water
uptake and extensive erosion during the first day, whereas PCL fibers swelled
gradually, without any significant erosion during the time frame of the release
experiment. Morphological examination showed that fibers with high drug loadings
(above solubility limit) had drug crystals inside and outside the fibers, while fibers
with low drug content (below solubility limit) had drug encapsulated in amorphous
form. These results were further supported by DSC analysis, where thermograms
of low drug loading fibers didn’t show the peak corresponding to drug melting.
The high loadings fibers showed higher extent of burst and shorter periods of
release (almost 90 % of drug released after 2 days) than low drug content fibers
(around 50 % of drug released after 52 days), suggesting that loading and drug
encapsulation in either crystalline or amorphous form are interrelated and control
the release rate, especially in the burst stage. Thus, in long term release applications
where high amounts of loaded drug are desirable, a compromise must be found
in order to balance the loading and release rate that seem to vary in opposite
directions according to the present study.
Total release was not attained at low loadings, suggesting that the last stage of
the release kinetics was polymer degradation limited. Moreover, it was observed
that timolol maleate was released faster than acetazolamide in the same type of
fibers and similar loadings, indicating that drug solubility in polymer influenced
the partition of drug between polymer and elution medium. This could offer a
mean to control the total percentage of released drug by choosing the best pair
of polymer and drug, although some applications require very specific material
properties that may not match in terms of compatibility the drugs used in the
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treatment of the targeted diseases. Finally, the modelling of release data implied a
three stage release mechanism: a dissolution stage (mainly produced by crystalline
drug that was not properly encapsulated), a drug desorption coupled to diffusion
stage, followed by polymer degradation control stage. The fiber composition
also controlled drug release, since release was slower from PCL fibers than from
bicomponent fibers regardless of the drug type. By choosing the polymers making
up the bicomponent fibers and their ratio, the magnitude of the dissolution or
diffusion stage can be controlled, attaining the targeted short or long term release
application, respectively.
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Chapter 4
A poly(ε-caprolactone) device for
sustained release of an
anti-glaucoma drug
The text that comprises this Chapter was published in the journal Biomedical
Materials (2011), volume 6, pages 025003 (in press).
Abstract
Implantable dorzolamide loaded disks were prepared by blending
poly(ε-caprolactone), PCL with poly(ethylene oxide)-b-poly(propylene
oxide)-b-poly(ethylene oxide), Lu. By blending, crystallinity, water uptake and
mass loss were modified relative to the pure polymers. Burst was diminished
by coating the disks with a PCL shell. All samples presented burst release
except PCL-coated samples that showed controlled release during 18 days. For
PCL-coated samples, barrier-control of diffusion coupled with partition control
from the core slowed down the release, while for 50/50 Lu/PCL-coated samples,
the enhancement in porosity of the core diminished partition-control of drug
release. Non-linear regression analysis suggested that a degradation model fully
describes the release curve considering a triphasic release mechanism: the
instantaneous diffusion (burst), diffusion and polymer degradation stages. MTT
test indicated that the materials are not cytotoxic for corneal endothelial cells. A
good in vitro-in vivo correlation was obtained, with similar amounts of drug
released in vitro and in vivo. The disks decreased intraocular pressure (IOP) in
normotensive rabbit eyes by 13.0 % during 10 days for PCL-coated and by 13.0 %
during 4 days for 50/50 Lu/PCL-coated. The percentages of IOP decrease are
similar to those obtained by dorzolamide eyedrop instillation (11.0 %).
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4.1 Introduction
Glaucoma is a condition affecting the posterior segment of the eye and major
cause of irreversible blindness (Quigley [2005]). Progressive visual loss is associated
with elevated intraocular pressure, IOP which damages the optic nerve. Current
treatments for glaucoma can be divided into three main modalities: pharmaceutical,
laser and surgical. Despite continued advances in laser and filtration surgery, medical
therapy still appears to be the primary means by which IOP is controlled (Schwartz
and Budenz [2004]). These studies have focused on the role of lowering IOP in the
prevention of field loss and optic nerve damage. It was shown that reducing IOP is
effective in preventing disease progression in ocular hypertension, primary open
angle glaucoma, and even in normal tension glaucoma (Khaw et al. [2004]).
In most glaucoma patients, medical therapy consists of topical eyedrops and
oral tablets. Eyedrops present low ocular bioavailability and produce undesired
side effects (Amo and Urtti [2008]). A large portion of the drop can be lost
due to overflow from the cojunctival sac, while the drop remaining on the ocular
surface can be washed away through the nasolacrimal duct, thereby decreasing the
amount of the drug that reaches the targeted ocular structures. High systemic
bioavailability of ophthalmic drugs can occur due to systemic drug loss, which can
be highly dangerous to patients suffering from cardiovascular and/or respiratory
diseases (Korte et al. [2002]). Moreover, patients do not use their eyedrops as
prescribed. The poor compliance can be due to uncomfortable sensations (Noecker
et al. [2004]), as well as difficulty of instillation or forgetfulness (Kulkarni et al.
[2008]).
Controlled drug release devices were shown to produce continuous release of
drug at predetermined rates which allows the elimination of frequent dosing by
the patient, ensures night time medication and provides better patient compliance
(Bourges et al. [2006]). Furthermore, therapeutic drug levels are achieved without
exposure of ocular tissues to toxic level of drugs. The devices are more economic
because smaller amounts of drugs are required to achieve the same effect as eyedrops
since these systems release the drugs over extended periods of time.
For topical ocular use, gel forming solutions (Timoptic-XE®, Pilogel®, Aza-
site®) are already in clinical use. These formulations enhance the drug retention
relative to eyedrops and produce increased drug absorption into the eye and reduce
dosing frequency (Nanjawade et al. [2007]). However, the duration of drug activity
can be increased by hours, not by days or weeks. Other sustained release systems
include contact lenses (Costa et al. [2010], Hiratani et al. [2005]), mucoadhesive
formulations (Ludwig [2005]), hydrogels (Natu et al. [2007], Anumolu et al. [2009]),
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hybrid systems (Barbu et al. [2009]), particulates (Marchal-Heussler et al. [1993],
Kaur et al. [2004], Zimmer and Kreuter [1995]), fiber composites (Kashanian et al.
[2010]) and ocular inserts (Macoul and Pavan-Langston [1975], Baeyens et al.
[2002], Pijls et al. [2007], Sasaki et al. [2003]). Only the latter category is capable
of sustained release of drugs during several days. Unfortunately, such ocular inserts
generally require patient self-administration and a sufficient degree of manual
dexterity. In addition, inadvertent loss of the ocular device due insert movement
can occur (Macoul and Pavan-Langston [1975]).
Implantable devices with prolonged action exist on the market or undergoing
clinical trials: non-biodegradable implants such as Medidur®, Retisert®, Vit-
rasert®or biodegradable implants such as Posurdex®. Unfortunately, they were
developed for the treatment of diseases that affect the posterior segment of the
eye such as diabetic macular edema, uveitis or cytomegalovirus retinitis (Amo and
Urtti [2008]) and not glaucoma.
Our long-term goal is to prepare a drug loaded biodegradable implant designed
to provide a localized, sustained release of dorzolamide hydrochloride (a carbonic
anhydrase inhibitor used to lower IOP) that can be used in the treatment of
open-angle glaucoma. The implant will degrade within the site of implantation
thereby slowly releasing the drug at the site to be treated until the entire implant
will degrade without the need for further surgery. A subconjunctival placement of
the implant is simple to perform because of easy access to the implantation area
and low vascularization. By delivering controlled amounts of drug, the implant
would be highly efficient, increase patient compliance and cost effectiveness.
Polymer blending is a simple process in which specific properties from different
polymers can be combined in order to tailor the degradability and the drug release
properties (Shen et al. [2000], Lyu et al. [2005]). For the present study, poly(ε-
caprolactone), PCL and Lutrol F 127, Lu were selected because they are both
biocompatible, biodegradable and they can be easily processed by conventional
polymer processing techniques. Moreover, they are commercially available, inexpen-
sive and well characterised polymers. PCL is a slowly degradable polymer, while Lu
can be used as a release modulator (Natu et al. [2008, 2010]). Unfortunately, some
controlled drug release systems present a burst stage due to surface deposited drug
(Natu et al. [2010]), which can be pharmacologically dangerous and economically
inefficient. One strategy to diminish/remove burst is through additional polymer
coating which can provide a layer/shell that separates the drug in the core of the
device and acts as an extra diffusional barrier to drug transport. Moreover, this
device is capable of achieving a zero-order drug delivery due to the fact that the
drug diffuses through the membrane at a finite, controllable rate (Huang and Brazel
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[2001]).
In this work, we studied how crystallinity, water uptake and mass loss are
changed by blending and how these new properties influence the drug release
and release mechanism. Disks were prepared and coated or used as such in in
vitro and in vivo drug release experiments. Non-linear regression analysis using
a degradation model and diffusion model was done in order to understand the
underlying phenomena involved in the drug release. The implantable drug loaded
disks were further evaluated in vivo by measuring the capacity to decrease IOP
in normotensive rabbit eyes and compared in terms of performance with available
eyedrop treatment (Trusopt®, dorzolamide eydrops).
4.2 Materials and methods
4.2.1 Device preparation
Poly(ε-caprolactone) (PCL, average Mw 65000 g/mol, Sigma-Aldrich) and
Lutrol F 127 (Lu, poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene
oxide), 9000-14000 g/mol, 70 % by weight of polyoxyethylene, BASF) films were
prepared by solvent casting from acetone (UV grade, Sigma-Aldrich) at 40 ◦C,
using a 15 % w/v total polymer concentration. Films (Lu/PCL: 25/75, 50/50 %
w/w) were vacuum dried (37 ◦C until constant weight) and cut in rectangular pieces
and used as such in different characterization tests. The blend 75/25 Lu/PCL was
not studied since it dissolves in PBS at 37 ◦C and thus it is not a good material
for the intended application.
Disks with a diameter of 6 mm and a thickness of 1 mm were punched out from
dorzolamide hydrochloride (Chemos GmbH) loaded films (2/1 (w/w) polymer/drug,
approximately 1 mg of drug in each disc) and then coated by dip-coating in 0.15
g/ml PCL solution or used as such in drug release experiments.
4.2.2 Characterization tests
Dynamic mechanical analysis (DMA) was performed on polymer films (10 mm×5
mm×0.1 mm, lwt) using a Tritec 2000 DMA (Triton Technology) equipment in
tension mode in multifrequency, with a heating rate of 2 ◦C/min from -150 to 100
◦C, using liquid nitrogen. The glass transition temperature (Tg) was determined at
the frequency-dependent peak in tan δ plot (with tan δ = E ′′/E ′, where E ′′ and
E ′ are the loss and storage modulus, respectively) and accompanied by a decrease
in the loss modulus value.
4.2 123
Differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA)
were carried out using a SDT Q 600 equipment (TA Instruments). Nitrogen at a
rate of 100 mL/min was used as purge gas. Samples with masses between 5 and
10 mg were heated until 600 ◦C, at a heating rate of 10 ◦C/min. The degradation
temperature (Td) was determined at the onset point of the TGA plot. The relative
crystallinity of the films was calculated as previously described considering the
melting enthalpy of 100 % crystalline PCL (ATHAS) and 100 % crystalline Lu
(Natu et al. [2010]).
X-ray diffraction was performed using Philips X’Pert diffractometer employing
Co radiation. A scan range between 10◦ and 50◦ and a step of 0.04◦/s was used
to obtain the diffraction patterns. Samples were analysed as films or as powders
in the case of constitutive polymers. The degree of crystallinity was calculated as
the percentage of the scattered intensity of the crystalline phase over the scattered
intensity of the crystalline and amorphous phases. The decomposition of crystalline
and amorphous intensity profiles from the total intensity profile was accomplished
by a curve fitting technique using a Voigt function (Peak fitting module, Origin v.6
software) (Cao and Billows [1999]).
4.2.3 Water uptake and degradation
Water uptake and mass loss experiments were performed as previously reported
(Natu et al. [2010]). The water uptake was calculated using Eq.4.1.
Water content (%) =
Mt −Mi
Mt
× 100 (4.1)
where Mt denotes the mass of the wet sample at immersion time t and Mi denotes
the initial mass of the sample.
The percentage of mass loss was calculated using Eq.4.2.
Mass loss (%) =
Mi −Md
Mi
× 100 (4.2)
where Mi denotes the initial mass and Md is the mass of the dried sample after a
certain immersion time.
4.2.4 Dorzolamide hydrochloride release
Dorzolamide hydrochloride release was performed as previously reported (Natu
et al. [2010]) in 10 ml PBS, with the drug concentration determined by UV
spectroscopy at 254 nm (Jasco V-650 Spectrophotometer). The percentage of
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released drug was calculated using Eq.4.3.
Released drug (%) =
Mt
Mtotal
× 100 (4.3)
In Eq. 4.3, Mt is mass of dorzolamide hydrochloride released at time t and Mtotal
is the total mass of loaded drug (that was determined by dissolving the discs in 4/1
(v/v) THF/methanol solution and adding this residual drug mass to the released
mass of drug).
The power law equation (Eq.4.4) was fit to the release data in order to determine
the release mechanism (Natu et al. [2010]).
Mt
Mtotal
= k tn (4.4)
In Eq. 4.4, Mt/Mtotal is the fractional release of the drug, k is the kinetic constant
and n is the release exponent, indicating the mechanism of drug release.
An alternative model (Eq.4.5) based on polymer degradation control of drug
release was used to fit the release data. In this model, two pools of drug are
considered: a pool of mobile drug which readily diffuses out of the matrix upon
immersion in an aqueous medium and a pool of immobilized drug which can diffuse
only after matrix degradation (Tzafriri [2000]). This model can be applied to
slow-degrading polymers such as PCL due to the fact that polymer degradation
is much slower than drug diffusion and as such it is the rate limiting step for
immobilized drug transport.
M(τ) = A0 + |Ω|S0 (1− exp (−τ)), α¯−1lmn → 0 (4.5)
In Eq. 4.5, A0 is the load of the mobile active agent, S0 is the initial concentration
of immobilized active agent, τ is the dimensionless time and is defined by τ = µ t
(µ is the degradation rate constant) and Ω is the geometrical factor. The model
parameters were determined by non-linear regression and the goodness of the fit
was assessed.
4.2.5 Biocompatibility evaluation
Corneal endothelial cells were obtained and cultured as previously reported
(Natu et al. [2007]). For all the experiments, the samples were sterilised using UV
radiation for 30 minutes and preconditioned in culture media for 24 hours prior
to seeding. Second passage endothelial corneal cells were seeded, at a density of
200000 cells per well, into a 96 well glass-bottom plate (P96G-0-5-F, MatTek Corp.
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USA) containing the biomaterials. The plate was incubated at 37◦C, under carbon
dioxide (5 %) atmosphere, for 24 hours. After the incubation, the mitochondrial
redox activity was assessed through the reduction of the MTT reagent (3-[4,5-
dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide, MTT colorimetric assay kit,
ATCC). 50 µl of MTT (5 mg/ml PBS) were added to each sample and incubated
for 4 h at 37◦C, under carbon dioxide (5 %) atmosphere. Medium was aspirated
and the culture cells were treated with 50 µl of isopropanol/HCl (0.04 N) for 90
minutes. The absorbance at 570 nm was measured using a Biorad Microplate
Reader Benchmark. Wells containing cells in culture medium without biomaterials
were used as negative control.
4.2.6 In vivo performance - Intraocular pressure measure-
ment
New Zealand white rabbits, males and females, with an age of 10 weeks and a
weight 2.6± 0.3 kg were used in animal experiments in agreement with European
Union Council Directive 86/609/EEC regarding the protection of animals used for
experimental and other scientific purposes (86/609/EEC, 2007/526/EC). Animal
experimentation was approved by the Ethics Committee of the University of
Coimbra (document reference: 078-CE-10). Corneal thickness (349.2±15.4 µm)
was determined with a pachymeter (PachPen, Accutome). Animals were housed
under a 12-hour light, 12-hour dark cycle with free access to food and water. Prior
to the beginning of the experiments, the rabbits were accustomed to the laboratory
environment, handling and measurement procedure in order to reduce stress and
encourage cooperation during measurement routine.
Animals were anesthetized with intramuscular ketamine (50 mg/kg, Ketalar
injectable solution 50 mg/ml, Pfizer) and topical oxybuprocaine hydrochloride
(Anestocil eyedrops 4 mg/ml, Edol). A small incision was made under the con-
junctiva, forming a pocket in the upper part of the eyeball at 5 mm from the
limbus region. The disks were introduced in the subconjunctival pocket and care-
fully covered by the conjunctiva, without any sutures. Azithromycin eyedrops
(Azyter, 15 mg/g, The´a) were instilled during some days in order to treat eyes that
presented symptoms of conjunctivitis. The animals were divided in two groups:
group 1 received drug loaded polymer disks (the right eye contained the drug
loaded disk, while the left had the control disk) and group 2 was submitted to
Trusopt®eyedrops (dorzolamide hydrochloride 2 %, Chibret) treatment (1 drop
three times a day in the right eye, while the left eye received a drop of balanced
salt solution, BSS sterile solution, Alcon).
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The IOP measurement was performed using a Schiotz tonometer, every 3 hours
during the first 10 hours, followed by once or twice a day (morning and evening)
measurements thereafter. During the measurement, the animal was kept in prone
position, one to two drops of oxybuprocaine hydrocholoride was applied on the
surface of the eye, the tonometer was placed perpendicularly on the cornea and
the scale was read.
4.2.7 Statistics
All values are presented as mean and standard error of the mean (SEM).
Experiments were performed in triplicates. Statistical analysis (paired T-test,
two-tailed, for the IOP results and independent T-test, two-tailed, for the rest of
the results) was done using OpenOffice.org Calc 3.1 (Openoffice).
4.3 Results and discussion
4.3.1 Characterization tests
Blend miscibility can influence blend crystallinity, since either co-crystallization
of the components takes place or crystallization restriction of one component occurs
due to the presence of the second (Ajili and Ebrahimi [2007]). In Table 4.1, the Tg
values of the blends are presented. It can be seen that the blends are immiscible and
present two Tg probably because as Lu is an amphiphilic copolymer, there is a phase
segregation on addition of PCL. PCL will interact more with the polypropylene
oxide segment and not with the more hydrophilic polyethylene oxide block. This
will cause the appearance of two Tg in the tan δ curve corresponding to a two phase
system that replaces the initial one phase system (Chen et al. [2003]).
Sample Tg (◦C) Td (◦C) Tm (◦C) Xrel (%)
XRD DSC
PCL -47.5 389.5 65.5 53.6 54.2
25/75 Lu/PCL -53.2, 49.3 367.8 65.6 54.8 51.4
50/50 Lu/PCL -54.0, 44.1 341.3 62.8 56.2 57.7
100/0 Lu/PCL -58.2 358.8 59.4 56.8 60.5
Table 4.1: Thermo-mechanical properties
Polymer crystallinity is known to play an important role in determining degrad-
ability, water and drug permeability because the bulk crystalline phases are more
inaccessible to water (Tsuji and Ikada [1998]). PCL and Lu are semi-crystalline
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Figure 4.1: a) DSC comparative scans and b) X-ray diffraction patterns (plots were
shifted vertically for the sake of clarity)
(co)polymers and their blends are expected to be semi-crystalline also. The relative
degree of crystallinity (Xrel) was determined by DSC and XRD analysis. The melt-
ing endotherms are presented in Fig.4.1(a), while Fig.4.1(b) shows the diffraction
patterns. Two diffraction peaks were identified for Lu at 2θ=22.2, 27.1, whereas
two characteristic peaks at 2θ=24.9, 27.5 are noted for PCL in agreement with
the literature (Ha et al. [1999]). The blends have three characteristic peaks: for
sample 50/50 Lu/PCL, the sharp crystalline peak of PCL at 2θ=24.9 was relatively
reduced, whereas characteristic peaks of Lu appeared as a result of the blending.
Sample 25/75 Lu/PCL also shows three peaks with a higher intensity for the peak
corresponding to PCL as it has a higher fraction of PCL.
The melting temperatures and crystallinity values (Xrel) are presented in Table
4.1, where it can be seen that the relative crystallinity of the blends decreases
when PCL ratio is increased. On addition of PCL, phase seggregation occurs so
that crystallization capacity of Lu is restricted and crystallinity decreased (Qiu
et al. [2003]). There is agreement between the values obtained by XRD with those
determined using DSC. The results suggest that the crystallinity of the blends can
be controlled by the composition with possible effects on drug release (as discussed
in section 4.3.3).
4.3.2 Water uptake and degradation
Since these blends are designed to perform and degrade in biological environ-
ments, their water uptake behaviour plays an important role. Fig. 4.2(b) shows
the change of water content percentage with time, and similar trends can be ob-
served for the blends. Water absorption increased steadily with time, reached a
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Figure 4.2: a) Mass loss and b) water uptake (all differences between PCL and
blend mass loss and water uptake values are statistically significant at p = 0.05
level)
maximum and then decreased. This pattern is the result of the superposition of
two phenomena: the dissolution of water-soluble Lu and the water uptake of the
residual material. After the ascending portion of the curve, corresponding to water
uptake, there is a maximum and then the descending part, corresponding to water
and polymer loss. As more polymer is dissolved due to water uptake, there is mass
loss and less water is kept in the blend. The blends absorbed higher amounts of
water since they are more hydrophilic (lowest contact angle) than PCL, while PCL
had very low water content (Natu et al. [2008]).
Poly(ε-caprolactone) is known to undergo hydrolytic degradation, catalysed by
the carboxylic acid residues formed in the reaction. Water access to the ester bonds
is determined by the combined effect of the polymer hydrophobicity/hydrophilicity,
the crystallinity of the sample, the molecular weight and the bulk sample dimensions
(Tsuji and Ikada [1996], Grizzi et al. [1995]). When the polymers undergo hydrolysis
of the main chain of the polymers, the mass loss of the films will take place, in
addition to a change in the molecular weight. In Fig. 4.2(a), it can be observed
that mass loss of PCL increased very slowly, while Lu/PCL samples lost mass very
rapidly during the first day of test (45.5 % for sample 50/50 Lu/PCL and 16.2 %
for 25/75 Lu/PCL), followed by small variations in mass loss thereafter. Mass loss
of PCL is detectable only after the molecular weight reaches a value of 10000 g/mol
(Hglund et al. [2007]) and thus the initial high mass loss of Lu/PCL samples can
only be attributed to the dissolution of Lu as the sample with higher Lu content
had the highest mass loss. We are going to discuss how this behaviour affect drug
release in section 4.3.3.
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Figure 4.3: Release kinetics and regression curves for a) PCL and b) 50/50 Lu/PCL
4.3.3 Dorzolamide hydrochloride release
As already mentioned, some of the blends were loaded with dorzolamide hydro-
choride and used as such in drug release experiments or coated in order to diminish
burst effect and better control the release. PCL and 50/50 Lu/PCL were selected
so that a higher difference existed between the samples in terms of hydrophilicity
and erodability. Table 4.2 presents the disk masses and the corresponding drug
mass used in drug release experiments and in vivo tests.
The cumulative percentage of released drug is presented in Fig. 4.3(a) and Fig.
4.3(b). It can be observed that all samples except PCL-coated samples showed a
certain degree of burst release. Burst is expected for the uncoated samples due
to the high drug loadings (average drug loading 24.1±3.7 %, by weight) as high
amounts of drug are deposited at the surface of the disk. The coating is efficient in
the case of PCL (where no burst is shown) and makes only a small difference for
50/50 Lu/PCL. For reservoir systems, we can consider two controlling phenomena:
diffusion through the polymer shell (barrier diffusion) or partition of the drug from
the core to the shell. Shell porosity must be carefully controlled since the drug
from the core will be released through water-filled channels rather than through
the barrier/shell polymer (Tiwari et al. [2010]). In the case of 50/50 Lu/PCL,
there is effectively no partitioning because of the porosity created by Lu dissolution
(this blend is highly erodible (see Fig. 4.2(a)). Thus, the release is mostly a burst
release. On the other hand, PCL-coated sample shows controlled release during
18 days (it should be noted that in this case, there is barrier-control of diffusion
coupled with partition control from the core). In the case of 50/50 Lu/PCL, the
added porosity of the core to the membrane porosity diminishes both partition and
diffusion-control of drug release.
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Sample Drug mass (mg) Disk mass (mg) Released (%)
in vitro in vivo
PCL-coated 1.29 6.38 83.46 81.29
PCL 0.82 4.43 81.20 -
50/50 Lu/PCL-coated 0.81 5.20 100.00 95.93
50/50 Lu/PCL 0.80 3.81 96.25 -
Table 4.2: Comparison between the amounts of released drug in vitro and in vivo
from the disks
In Table 4.3, the non-linear regression results are presented (in spite of the
fact that Eq. 4.4 and Eq. 4.5 were not developed taking into account polymer
erosion phenomenon contribution to drug release, regression analysis results for
50/50 Lu/PCL samples are presented for comparative purposes). The objective
behind fitting these equations to the release data was to understand the underlying
phenomena involved in the drug release mechanism. If A0 (or the load of the mobile
drug) has higher values, then the instantaneous diffusion (or burst) contributes
more to the release as it is shown by the uncoated samples (19.20 for PCL and 20.75
for 50/50 Lu/PCL). Smaller values for S0 suggest higher amounts of immobilized
drug that will not be released (46.78 for PCL-uncoated and 27.89 for 50/50 Lu/PCL-
uncoated). The percentage of immobilized drug is higher for PCL than for 50/50
Lu/PCL because in the latter case erosion creates more surface area and exposes
more drug to dissolution that otherwise would be trapped. It is important to note
that in the case of the studied polymers, physical immobilization of the drug occurs
due to the presence of crystalline regions where the drug is trapped. Diffusion from
these regions is hindered because water enters initially only in the amorphous parts
(Loo et al. [2005]). This fraction of the drug (that is immobilized in the crystalline
regions) will be released only with polymer degradation (due to the time scale of
the release experiment that is much shorter than the time required for polymer
degradation, the steady state value of released drug percentage is smaller than 100
%, which would correspond to total release).
The regression results obtained using power law equation reinforce the previous
observations. The high value of k indicates the extent of burst, much higher for
uncoated than for coated samples (72.27 versus 54.48 for 50/50 Lu/PCL). The
smaller value of n, the faster the release (0.47 for PCL and 0.30 for 50/50 Lu/PCL).
The range of values for the release exponent is indicative of a diffusion mechanism
for drug release (Peppas and Brannon-Peppas [1994]). This model fails to explain
the last stage of the release (“the plateau” that appears at less than 100 % released
drug) as it does not consider the effect of polymer degradation (better fit is obtained
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Sample Degradation model Power law
A0 S0 µ
(day−1)
R2adj k
(day−n)
n R2adj
PCL-coated 2.14
(0.82)
80.96
(1.41)
0.22
(0.01)
0.9965 23.41
(1.60)
0.47
(0.03)
0.9821
PCL 19.20
(3.47)
53.22
(3.74)
2.19
(0.46)
0.9319 52.92
(1.34)
0.16
(0.01)
0.9504
50/50 Lu/PCL-
coated
0.00
(1.53)
98.16
(1.39)
1.37
(0.09)
0.9924 54.48
(5.68)
0.30
(0.05)
0.8548
50/50 Lu/PCL 20.75
(2.11)
72.11
(2.28)
4.01
(0.34)
0.9876 72.27
(2.87)
0.15
(0.02)
0.8618
Table 4.3: Model parameters determined by non-linear regression for in vitro tested
disks
with Eq.4.5 than with Eq.4.4 as inferred from R2adj values). In conclusion, the
release takes place in three stages: the instantaneous diffusion (or burst), followed
by the diffusion-controlled stage, succeeded by the polymer degradation-controlled
stage. Some samples, like 50/50 Lu/PCL samples show only the burst stage, while
PCL samples present all three stages, with total release expected to occur only
when water penetration and degradation extends to the crystalline regions. By
selecting the proper ratio between the components, the prevalence of a certain
stage during drug release can be changed, obtaining an overall effect in drug release
that fits the intended application.
A good in vitro-in vivo correlation was obtained, with similar amounts of drug
released in vitro and in vivo (83.46 % released in vitro versus 81.29 % released in
vivo for PCL-coated sample, see Table 4.2).
4.3.4 Biocompatibility evaluation
Before testing the materials in vivo, we performed cytotoxicity assessment
using MTT test. Fig.4.4 shows the corneal endothelial cell viability test (the
cells were chosen considering the application as materials for controlled release in
ophthalmology). The results indicated that PCL effect on the cell viability is similar
(p value = 0.65) to that of the negative control (glass-bottom multiwell culture
plate, see section 4.2.5), while the blends presented slightly lower cell viability
(approximately 80%, p value ≤ 0.05) than the negative control.
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Figure 4.4: MTT assay results (∗, p≤ 0.05 with respect to negative control)
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Figure 4.5: IOP values in eyes treated with a) PCL-coated implants and b) 50/50
Lu/PCL-coated implants (∗, p≤ 0.05 with respect to control eye)
4.3.5 In vivo performance - Intraocular pressure measure-
ment
The surgical procedure to insert the disks is relatively easy to perform because
of easy access to the implantation area and low vascularization. Moreover, the
wound does not need to be sutured because a pocket is created that keeps the disk
in place. The fixation of the disk is further enhanced by fast wound healing (the
disk is completely encapsulated by the conjunctiva after approximately 1 week).
Ocular adverse events included conjunctivitis, that resolved clinically in less than 1
week (with antibiotic eyedrops). No other events were observed.
Disks were tested in rabbit normotensive eyes that presented an average IOP
value of 20.1±0.8 mmHg. Dorzolamide is known to decrease IOP in normotensive
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Figure 4.6: IOP values in eyes treated with Trusopt eyedrops (∗, p≤ 0.05 with
respect to control eye; the arrow indicates the moment when the last drop of
Trusopt was instilled)
eyes (Harris et al. [2000]). In Fig. 4.5(a) and Fig. 4.5(b), it can be seen that sample
PCL decreased in average IOP by 13.0 % getting closer to the baseline value after
10 days, while sample 50/50 Lu/PCL decreased IOP in average by 13.0 % during
4.5 days. The decrease in IOP obtained with the disks was comparable with the
one obtained by applying Trusopt eyedrops (11.0 % in average). A decrease of
around 20% is desired in order to reduce the rate of open angle glaucoma-related
damage (Yudcovitch [2010]). The obtained values for IOP decrease with Trusopt
are in agreement with literature values for normotensive eyes (Harris et al. [2000],
Scozzafava et al. [1999]), while those obtained with the drug delivery systems
are similar with the decrease in IOP with Ocusert ocular insert (Macoul and
Pavan-Langston [1975]).
Peak IOP decrease (22.6 %) occurred for 50/50 Lu/PCL after the first day,
while peak IOP decrease (22.6 %) occurred for PCL after 3 days. This behaviour
is in agreement with the release kinetics and mass loss tests. Most of the polymer
erosion takes place during the first day and the highest amount of released drug
with direct effect on IOP is expected in the same period. For Trusopt peak IOP
decrease (18.2 %) happened after 9 hours from instillation, faster than from the
implanted disks. Drug release is insignificant in the absence of water and as such a
lag time is expected between implantation time and actual release from the disks.
In contrast, drug release from the eyedrop formulations is faster as there is no
carrier involved and the drug can diffuse across the ocular tissues the moment is
applied on the ocular surface.
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4.4 Conclusions
Implantable dorzolamide loaded disks were prepared by blending
poly(ε-caprolactone), PCL with poly(ethylene oxide)-b-poly(propylene
oxide)-b-poly(ethylene oxide), Lu. By blending, crystallinity, water uptake and
mass loss were modified relative to the pure polymers. PCL and 50/50 Lu/PCL
disks were coated with a PCL shell in order to diminish burst effect and better
control the release. All samples presented burst release except PCL-coated samples
that showed controlled release during 18 days. The uncoated samples showed
burst due to the high drug loading as high amounts of drug are deposited at
the surface of the disk. For PCL-coated, barrier-control of diffusion coupled
with partition control from the core, slowed down the release, while for 50/50
Lu/PCL-coated, the added porosity of the core (created by Lu dissolution)
diminished partition-control of drug release.
The release data was modeled with a degradation model, which considers that
the immobilized drug in the crystalline regions can only be released with polymer
degradation. This model produced a better fit than the diffusional model that
failed to explain the last stage of the release. The curve fitting to the release data
suggested a triphasic release mechanism: the instantaneous diffusion (or burst), the
diffusion-controlled stage, followed by the polymer degradation-controlled stage.
Some samples, like 50/50 Lu/PCL samples showed only the burst stage, while PCL
samples presented all three stages, with total release expected to occur only when
water penetration and degradation extends to the crystalline regions.
MTT test showed that the materials are not cytotoxic for corneal endothelial
cells and they were further evaluated in vivo. A good in vitro-in vivo correlation
was obtained, with similar amounts of drug released in vitro and in vivo. Ocular
adverse events included conjunctivitis, that resolved clinically in less than 1 week.
No other events were observed. The disks decreased IOP in normotensive rabbit
eyes by 13.0 % during 10 days for PCL-coated sample and by 13.0 % during 4 days
for 50/50 Lu/PCL-coated. The percentages of IOP decrease are similar to those
obtained by dorzolamide eyedrop instillation (11.0 %). This drug delivery system
offers promise in the treatment of open-angle glaucoma, providing an alternative
to eyedrops.
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Chapter 5
In vitro and in vivo evaluation of
an intraocular implant for
glaucoma treatment
The text that comprises this Chapter was submitted to the journal European
Journal of Pharmaceutics and Biopharmaceutics (2011).
Abstract
Implantable disks for glaucoma treatment were prepared by blending poly(ε-
caprolactone), PCL, poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene
oxide) and dorzolamide. Their in vivo performance was assessed by their capacity
to decrease intraocular pressure (IOP) in normotensive and hypertensive eyes.
Drug mapping showed that release was complete from blend disks and the low
molecular weight (MW) PCL after 1 month in vivo. The high MW PCL showed
non-cumulative release rates above the therapeutic level during 3 months in vitro.
In vivo, the fibrous capsule formation around the implant controls the drug release,
working as a barrier membrane. Histologic analysis showed normal foreign body
reaction response to the implants. In normotensive eyes, a 20 % decrease in
IOP obtained with the disks during 1 month was similar to Trusopt®eyedrops
treatment. In hypertensive eyes, the most sustained decrease was shown by the
high MW PCL (40 % after 1 month, 30 % after 2 months). It was shown that the
implants can lower IOP in sustained manner in a rabbit glaucoma model.
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5.1 Introduction
Glaucoma is a chronic condition that requires long-term treatment in order to
stop progressive and irreversible blindness (Quigley [2005]). Treatment of glaucoma
focuses on preserving vision by slowing down damage to the optic nerve. Therapy
aims at preventing further damage by lowering IOP (or ocular hypertension) and
it usually consists of pharmaceutical treatment and laser or surgical procedures
(Schwartz and Budenz [2004]). It was shown that reducing IOP is effective in
preventing disease progression in ocular hypertension, primary open angle glaucoma,
and even in normal tension glaucoma (Khaw et al. [2004]).
In most glaucoma patients, medical therapy consists of topical eyedrops and oral
tablets. However, administration and compliance are often problematic. Eyedrops
produce low ocular bioavailability (Amo and Urtti [2008]), unnecessary systemic
exposure (Korte et al. [2002]) and have low patient compliance due to uncomfortable
sensations (Noecker et al. [2004]), as well as difficulty of instillation or forgetfulness
(Kulkarni et al. [2008]). Two main strategies have already been used clinically
to diminish such effects, namely gel forming (viscous) solutions (Nanjawade et al.
[2007]) and controlled drug delivery systems (CDDS).
CDDS in the form of intraocular implants can deliver therapeutically effective
amounts of drugs to targeted ocular tissues over sustained period of time without
significant ocular/systemic side effects (Bourges et al. [2006]). Thus, CDDS can
extremely suitable for chronic diseases, which require a constant level of medication
to be maintained in the body over a long period of time. The major motivation for
development and use of these devices is that they eliminate the need to take multiple
doses of a drug during the day or week, thereby improving patient compliance and
therapy outcomes (Amo and Urtti [2008]).
In a previous work, implants based on poly(ε-caprolactone), PCL were prepared
by solvent-casting, followed by dip-coating (Natu et al. [2011]). Unfortunately,
this preparation method is not reproducible and low drug loadings were achieved.
High drug loads are needed for long term treatment of chronic diseases such as
glaucoma. Moreover, the volume of such devices should be as small as possible
in order to be easily introduced at the implantation site. Melt compression is a
reproducible, easily scalable method of producing implants of different shapes and
sizes (Yasukawa et al. [2005], Kuno and Fujii [2010]). In addition, compact implants
can be obtained with small polymer-to-drug ratio, which enables high drug loads
in a relatively small implant volume.
The objective of the present work was to prepare a drug loaded biodegradable
implant designed to provide a localized, long-term (6 months to 2 years) sustained
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release of the drug, that can be used in the treatment of glaucoma. A subcon-
junctival placement of the implant is simple to perform because of easy access
to the implantation area and low vascularization. PCL and Lutrol F 127, Lu
were selected because they are both biocompatible, biodegradable and they can
be easily processed by conventional polymer processing techniques (Breitenbach
[2002]). Moreover, they are commercially available, inexpensive and well charac-
terised polymers. PCL is a slowly degradable polymer, while Lu can be used as a
release modulator (Natu et al. [2008, 2010]). Two molecular weights of PCL were
used because it was shown that molecular weight determines the time lag before
erosion and the rate of bioerosion in vivo (Pitt et al. [1981]). The implantable drug
loaded disks were prepared by melt compression and their performance in vivo was
evaluated by assessing the capacity to lower IOP in normotensive and hypertensive
rabbit eyes.
5.2 Materials and methods
5.2.1 Preparation of polymer disks
Poly(ε-caprolactone) (PCL40, average Mw 65000 g/mol and PCL10, average
Mw 15000 g/mol, Sigma-Aldrich) and Lutrol F 127 (Lu, poly(ethylene oxide)-b-
poly(propylene oxide)-b-poly(ethylene oxide), 9000-14000 g/mol, 70 % by weight
of polyoxyethylene, BASF) films and dorzolamide hydrochloride (Chemos GmbH)
loaded films (Lu/PCL: 13/87, 6/94, 0/100 % w/w) were prepared by solvent casting
from acetone (UV grade, Sigma-Aldrich) at 40 ◦C, using a 15 % w/v total polymer
concentration and 33.3 % w/w theoretical drug loading. Polymer sheets were
fabricated by compression moulding of the polymer films in a stainless steel mould
by applying a pressure of 201.5 kg/m2 for 20 minutes at 100◦C. The mould was
subsequently cooled under a jet of cold water (20◦C) during 2 minutes. Discs of
4 mm diameter (1 mm thickness, 4-5 mg drug mass, 13-16 mg total mass) were
punched from the polymer sheets. They were used as such in characterization tests.
Prior to in vivo implantation, the disks were sterilized using UV radiation during
20 minutes (at 254 nm) in a UV chamber (Camag UV cabinet).
5.2.2 Disk characterization
Differential scanning calorimetry (DSC) was carried out using a DSC Q100
equipment (TA Instruments) under nitrogen atmosphere (100 mL/min). Samples
with masses of approximately 5 mg were heated until 100◦C, at a heating rate
of 10◦C/min. The relative crystallinity of the disks was calculated as previously
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described considering the melting enthalpy of 100 % crystalline PCL and 100 %
crystalline Lu (Natu et al. [2010]). Thermogravimetric analysis (TGA) was carried
out using a SDT Q 600 equipment (TA Instruments). Samples with masses of
approximately 10 mg were heated until 600◦C, at a heating rate of 10◦C/min. The
degradation temperature (Td) was determined at the onset point of the TGA plot.
Water contact angle was evaluated by static contact angle measurements using
an OCA 20 Video-Based Contact Angle Meter (Dataphysics) and employing the
sessile drop method.
Drug loading of the disks was assessed by elemental analysis (quantification of
sulphur, present only in the drug molecule).
5.2.3 Morphology and drug distribution
The morphology of the disks (before and after implantation) was examined
using scanning electron microscopy, SEM (JSM 5310, Jeol). The drug mapping
(elemental sulphur) of the disks surface and cross-section (showing the center of
the disk) was done using electron probe microanalysis, EPMA (Camebax SX50,
Cameca) at 15 kV accelerated voltage and 40 nA probe current.
5.2.4 In vitro and in vivo degradation
The extent of hydrolytic degradation of the disks (as prepared, in vitro degraded
and in vivo degraded) was evaluated by determining the change of MW in time.
Polymer disks were placed in 4 mL PBS with 0.001 % sodium azide, at 37◦C.
The changes in the MW were measured by size exclusion chromatography (SEC),
using chloroform as mobile phase (1 ml/min, 30 ◦C) and a PLgel MIXED-C
column (300 mm×7.5 mm, 5 µm, Varian). PL-EMD 960 (Polymer Laboratories)
evaporative light scattering detector was used to acquire the data. Universal
calibration was performed using polystyrene (PS) standards and Mark-Houwink
parameters kPCL=1.09 ×10−3 dl/g, αPCL=0.60, kPS=1.25 ×10−4 dl/g, αPS=0.71.
Peak integration was performed using Clarity chromatography software (DataApex).
5.2.5 In vitro drug release and release modelling
Dorzolamide hydrochloride release was studied in 10 ml phosphate saline buffer
medium (PBS tablets, pH 7.4, 10 mM phosphate, 137 mM sodium, 2.7 mM
potassium, Sigma-Aldrich) at 37◦C. At scheduled time intervals, samples were
taken and the entire medium volume was replaced with fresh medium to maintain
sink conditions. The mass of dorzolamide hydrochloride released at time t was
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determined by UV spectroscopy at 254 nm (Jasco V-650 Spectrophotometer). The
percentage of in vitro released drug was calculated using Eq.5.1.
Released drug in vitro (%) =
Mdt
Md0
× 100 (5.1)
In Eq. 5.1, Mdt is the drug mass released at time t and Md0 is the initial drug
mass.
In order to study the drug release mechanism, the power law equation, which is
based on diffusional model of drug transport, was used (Natu et al. [2010]). An
alternative model (Eq.5.2) based on polymer degradation control of drug release
was also used to fit the release data. In this model, two pools of drug are considered:
a pool of mobile drug which readily diffuses out of the matrix upon immersion in an
aqueous medium and a pool of immobilized drug which can diffuse only after matrix
degradation (Natu et al. [2010]). This model can be applied to slow-degrading
polymers such as PCL due to the fact that polymer degradation is much slower
than drug diffusion and as such it is the rate limiting step for drug transport. In
Eq. 5.2, A0 is the load of the mobile drug, S0 is the load of immobilized drug,
τ is the dimensionless time and is defined by τ = µ t (µ is the degradation rate
constant) and Ω is the geometrical factor. The model parameters were determined
by non-linear regression and the goodness of the fit was assessed.
M(τ) = A0 + |Ω|S0 (1− exp (−τ)), α¯−1lmn → 0 (5.2)
5.2.6 Disk implantation, glaucoma model, intraocular pres-
sure measurement and in vivo drug release
New Zealand white rabbits were used in animal experiments in agreement with
European Union Council Directive 86/609/EEC regarding the protection of animals
used for experimental and other scientific purposes as described before (Natu et al.
[2011]). The disk implantation procedure and the IOP measurement by tonometry
were already described (Natu et al. [2011]). In order to produce high IOP, we
used a low temperature ophthalmic cautery (Bovie, Aaron Medical) to produce
30 to 50 burns that were directed at the limbal plexus and at the episcleral veins
(Levkovitch-Verbin et al. [2002], Ruiz-Ederra and Verkman [2006]).
The animals were divided in three groups: group 1 (n=26) received drug
loaded polymer disks (the right eye contained the drug loaded disk–PCL40, PCL10,
6%Lu,PCL40 and 13%Lu,PCL40, while the left had the control disk–polymers
without drug), group 2 (n=3) was submitted to Trusopt®eyedrops (dorzolamide
hydrochloride 2 %, Chibret) treatment (1 drop twice a day in the right eye, while
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the left eye received a drop of balanced salt solution, BSS sterile solution, Alcon),
while group 3 (n=3) was the glaucoma model reference.
For in vivo release tests, previously weighed polymer disks were implanted
as described before for predetermined periods of time and subsequently removed,
cleaned of ocular tissues, rinsed with distilled water and vacuum-dried to constant
weight. The in vivo released mass of drug was determined gravimetrically using Eq.
5.3. In Eq. 5.3, Mi is the initial disk mass, Mt is the disk mass after implantation
time t, Mc is the mass loss of the control disk and Md0 is the initial drug mass.
Released drug in vivo (%) =
Mi −Mt −Mc
Md0
× 100 (5.3)
In vivo drug released percentages were also determined by elemental analysis
(the residual drug was determined after in vivo implantation).
5.2.7 Histologic evaluation
The local implant site and important organs were excised for histological
evaluation. The collected organs included kidneys, spleen, liver, lung (only after 2
months implantation). The organs and tissue samples were fixed in 10 % neutral
buffered formaldehyde. The samples were then embedded in paraffin and dehydrated
by isopropanol processing. Thin layers were cut from the samples with a microtome
and stained with hematoxylin and eosin for optical microscopy.
5.2.8 Statistics
All values are presented as mean and standard error of the mean (SEM).
Experiments were performed in triplicates. Statistical analysis (Student’s T-test,
independent, two-tailed) was done using OpenOffice.org Calc 3.1.
5.3 Results and discussion
5.3.1 Disk characterization
In Table 5.1, melting (Tm) and degradation temperatures (Td) are presented for
drug loaded and control disks because their knowledge is required when dealing
with polymer processing methods for the manufacture of drug-eluting implants.
Blend disks are more hydrophilic than PCL disks due to the incorporation of
hydrophilic Lu (Natu et al. [2008, 2010]) as shown by the lower contact angle values.
The low Tm enables processing at temperatures much lower than the degradation
temperature of dorzolamide (Td=251.26
◦C). The PCL samples show a two step
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Sample Td (
◦C) Tm (◦C) Contact angle (deg)
PCL40+drug 279.38, 420.20 61.53 (0.03) 80.23 (2.63)
PCL40 375.51 61.26 (0.31) 73.88 (3.31)
PCL10+drug 275.00, 420.33 60.67 (0.19) 78.26 (1.24)
PCL10 269.62, 421.88 61.23 (0.61) 70.24 (1.86)
6%Lu,PCL40+drug - 61.45 (0.42) 46.87 (2.78)
6%Lu,PCL40 - 62.07 (0.17) 32.52 (2.12)
13%Lu,PCL40+drug - 58.22 (0.26) 39.88 (0.80)
13%Lu,PCL40 - 58.86 (0.45) 40.20 (2.53)
Lu 358.80 55.57 (0.65) 59.33 (0.35)
Table 5.1: Water contact angle, melting and degradation temperatures of the disks
degradation process, the first step corresponding to drug degradation, while the
second corresponds to polymer degradation.
All disks presented an average content of sulphur of 33.6 %, which corresponds
to approximately 5 mg of loaded drug in each disk.
5.3.2 General considerations about implantation surgical
procedure and animal wellbeing
The surgical procedure to insert the disks is relatively easy to perform because
of easy access to the implantation area and low vascularization. Moreover, the
wound does not need to be sutured because a pocket is created that keeps the disk
in place. The fixation of the disk is further enhanced by fast wound healing as the
disk is completely encapsulated by the conjunctiva. Ocular adverse events included
conjunctivitis (6 eyes in 64 eyes), that resolved clinically in less than 1 week (with
antibiotic eyedrops). No other events were observed. It should be mentioned that
such ocular adverse events (conjunctival hyperemia, stinging, burning, foreign body
sensation, tearing, vision blurring) are quite frequent in topical treatment with
eyedrops (Noecker et al. [2004]).
5.3.3 In vitro and in vivo drug release
Each disk was loaded with approximately 5 mg of drug in order to achieve a
release rate of 18 µg/day (similar with the one obtained with Trusopt 2% instillation
three times a day (Schmitz et al. [1999])) for at least 4.5 months (we considered 50
% drug losses during the transport from conjunctiva to cilliary body).
The release kinetics shown in Fig. 5.1(b) presents similar released drug percent-
ages regardless of the PCL molecular weight. Fig. 5.1(a) presents the release from
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(a) (b)
Figure 5.1: In vitro drug release for a) PCL40 and PCL10 samples and b)
6%Lu,PCL40 and 13%Lu,PCL40 (the red arrow indicates the point on the ki-
netics curve when the released dose is smaller than the effective dose)
blends: release is almost complete after 10 days for 13%Lu,PCL40 and after 20
days for 6%Lu,PCL40.
A comparison between released drug percentages in vitro and in vivo is shown
in Table 5.2. It can be noted that there are significant differences between released
percentages in vitro and in vivo for PCL40 and PCL10 samples, while the released
drug percentages of 6%Lu,PCL40 and 13%Lu,PCL40 are similar in vitro and in
vivo. In vivo drug released percentages (calculated by mass balance) for PCL40
implant were confirmed by elemental analysis (the residual drug was determined
after in vivo implantation): after 8 days, 22.69 (5.82) % released drug, after 14
days, 24.09 (2.93) % released drug and after 22 days 35.74 (11.54) % released drug.
In vivo release kinetics (Fig. 5.2) seems to approach a zero-order kinetics,
while the in vitro kinetics curves (Fig. 5.1(b)) appear to have a t0.5 profile. This
may be due to different release controlling phenomena: in vitro, diffusion controls
drug release (from here the classic, Fickian t0.5 profile), while in vivo, the fibrous
capsule formation around the implant (see section 5.3.7) controls the drug release,
functioning as a barrier membrane that slows down release. Thus, there should be
significant differences between drug released in vitro and in vivo (see Table 5.2) for
PCL40 and PCL10 samples. For blend samples, due to polymer erosion that takes
place mostly in the first day of release (Natu et al. [2010]), the fibrous capsule/barrier
control is absent (only after 1 week, the disks were fully encapsulated) and as such
the released drug percentages are similar both in vitro and in vivo.
In Table 5.3, the non-linear regression results are presented. The objective
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Figure 5.2: Comparison between in vivo and in vitro drug release for sample PCL40
Sample In vitro In vivo
Rel. drug (%) Rel. drug mass (mg) Rel. drug (%)
1 month 2
months
1 month 2
months
1 month 2
months
PCL40 40.14
(6.48)
51.88
(6.07)
2.22
(0.72)
3.72
(0.13)
42.99
(14.06)
72.02
(2.49)
PCL10 47.29
(0.96)
- 4.47
(0.18)
- 83.30
(4.01)
-
6%Lu,PCL40 90.98
(1.06)
- 4.74
(0.20)
- 96.80
(1.62)
-
13%Lu,PCL40 90.57
(3.79)
- 4.95 - 94.56 -
Table 5.2: Released drug percentages for in vitro tested disks and disks implanted
during 1 month or 2 months
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Sample Power law Degradation model
k
(day−n)
n R2adj A0 S0 µ
(day−1)
R2adj
PCL40 17.05
(0.65)
0.26
(0.01)
0.98 10.75
(1.42)
62.21
(1.64)
0.02
(0.00)
0.96
PCL10 24.11
(0.60)
0.19
(0.01)
0.97 15.86
(1.67)
51.45
(1.86)
0.04
(0.00)
0.92
6%Lu,PCL40 41.31
(3.14)
0.27
(0.03)
0.92 5.90
(1.33)
84.12
(1.46)
0.42
(0.03)
0.99
13%Lu,PCL40 56.23
(3.53)
0.17
(0.02)
0.83 7.01
(0.66)
83.41
(0.69)
1.66
(0.04)
1.00
Table 5.3: Model parameters determined by non-linear regression
behind fitting these equations to the release data was to understand the underlying
phenomena involved in the drug release mechanism. Smaller values for S0 suggest
higher amounts of immobilized drug that will not be released (37.8 % for PCL40 and
16.6 % for 13%Lu,PCL40). The percentage of immobilized drug is higher for PCL40
than for blend samples because in the latter case erosion creates more surface area
and exposes more drug to dissolution that otherwise would be trapped. In the case
of the studied polymers, physical immobilization of the drug occurs due to drug
entrapment in crystalline regions. Drug diffusion from these regions is hindered
because water enters initially only in the amorphous parts. The immobilized
fraction of the drug will be released only with polymer degradation (this explains
why the steady state value of released drug percentage is smaller than 100 %, which
would correspond to total release).
The regression results obtained using power law equation reinforce the previous
observations. The high value of k indicates the extent of burst, higher for blend
samples. The range of values for the release exponent is indicative of a diffusion
mechanism for drug release. This model fails to explain the last stage of the release
(steady-state at less than 100 % released drug) as it does not consider the effect of
polymer degradation.
The release kinetics suggested a three stage release mechanism, with different
steps depending on disk composition. Dissolution of the surface loaded drug and
subsequent diffusion, followed by diffusion of the mobile drug through water-filled
pores (created either due to Lu leaching or polymer recrystallization (Natu et al.
[2010], Miyajima et al. [1997])), while the last stage was controlled by polymer
degradation and subsequent diffusion of the immobilized drug. In blends, most of
the drug is released due to polymer erosion, while the residual drug was released
by diffusion through water-filled pores. The mechanism from PCL40/PCL10 disks
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and blend disks are essentially the same, except for the initial stage when drug
diffusion is coupled with polymer erosion in the case of blends. By selecting the
proper ratio between the components, the preponderance of a certain stage during
drug release can be changed, obtaining an overall effect in drug release that fits
the intended application.
5.3.4 Intraocular pressure measurement
In order to simulate ocular hypertension, we developed a rabbit glaucoma
model by increasing the IOP values (Fig. 5.3(d)) from an average of 20.9 mmHg
(normotensive eyes) to an average of 30.1 mmHg (hypertensive eyes). A second
procedure was performed after 1 month because IOP values returned to baseline
after this period (in Fig. 5.3(a), Fig. 5.3(c) and Fig. 5.3(d), the red arrow indicated
the point when a second cauterization was performed) (Levkovitch-Verbin et al.
[2002], Ruiz-Ederra and Verkman [2006]). Disks were first tested in normotensive
eyes in order to select the best performing systems. In Fig. 5.3(e) and Fig. 5.3(f),
it can be seen that sample 13%Lu,PCL40 decreased IOP by 16.59 % (see also Table
5.4) reaching the baseline value after 15 days, while sample 6%Lu,PCL40 decreased
IOP by 23.85 % during 25 days. More sustained decrease in IOP was shown by
sample PCL40 (16.91 %) and PCL10 (23.73 %) during the 30 days of test. The
decrease in IOP obtained with the disks was comparable with the one obtained by
applying Trusopt eyedrops (16.55 %). A decrease of at least 20% is desired in order
to reduce the rate of open angle glaucoma-related damage (Yudcovitch [2010]).
Fig.5.3(a) and Fig.5.3(b) present IOP change in hypertensive eyes with im-
planted disks and in eyes treated with Trusopt®(Fig. 5.3(c)). PCL40 presented a
decrease of 42.78 % after 1 month and a decrease of 33.21 % after 2 months, which
is particularly suitable for patients with moderate to severe glaucoma (Yudcovitch
[2010]). IOP values in eyes with PCL40 implants are expected to approach the
baseline values after approximately 3 months (see Fig. 5.1(b)). Samples PCL10 and
6%Lu,PCL40 showed similar IOP decrease percentages and peak IOP percentage
in hypertensive eyes, while peak IOP was attained faster for sample 6%Lu,PCL40
due to faster drug release (see section 5.3.3). Thus, the release rate from the disks
can be manipulated by blending in order to achieve the desired decrease in IOP.
Table 5.4 presents the average IOP decrease percentages achieved by the im-
planted disks in normotensive and hypertensive eyes, while Table 5.5 shows the
peak IOP decrease and the time interval from instillation/implantation to peak
IOP. It can be noted that there was a higher IOP decrease in hypertensive eyes
than in normotensive eyes for eyedrops and disks. Sample PCL40 showed the
best performance in vivo (constant decrease in IOP for longer time) due to more
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(a) (b)
(c) (d)
(e) (f)
Figure 5.3: a), b) IOP in hypertensive eyes undergoing implant treatment, c) IOP
in hypertensive eyes undergoing Trusopt treatment, d) IOP in glaucoma model
group, e), f) IOP in normotensive eyes undergoing implant treatment
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Sample Average IOP reduction (%)
Normotensive eyes Hypertensive eyes
1 month 1 month 2 months
Trusopt 23.89 (7.53) 28.46 (9.99) 29.52 (13.41)
PCL40 16.91 (6.43) 40.30 (12.23) 33.33 (9.64)
PCL10 23.73 (8.15) 39.61 (11.90) -
6%Lu,PCL40 23.85 (7.24) 39.24 (15.21) -
13%Lu,PCL40 13.35 (9.31) - -
Table 5.4: Average IOP reduction
sustained drug release. The obtained values for IOP decrease with Trusopt®are in
agreement with literature values for normotensive (Harris et al. [2000], Scozzafava
et al. [1999]) and hypertensive eyes (Konstas et al. [2008], Seki et al. [2005]). There
was a higher decrease in IOP for eyes treated with disks than in those treated with
eyedrops probably because of higher amounts of drug released by the disks (average
in vitro release rate of 0.43 (0.04) mg/day for PCL40 or 1.34 (0.12) mg/day for
PCL10 during 1 month versus 0.02 mg/day delivered by eyedrops (Schmitz et al.
[1999])). The changes in IOP obtained in the eyes with implanted disk are similar to
those obtained with the Ocusert drug delivery system (Macoul and Pavan-Langston
[1975]). Trusopt®eyedrops produced the fastest decrease in IOP in normotensive
eyes with peak IOP attained after 0.96 days, followed by blend disks in agreement
with in vitro release results (peak IOP was reached fastest for blend disks with
higher content of Lu). In hypertensive eyes, the same trend in IOP decrease was
maintained, but the average IOP and peak IOP values were higher than those
obtained in normotensive eyes. Peak IOP occured at similar times in hypertensive
eyes, except for Trusopt®. Probably, dorzolamide administered by eyedrops might
require multiple doses to build up to steady state levels of concentration in the
cilliary processes that are required for IOP decrease in hypertensive eyes.
5.3.5 Morphology and drug distribution, SEM and EPMA
SEM and EMPA were performed in order to determine the morphology of
the disks and the drug distribution inside the disks before and after the in vivo
implantation.
Fig. 5.4(a) to Fig. 5.4(f) show the surface morphology of the prepared disks and
in vivo degraded disks. There are significant signs of degradation on the implanted
disk surface such as pores (Fig. 5.4(b)), cracks (Fig. 5.4(d)) and scales (Fig. 5.4(f)).
The in vitro degraded samples showed fewer signs of material cracking (images not
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(a) (b)
(c) (d)
(e) (f)
Figure 5.4: SEM of disks (with drug) surface. a) PCL40 as prepared, b) PCL40
in vivo, c) PCL10 as prepared, d) PCL10 in vivo, e) 6%Lu,PCL40 as prepared, f)
6%Lu,PCL40 in vivo
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Sample Peak IOP reduction (%)/time (days)
Normotensive eyes Hypertensive eyes
1 month 1 month 2 months
Trusopt 27.85/0.96 36.59 (2.37)/3.38 40.73 (3.65)/34.56
PCL40 25.67/7.35 55.26 (0.98)/6.90 43.24 (2.55)/25.06
PCL10 35.92/6.90 50.21 (0.00)/6.94 -
6%Lu,PCL40 32.00/4.38 55.23 (5.03)/3.18 -
13%Lu,PCL40 29.96/2.42 - -
Table 5.5: Peak IOP and the time interval from instillation/implantation to peak
IOP
shown). This suggested enhanced degradation in vivo in comparison with in vitro
conditions (see section 5.3.7).
After preparation, the disks presented a heterogeneous drug distribution (Fig.
5.5(a)) probably because of phase separation between drug and polymers due to the
high drug loading. After in vivo testing, there was almost no drug at the surface
(Fig. 5.5(b)), while in the disk cross-section there were still significant amounts of
drug present in sample PCL40 after 1 month in vivo (Fig. 5.5(c)). The mapping
of the other disks sections show that the release was complete after 1 month of
implantation.
5.3.6 In vitro and in vivo degradation
To differentiate between a physical or a chemical degradation mechanism, the
crystallinity and MW was determined for initial, in vitro and in vivo degraded
samples, the table 5.6 presents the change of disk crystallinity and MW due
to in vitro and in vivo degradation). There was MW decrease due to chemical
hydrolysis for PCL40+drug sample both after 1 month and 2 months and for
6%Lu,PCL40+drug after 1 month. Sample PCL10+drug did not degrade in
vivo probably due to higher initial crystallinity as crystalline regions are more
inaccessible to water uptake. The MW of the in vitro degraded samples was also
determined, but the obtained differences were not statistically significant (p≥0.17).
The samples presented lower crystallinity than the pure polymers (50.26 (0.33)
% for PCL40 and 68.51 (2.12) % for Lu) and the drug loaded samples showed
lower crystallinity than the control samples probably due to co-crystallization of
dorzolamide (that is above the solubility limit in the polymer). In general, there
was an increase in crystallinity for in vitro and in vivo degraded samples because
the amorphous regions are degraded first and because during drug elution, the
mobile polymer chains rearrange themselves and crystallize (Natu et al. [2010],
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(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 5.5: Sulphur drug mapping after 1 month in vivo. a) PCL40 surface as
prepared, b) PCL40 surface in vivo, c) PCL40 section in vivo, d) PCL10 surface
as prepared, e) PCL10 surface in vivo, f) PCL10 section in vivo, g) 6%Lu,PCL40
surface as prepared, h) 6%Lu,PCL40 surface in vivo, i) 6%Lu,PCL40 section in
vivo (in the scale bar, the colour gradient represents 0% drug (pink) and 100%
drug (red))
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Miyajima et al. [1997]). Crystallinity was higher only for some in vivo degraded
samples with respect to the in vitro degraded samples, suggesting that there is
crystallinity increase and enhanced mechanical breakdown in vivo (see section
5.3.7).
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5.3.7 Histologic evaluation
The tissue samples collected from various organs showed normal cell morphology.
The histological analysis of the tissues from the implantation site showed rapid
resolution of the acute and chronic inflammatory stages and the development of
normal foreign body reaction, consisting of adherent macrophages (Fig. 5.6(b)),
fibroblasts, lymphocytes and foreign body giant cells (Fig. 5.6(c)) on the surface
of the disk and fibrous capsule formation (Fig. 5.6(d)). Blood vessels (Fig. 5.6(a))
that formed in the fibrous capsule were also observed. There was a higher density of
cells on the drug loaded disk with respect to control disks. No acute and/or chronic
inflammation was seen after 2 months, indicating that the disks were biocompatible
and did not produce inflammatory reactions characteristic to toxic materials.
(a) (b)
(c) (d)
Figure 5.6: Light microscopy images of implanted disk showing a) cells and blood
vessel (shown in the ellipse); b) macrophage cells (highlighted by circles); c) foreign-
body giant cell; d) fibrous capsule
5.4 Conclusions
Subconjunctival disks based on PCL and loaded with dorzolamide hydrochloride
were implanted in rabbit eyes and their in vivo performance was assessed by their
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capacity to lower IOP in normotensive and hypertensive eyes. The high MW PCL
showed non-cumulative release rates above the therapeutic level during 3 months.
Histologic analysis showed normal foreign body reaction response consisting of
adherent macrophages, fibroblasts, lymphocytes, foreign body giant cells and fibrous
capsule formation. The release kinetics suggested a three stage release mechanism
based on drug diffusion, polymer erosion and polymer degradation, with different
steps depending on disk composition. In vivo, the fibrous capsule formation around
the PCL implant controls the drug release, working as a barrier membrane. For
blend disks, due to polymer erosion that takes place mostly in the first day of
release, the fibrous capsule/barrier control is absent.
In normotensive eyes, a 20 % decrease in IOP obtained with the disks during 1
month was comparable with the one obtained by applying Trusopt®eyedrops. In
hypertensive eyes, higher decrease percentages (around 40 %) were obtained for all
samples, with the most sustained decrease from the high MW PCL (40 % after
1 month, 30 % after 2 months). Peak IOP occured earlier for blend disks due to
enhanced drug release triggered by polymer erosion. It was proven that the devices
can lower IOP in sustained manner in a rabbit glaucoma model. The blending
offers the possibility to manipulate release rate and the amount of released drug
in order to prepare devices tailored to the needs of patients (target IOP decrease
percentages should take into account risk factors and disease progression).
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Chapter 6
Long term degradation of
poly(ε-caprolactone) constructs
obtained through different
polymer processing techniques
The text that comprises this Chapter was submitted to the journal Polymer
Degradation and Stability (2011).
Abstract
Films, fibers, sponges and disks, based on poly(ε-caprolactone), PCL were
prepared using solvent-casting, electrospinning, supercritical fluid processing and
melt-compression, respectively. The influence on degradation rate of several factors
(construct type, crystallinity, MW, drug presence, blending) was assessed through
water uptake, mass loss, crystallinity and molecular weight (MW) evaluation. The
degradation rate was higher for blends than for PCL and it was similar between
the two type of blends. The low MW disks had a degradation rate that was lower
by one order of magnitude than high MW constructs. Porosity was shown to be
a very important factor because at initial stage (or initial porosity) will enhance
water uptake and degradation, while at a later stage (or developed porosity) will
decrease degradation rate because of diminished autocatalytic effects. High initial
porosity produced an acceleration of degradation for sponges, fibers and films when
compared to disks, while developed porosity reduced degradation for drug-loaded
disks when compared to disks without drug. Modelling of the experimental data
suggested that the contribution of surface effects was as significant as autocatalytic
effects in overall bulk degradation.
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6.1 Introduction
Solvent-casting, compression, supercritical fluid (SCF) processing and electro-
spinning are well known techniques to produce materials for tissue engineering and
controlled drug delivery (CDDS) applications (Morales and McConville [2010], Kuno
and Fujii [2010], Davies et al. [2008], Liang et al. [2007]). Poly(ε-caprolactone),
PCL and other polyesters are usually the materials of choice for the prepara-
tion of scaffolds for tissue engineering applications and of implants/matrices for
CDDS applications (Woodruff and Hutmacher [2010]). These polymers are com-
mercially available, inexpensive, biocompatible and biodegradable (which ensures
scaffold/implant integration at the site of implantation). Moreover, they can be
easily processed using diverse techniques, that allow control of scaffold/implant
morphology and/or control of drug loading and distribution and subsequently
release profile.
Degradation profile has to be carefully controlled because it will directly influence
the in vivo performance of the scaffold or CDDS. Usually, during degradation
several simultaneous physical (water uptake, dissolution) and chemical phenomena
(thermolysis, oxidation, hydrolysis) take place that will lead to a change in material
properties and induce a certain in vivo response. For a scaffold, the degradation
period of the polymer has to be manipulated in a such a way that the scaffold
ensures the support to three-dimensional tissue formation and then it gradually
disappears in order to integrate the new tissue with the surrounding one. For a
CDDS, the degradation period can determine the drug release period and/or the
release profile (Woodruff and Hutmacher [2010]).
Several factors that influence the degradation process of polyesters were studied
such as polymer chemical stability, polymer molecular weight (MW), sample size
and geometry, surface-to-volume ratio, degradation medium (type, temperature
and pH), blending, end-group chemistry, hydrophilicity, crystallinity, drug presence,
drug loading, polymer processing, sterilization (Alexis [2005]).
Blending or copolymerization of hydrophlic compounds/polymers/blocks was
shown to produce an increase in degradation rate due to an enhancement in water
uptake (Lam et al. [2008]). Other authors have not found such a correlation
between hydrophilicity and degradation (Li et al. [1998]). The shape or the size of
the samples was shown to influence degradation, with larger particles degrading
faster than smaller ones due to an enhancement in autocatalytic effect (Dunne
et al. [2000]), while in other works no evidence was found for internal catalysis
(Lam et al. [2009]).
Degradation kinetics was also shown to be highly dependent upon the MW of
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the polymer. An increase in MW resulted in a decrease in the degradation rate
(Jenkins and Harrison [2008]), while other authors found an opposite relationship
between degradation and MW, with higher degradation rate for high MW polymer
(Wu and Wang [2001]). A higher crystallinity was indicated as a reason for the
decrease in degradation, because degradation rate of amorphous regions is higher
than that of crystalline regions. Nevertheless, other works found that samples
with initial higher crystallinity degraded faster due to the formation of a highly
microporous structure (Alexis [2005]). Careful consideration of processing method
is necessary when comparing results from various works, because there can be
differences in degradation kinetics even between semi-crystalline samples that have
crystallites of different sizes (Hou et al. [2007]). Moreover, during degradation,
several material properties change simultaneously, which makes the assessment of
factor influence on degradation difficult.
Porosity is another factor that was found to influence enzymatic degradation,
with more porous sponges degrading faster than less porous films, due to a higher
surface area in the former case (Vidaurre et al. [2008]). In many degradation
studies, no attempts were made to determine the degradation kinetics. Thus, it
is not surprising to find differences between degradation profiles: in vivo, MW
variation was found to follow an exponential decay (Pitt et al. [1981]), while other
authors presented a linear variation (Sun et al. [2006]).
In this work, various constructs based on PCL and Lutrol F127
(poly(oxyethylene-b-oxypropylene-b-oxyethylene), Lu were prepared using
different processing techniques (solvent-casting, compression, SCF processing
and electrospinning) so that samples of certain morphology and composition
were obtained. Lu was shown to work as a hydrophilicity enhancer and release
modulator (Natu et al. [2008]). Moreover, two MW of PCL were used as well
as drug incorporation in some of the constructs. This allowed the assessment
of different factors (such as construct type, crystallinity, MW, drug presence,
composition) influence on degradation profile. Additionally, degradation rates
were determined by regression to MW data using a zero-order and a first-order
model (autocatalytic equation) of hydrolytic degradation (Tsuji and Ikada [1998],
Levenspiel [1999a]).
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6.2 Materials and methods
6.2.1 Construct preparation
Poly(ε-caprolactone) (PCL, average Mw 65000 g/mol and PCL10, average
Mw 15000 g/mol, Sigma-Aldrich) and Lutrol F 127 (Lu, poly(ethylene oxide)-b-
poly(propylene oxide)-b-poly(ethylene oxide), 9000-14000 g/mol, 70 % by weight
of polyoxyethylene, BASF) and dorzolamide hydrochloride (Chemos GmbH) were
used to prepare drug-loaded disks (33.3 % w/w theoretical dorzolamide loading)
and control disks (no drug) by melt compression as already described. The ratio of
polymers in the blends was : 0/100, 25/75, 50/50 % (w/w) Lu/PCL. The same
polymer and the same ratios were used to prepare disks (by melt-compression),
films (by solvent-casting), fibers (by electrospinning) and sponges (by supercritical
fluid processing, SCF) as previously reported (Natu et al. [2011b, 2008, 2010]).
The dimensions of the constructs were the following: 4 mm × 1 mm, diameter ×
thickness (for disk), 10 mm × 10 mm × 0.5 mm, length × width × thickness (for
films and fibers) and 4 mm × 4 mm × 4 mm, length × width × thickness (for
sponges). The samples were used as such in degradation experiments.
6.2.2 Construct characterization
The relative crystallinity of the constructs was determined by differential scan-
ning calorimetry (DSC) and calculated as previously described, considering the
melting enthalpy of 100 % crystalline PCL and 100 % crystalline Lu (Natu et al.
[2010]). Water contact angle was evaluated using the sessile drop method as
previously reported (Natu et al. [2010]).
6.2.3 Morphology
The morphology of the disks was examined using scanning electron microscopy,
SEM.
6.2.4 Mass loss
Mass loss experiments were performed as previously reported (Natu et al. [2010]).
The percentage of mass loss was calculated using Eq.6.1.
Mass loss (%) =
Mi −Mt
Mi
× 100 (6.1)
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where Mi is the initial mass and Mt is the dried sample mass after immersion time,
t.
6.2.5 Molecular weight evolution
The changes in the MW and polydispersity index, PI (due to hydrolytic degra-
dation) were measured by size exclusion chromatography (SEC) as described
previously (Section 5.2.4). The degradation rate constant was determined by
regression using Eq. 6.4 and Eq. 6.6.
Eq. 6.4 is obtained by assuming that hydrolysis is autocatalysed by the
carboxylic groups of the polyester chains, with reaction rate (r) proportional to
water (cwater) and polyester (cester) concentrations.
− r = −dcacid
dt
= k · cacid · cester · cwater (6.2)
If the concentration of water and polyester is assumed constant because the
chain cleavage is small, a pseudo-first order equation (Eq. 6.3) is obtained, which,
by integration leads to Eq. 6.4:
− r = −dcacid
dt
= k · cacid (6.3)
Mn,t = Mn,0 · exp(−kt) (6.4)
where Mn,0 and Mn,t are the number-average MW of the undegraded sample and of
the degraded sample after hydrolysis time t, respectively, while k is the degradation
rate constant (Tsuji and Ikada [1998].
Polyester hydrolysis is a diffusion-reaction phenomenon, involving mass trans-
port and chemical reaction simultaneously. Thus, a shrinking core model for
particles of unchanging size might be used (Levenspiel [1999a]). In the case of
semi-crystalline polymers, the “particles” can be interpreted as micro-regions, where
the polymer chains are grouped either in amorphous or crystalline state inside
the polymer bulk. For slow degrading polymers, like PCL, the controlling step is
chemical reaction, while for fast degrading polymers (like PLGA) the controlling
step is water diffusion. Since the progress of the reaction is not affected by any
diffusion resistance, the rate is proportional to the available non-reacted surface
(Levenspiel [1999b]). Thus, an equation based on a zero-order model can be used
to fit the MW data.
− r = −dcacid
dt
= k (6.5)
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Mn,t = Mn,0 − kt (6.6)
6.2.6 Statistics
All values are presented as mean and standard error of the mean (SEM).
Experiments were performed in triplicates. Statistical analysis (linear regression,
independent two-tailed T test, one-way ANOVA and Tukey HSD test) was done
using OpenOffice.org Calc 3.2 and OOoStat Statistics Macro 0.5. The results were
considered statistically significant when p ≤ 0.05.
6.3 Results and discussion
6.3.1 Construct characterization
In Table 6.1, an overview of the methods used to load the drug and process the
samples is presented. In general, there was an increase in hydrophilicity with Lu and
drug addition. The disks (either with or without drug) showed a similar hydrophilic-
hydrophobic character regardless of MW. The most significant differences were
exhibited by blend samples processed by electrospinning and SCF that did not
contain any drug and still presented very low values of the water contact angle.
This behaviour can be correlated to the porosity of these samples, which present
two different regions of porosity (macroporosity region with pores on the µm scale
and a porosity region with pores on the nm scale) (Natu et al. [2011a, 2010]). In
a fiber mat or sponge, there are regions of macroporosity where water can easily
penetrate, while in films or disks these regions are smaller (see for comparison Fig.
6.1(c), Fig. 6.2(c), Fig. 6.3(c) and Fig. 6.4(e)).
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Overall, there was a decrease in crystallinity with Lu and drug addition, the
presence of an additional component (either drug or another polymer) in the
mixture producing crystallization restriction of the other component, as evident
from the decrease in melting temperature (Tm) in blends when compared to the
single-component samples (only Tm corresponding to PCL is presented in Table
6.1, but the same observation is valid for Tm corresponding to Lu). This trend,
which was observed for disks, was not observed for films and fibers in terms of
crystallinity values. Nevertheless, a decrease of Tm with blending was registered
for all samples.
PCL films presented the lowest crystallinity, while blend fibers showed the
highest crystallinity values from all the constructs. In electrospinning, polymer
chain alignment takes place during the stretching of the polymer solution jet in a
similar fashion to crystallinity increase after fiber drawing. The sponges presented
higher crystallinity values than films and disks and the highest Tm. This can be
explained by the SCF-solvent induced crystallization during processing, since SCF
swells and plasticizes polymers (Lo´pez-Periago et al. [2009]). Regarding the effect
of MW, PCL10 disks showed higher crystallinity than PCL disks as shorter PCL
chains are expected to crystallize in a higher proportion than longer PCL chains.
We will discuss how the crystallinity will influence degradation in section 6.3.5.
6.3.2 Morphology
In this section, images showing the morphology of the non-degraded and de-
graded constructs are presented. Initially, the films present large pores (Fig. 6.1(a))
or fine grooves (Fig. 6.1(c)) due to solvent evaporation. Fine grooves are formed for
blends instead of pores probably because of phase separation after solvent casting.
PCL chains can not aggregate intra-molecularly because of the presence of Lu and
as such the solvent can easily exit the polymer phase without producing large pores.
With aging, spherulites (that are composed of lamellae spreading from nuclei)
separated by large pores (≥ 10 µm) are formed due to polymer re-crystallization in
PCL films (Fig. 6.1(b)) or pores (∼ 1 µm) obtained due to Lu leaching are formed
in blend films (Fig. 6.1(d)).
With aging, the fibers lost their structural integrity: large diameters fibers
collapsed and small diameter fibers “glued” on the larger ones in PCL samples
(Fig. 6.2(b)), while for blend samples, the fiber mat was almost transformed into a
film, with fine grooves showing the position of the initial fibers (Fig. 6.2(d)).
With SCF processing (supercritical carbon dioxide), in the depressurization step,
carbon dioxide passes from the supercritical to the gas state and exits the polymer
matrix, creating pores (Fig. 6.3(c)). Due to the fact that the SCF decreases the
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(a) (b)
(c) (d)
Figure 6.1: Films a) PCL as prepared, b) PCL degraded during 12 months, c)
50/50 Lu/PCL as prepared, d) 50/50 Lu/PCL degraded during 12 months
melting temperature of PCL, this sample melts during SCF processing and solidifies
at depressurization. Thus, PCL sample shows a slightly different morphology than
blend samples, with smaller pores (Fig. 6.3(a)). During degradation, all the samples
preserve their initial morphology (Fig. 6.3(b) and fig. 6.3(d)).
In Fig. 6.4(a), circular structures can be observed probably corresponding to
spherulites (as we have seen in section 6.3.1, the disks without drug have higher
crystallinity than drug-loaded disks). The drug-loaded disks present a rougher
morphology due to drug crystallization and phase separation from the polymer
phase (Fig. 6.4(c) and Fig. 6.4(e)). With aging, the morphology of PCL disk
without drug does not change much with the exception of the appearance of some
pores (Fig. 6.4(b)). On the other hand, the surface of drug-loaded shows significant
modification: a filament-like structure composed of “channels” created by drug
elution and Lu leaching is shown by PCL (Fig. 6.4(d)) and blend disks (Fig. 6.4(f)),
while PCL10 disks present various pores, cracks and spherulitic structures (Fig.
6.4(h)).
6.3.3 Mass loss
The hydrolytic degradation mechanisms of PCL is a random chain scission pro-
cess. Polymer degradation is a complex process composed of several simultaneous
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(a) (b)
(c) (d)
Figure 6.2: Fibers a) PCL as prepared, b) PCL degraded during 12 months, c)
50/50 Lu/PCL as prepared, d) 50/50 Lu/PCL degraded during 12 months
physical (water uptake, swelling, dissolution, crystallization, stress cracking) and
chemical phenomena (thermolysis, oxidation, hydrolysis, photolysis). Nevertheless,
for polyesters, the most important steps are water uptake/diffusion and hydrolysis
(Woodruff and Hutmacher [2010]). Polyesters can present surface or bulk degrada-
tion mechanisms depending on the rate limiting step, which is water diffusion in
the first case and hydrolysis in the second case. Mass loss or erosion occurs when
water-soluble fragments that form due to hydrolysis, are able to leach out from the
polymer matrix. As hydrolysis is a random chain cleavage process, the probability
to obtain a water-soluble fragment that is small enough to diffuse from the bulk
increases as MW decreases. This explains the relatively low mass loss shown by
PCL before reaching a low MW.
The profile of mass loss curves for films and fibers is shown in Fig. 6.5(a)
and Fig. 6.5(b), respectively. Mass loss is constant after the first days for all the
constructs that did not contain drug because PCL is a bulk degrading polymer
and Lu is a water-soluble polymer (most of it being leached out in the first week).
Thus, even after 30 months, mass loss of 25/75 Lu/PCL fibers is approximately
20%, while mass loss of 50/50 Lu/PCL fibers is around 45%. The curves shown in
Fig. 6.7 present similar profiles (one-step mass loss for PCL and two-step mass
for blends) to fibers mass loss. Mass loss shown by films is slightly higher than
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(a) (b)
(c) (d)
Figure 6.3: Sponges a) PCL as prepared, b) PCL degraded during 12 months, c)
50/50 Lu/PCL as prepared, d) 50/50 Lu/PCL degraded during 12 months
mass loss of fibers during the same period of time: around 50% for 25/75 Lu/PCL
and approximately 60% for 50/50 Lu/PCL. Besides this, the films also show a
gradual increase in mass loss over time, uncharacteristic to the other constructs.
Mass loss can occur either due to erosion (as discussed above) or due to mechanical
breakdown during sample handling. Small parts of non-degraded material are lost
during handling procedure because of sample fragility. We believe that this is what
happened in the case of degraded blend films (that are highly porous and very thin,
see also Fig. 6.1(d)).
The mass loss of drug-loaded disks is shown in Fig. 6.6(a) and Fig. 6.6(b).
The curves present a different profile than the rest of the constructs: there is a
gradual increase in mass loss during 18 months due to the leaching of the drug.
A high amount of drug is released during the first 3 months of the study (the
so-called mobile drug), while the rest (the immobilized drug) is released only with
polymer degradation (Natu et al. [2010]). PCL10 disks show slightly higher mass
loss than PCL disks probably because of higher crystallinity and porosity (cracks
and spherulites are visible in Fig. 6.4(h)), which enhances drug elution.
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 6.4: Disks a) PCL as prepared, b) PCL degraded during 12 months, c)
PCL+drug as prepared, d) PCL+drug degraded during 12 months, e) 50/50
Lu/PCL+drug as prepared, f) 50/50 Lu/PCL+drug degraded during 12 months,
g) PCL10+drug as prepared, h) PCL10+drug degraded during 12 months
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Figure 6.5: Mass loss of a) films and b) fibers
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Figure 6.6: Mass loss of a) PCL disks with drug and b) PCL10 disks with drug
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Figure 6.7: Mass loss of sponges
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6.3.4 Evolution of crystallinity degree during degradation
Table 6.2 presents the evolution of crystallinity degree and of Tm during degra-
dation. For semi-crystalline polymers, crystallinity can change during processing
(as discussed in section 6.3.1) and/or during degradation. Usually, during degra-
dation, there is an increase in crystallinity due to mainly two mechanisms: on
one hand, solvent-induced crystallization of non-degraded polymer (water uptake
allows polymer chain rearrangement and subsequent crystallization) and, on the
other hand, crystallization of degraded fragments (oligomers) trapped in the non-
degraded polymer bulk. Thus, an increase in crystallinity is expected during
degradation. This trend is, in general, observed for disks, films and sponges, but
it is not observed for fibers that show only a slight increase in crystallinity for
PCL and a high decrease in crystallinity with degradation. Additionally, in some
cases (film and sponges), 50/50 Lu/PCL blend presents lower crystallinity after 6
months of test. This behaviour might be related with the presence in the blend
of a water-soluble polymer. Lu dissolution produces a decrease in crystallinity
because it can cause the fragmentation and erosion of non-degraded crystalline
regions (Lam et al. [2008]). Thus, there is a higher decrease in crystallinity for the
blend that contains more Lu (20% decrease in crystallinity for 25/75 Lu/PCL fiber
and 28% decrease in crystallinity for 50/50 Lu/PCL fiber only after 7 days). When
dissolution is complete, there is a slight increase in crystallinity of the remaining
PCL phase due to re-crystallization.
For drug-loaded disks, an increase in crystallinity was observed at 6 months
regardless the composition or MW. In this case, the more compact structure and
hydrophobicity produce slower water uptake and more gradual mass loss (see also
Fig. 6.6(a) and Fig. 6.6(b)). Only after 1 day, water content is very high for
fibers (81% for 50/50 Lu/PCL and 70% for 25/75 Lu/PCL) and sponges (69% for
50/50 Lu/PCL and 32% for 25/75 Lu/PCL), while lower for disks (23% for 50/50
Lu/PCL and 17% for 25/75 Lu/PCL). This will have high impact on Lu and drug
dissolution and subsequent erosion of crystalline regions. Moreover, due to the less
porous structure, it is more probable that oligomers will be trapped in the polymer
bulk and crystallize, contributing to an increase in the overall crystallinity (see
section 6.3.5).
Tm increased during the period of study for all samples in spite of a decrease or
increase in the degree of crystallinity. The increase in Tm is a proof of crystallite
growth and preferential hydrolysis of the amorphous regions. Usually, when
hydrolysis occurs in crystalline regions, Tm decreases because the crystallites are
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being destroyed. Only after 25 months, Tm does not increase anymore or starts
decreasing, suggesting that only now hydrolysis extends to crystalline regions in
agreement to previous works (Tsuji and Ikada [1998]).
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Figure 6.8: Weight average molecular weight and polydispersity index evolution of
a) films and b) disks
6.3.5 Evolution of molecular weight during degradation
In Fig. 6.8(a), Fig. 6.8(b) and Fig. 6.9(a) the change in weight-average MW
(Mw) and PI is presented for films, disks and fibers, respectively. It can be noted,
that in terms of Mw, there is a higher decrease in Mw at 6 months for PCL films
(10%) and fibers (8%) than for disks (1%), while the trend is reversed at 12 (21%
for disk, 16% for fiber, 17% for film) and 18 months (37% for disk, 28% for fiber,
17% for film). The slower degradation after 6 months for the PCL disks might be
related to their lower uptake (1% for disk, 23% for fiber, 17% for sponge after 1 day)
in relation to the other constructs. The water uptake is slower at the beginning
for the disks, but water will eventually penetrate the entire disk given enough
time. This observation is further supported by the fact that the blend disks show
statistically significant differences in Mw when compared to sponges, films or fibers
only at 6 (p≤0.01 for 50/50 Lu/PCL, p≤0.01 for 25/75 Lu/PCL) and 12 months
(p=0.03 for 50/50 Lu/PCL, p=0.03 for 25/75 Lu/PCL), but not at 18 months
(p=0.11 for 50/50 Lu/PCL, p=0.14 for 25/75 Lu/PCL). Thus, at 18 months water
content of the various constructs is expected to be similar. At 30 months, there is
again higher decrease in Mw for films (54% for PCL, 69% for 25/75 Lu/PCL) and
fibers (58% for PCL, 63% for 25/75 Lu/PCL) than for disks (40% for PCL, 56%
for 25/75 Lu/PCL).
The decrease in Mw is generally accompanied by an increase in PI (thus, higher
values for PI at 30 months for fibers and films in comparison with disks). A
relatively low scattering of PI values is shown by films, disks and sponges, while
fibers presented a much larger scattering of the values starting from 18 months.
This scattering might be explained by the occurrence of heterogeneous degradation.
182 CHAPTER 6. LONG TERM DEGRADATION
0 5 10 15 20 25 30
0
10000
20000
30000
40000
50000
60000
70000
1.2
1.4
1.6
1.8
2
2.2
time (months)
M
w
 (g
/m
ol
)
PI
(a)
0 5 10 15 20
0
10000
20000
30000
40000
50000
60000
70000
1.2
1.4
1.6
1.8
time (months)
M
w
 (g
/m
ol
)
PI
(b)
Figure 6.9: Weight average molecular weight and polydispersity index evolution of
a) fibers and b) sponges
A heterogeneous distribution of pores might result in regions with different degrees
of degradation. The fibers and PCL films showed a more heterogeneous morphology
than blend films or sponges (see also section 6.3.2) and thus present higher PI for
similar decrease in Mw (1.9 as fiber versus 1.6 as sponge for 50/50 Lu/PCL at 18
months). Also, PCL film has a similar PI to blend films at 30 months in spite of
lower decrease in Mw.
When comparing the degradation curves for different compositions of the same
construct, the blends degrade faster than PCL as films and fibers for the entire
period of study. When in disks, PCL degrades faster than the blends until 18
months. This behaviour might be explained by the autocatalytic effect as the
lower porosity of the PCL disk might promote entrapment of oligomers that can
catalyse the hydrolysis. After this time, pores and cracks will eventually develop
due an increase in crystallinity and degradation would slow down (at 30 months,
40% decrease for PCL, ∼57% decrease for blends). When the chromatograms were
analysed, peaks corresponding to oligomers (∼580, ∼320 g/mol) and monomers
(∼110 g/mol) were detected in the PCL disks after 3, 6, 12 and even after 18
months. Usually, the area of these peaks, which is proportional to the concentration,
decreased in time, being higher at 3 and 6 months. In contrast, the blends showed
only monomer peaks until 12 months in small concentrations because degradation
products could easily escape from the polymer bulk (see also section 6.3.2).
Degradation curves of the drug-loaded disks are shown in Fig. 6.10(a) and Fig.
6.10(b). It can be observed that the drug-loaded disks, in spite of lower initial
crystallinity and smaller increase in crystallinity during aging, present lower Mw
than disks without drug at similar time intervals. Additionally, there seems to
be no difference in degradation behaviour with respect to composition. This is
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Figure 6.10: Weight average molecular weight and polydispersity index evolution
of a) PCL disks with drug and b) PCL10 disks with drug
expected because of the porous structure created due to Lu and/or drug leaching
that will diminish autocatalytic effects.
Low MW disks degrade only slightly during 18 months, with no differences
(in terms of Mw and PI) due to drug addition or composition (10% for drug-
loaded PCL10, 9% for PCL10, 9% for 25/75 Lu/PCL10, 4% for 50/50 Lu/PCL10).
First, these disks have higher initial crystallinity than PCL disks (see Table 6.2).
Secondly, they have a compact structure that slows down water penetration (1%
water content after 1 month) and thirdly, crystallization during aging produces
polymer cracking (see Fig. 6.4(h)). Additionally, for a short chain polymer, there
is a higher probability to obtain short water soluble fragments at hydrolysis, that
leach out, especially through a porous structure (this was observed in the mass
loss curves, when PCL10 disks presented higher mass loss than PCL disks in spite
of similar drug loading, see Fig. 6.6(b)). Oligomers and monomers (∼340, ∼110
g/mol) in small concentrations were only detected at 3 and 6 months, while some
monomer (∼105 g/mol) was detected at 12 months. All these factors contributed
synergistically to the observed degradation delay.
In Fig. 6.9(b), Mw and PI evolution are presented for sponges obtained by
SCF processing. Sponges showed highest decrease in Mw from all constructs at 18
months (46% for PCL, 50% for 25/75 Lu/PCL, 49% for 50/50 Lu/PCL), but similar
decrease in Mw with films or fibers at 6 (17% as sponge and 16% as film, for 25/75
Lu/PCL, p=0.46 and 15% as sponge, 12% as film, for 50/50 Lu/PCL, p=0.37) and
at 12 months (36% as sponge, 31% as fiber, for 25/75 Lu/PCL, p=0.17). These
results suggest that again porosity and hydrophilicity have a great impact on water
uptake and consequently on degradation. As we have seen in the degradation of
drug-loaded disks, porosity that develops at a later stage (due to drug elution,
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Construct Drug Composition Autocatalytic eq. Zero-order eq.
k (month−1) R2 k
(g/mol·month)
R2
Films
no PCL 0.023 (0.005) 0.85 865.8 (159.7) 0.91
no 25/75 Lu/PCL 0.035 (0.007) 0.91 1134.1 (103.7) 0.98
no 50/50 Lu/PCL 0.038 (0.007) 0.91 1198.0 (91.9) 0.98
Disks
no PCL 0.020 (0.002) 0.95 786.0 (108.3) 0.93
no 25/75 Lu/PCL 0.034 (0.004) 0.95 1142.8 (77.6) 0.98
no 50/50 Lu/PCL 0.034 (0.003) 0.98 1145.2 (89.3) 0.98
yes PCL 0.024 (0.008) 0.83 1098.4 (349.7) 0.83
yes 25/75 Lu/PCL 0.024 (0.008) 0.82 1107.6 (349.6) 0.83
yes 50/50 Lu/PCL 0.022 (0.007) 0.82 1045.2 (351.1) 0.82
Disks
yes PCL10 0.005 (0.001) 0.83 75.4 (20.1) 0.82
yes 25/75
Lu/PCL10
0.005 (0.001) 0.95 70.1 (9.5) 0.95
yes 50/50
Lu/PCL10
0.002 (0.001) 0.74 35.3 (12.1) 0.74
Fibers
no PCL 0.028 (0.004) 0.93 1289.9 (122.8) 0.98
no 25/75 Lu/PCL 0.032 (0.002) 0.98 1377.6 (86.6) 0.99
no 50/50 Lu/PCL 0.038 (0.005) 0.95 1520.8 (149.0) 0.97
Sponges
no PCL 0.031 (0.008) 0.84 1423.3 (299.4) 0.88
no 25/75 Lu/PCL 0.039 (0.001) 0.99 1744.1 (72.3) 0.99
no 50/50 Lu/PCL 0.039 (0.002) 0.99 1746.7 (78.8) 0.99
Table 6.3: Degradation rate constant
for example) will decrease hydrolysis rate relative to disks without drug, due to a
decrease in autocatalytic effects. But, initial porosity will have a opposite effect on
degradation, because on one hand, there is a higher surface for reaction and on the
other hand, it enhances water uptake. Thus, sponges, films and fibers have high
initial porosity and high water uptake relative to disks and show fast degradation
at 6 months.
This effect is even more pronounced for blends than for PCL (fibers: 8% decrease
for PCL, 15% for 50/50 Lu/PCL). In this case, both samples are very porous,
but PCL fiber is much more hydrophobic and it inhibits water uptake (Natu
et al. [2010]). Thus, initial porosity is important only if it promotes water uptake.
Porosity and subsequently the surface available for reaction, that changes during
aging, has important consequences. Sponges maintain their high initial porosity
during aging (Fig. 6.3(c) and Fig. 6.3(d)), while PCL films and PCL/blend fibers
do not (Fig. 6.1(a) and Fig. 6.1(b)). This might be the reason why PCL fibers
(20% decrease in Mw) and films (17% decrease in Mw) are degraded less at 18
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months than sponges (46% decrease in Mw). Additionally, scattering of PI values
for sponges is very low, which suggests the occurrence of homogeneous degradation
due to homogeneous porosity.
Table 6.3 presents the degradation rate constant values obtained by regression.
It can be seen that, in general, the degradation rate is higher for blends than
for PCL and it is similar between the two type of blends. The highest difference
in degradation rate in terms of composition is shown by the disks without drug
(p=0.0014). The presence of the drug in the disks produces a decrease in hydrolysis
rate. The low MW disks have a degradation rate that is lower by one order of
magnitude than high MW constructs. It should also be noted that the zero-order
equation provides a better fit to the experimental data for all the samples, with
one exception: PCL disk without drug. For this sample, the autocatalytic equation
provides a slightly better fit for the reasons that were discussed above.
The contribution of surface reactions in the degradation of PCL was already
suggested in other works (Pitt et al. [1981]). As we have seen in section 6.3.4, there
is preferential degradation of amorphous regions until 24 months. Porosity will
have a significant influence on the degradation of these regions. On one hand, it
controls water transport in the polymer bulk and on the other hand, it increases
surface-to-volume ratio that will increase the number of ester groups that are
available for hydrolysis.
6.4 Conclusions
Various constructs were prepared based on PCL and Lu, such as films, fibers,
sponges and disks using different techniques such as solvent-casting, electrospinning,
supercritical fluid processing and melt-compression, respectively. The influence
on degradation rate of several factors (construct type, crystallinity, MW, drug
presence, composition) were tested. Overall, there was an increase in crystallinity
with degradation, although some constructs showed lower crystallinty after 6 months
due to the erosion of non-degraded crystalline regions during Lu or drug leaching.
Nevertheless, melting temperature increased steadily until 24 months, suggesting
preferential degradation of amorphous regions. The degradation rate was higher for
blends than for PCL and it was similar between the two type of blends. The blends
were more hydrophilic and had higher water content, which enhanced degradation.
The low MW disks had a degradation rate that is lower by one order of magnitude
than high MW constructs. These disks had high initial crystallinity, low initial
porosity (and consequently low water uptake) and high developed porosity, which
decreased degradation. Porosity was shown to be a very important factor because
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at initial stage (or initial porosity) will enhance water uptake and degradation,
while at a later stage (or developed porosity) will decrease degradation rate because
of diminished autocatalytic effects. Initial porosity that was high for sponges, fibers
and films produced an acceleration of degradation of these samples when compared
to disks, while developed porosity, like for drug loaded disks and blend disks reduced
degradation when compared to disks without drug. Thus, the presence of the drug
in the disks produced a decrease in hydrolysis rate. A zero-order equation provided
a better fit than a first-order equation to the experimental data for all the samples,
suggesting that the contribution of surface effects was as significant as autocatalytic
effects in overall bulk degradation.
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Chapter 7
Conclusions and outlook
In this work, in order to prepare CDDS for intraocular application, several
polymer processing and drug loading techniques were used.
Polymer blends can be easily impregnated with drugs using SCF technology
as long as the polymer swells under the action of SCF and/or the drug is soluble
in SCF. Better drug loading was achieved when a cosolvent was used and when
specific drug-polymer interactions occurred as a consequence of different chemical
structures due to polymer blending. Some process parameters, such as pressure can
also be manipulated in order to improve drug impregnation in the polymer matrix.
Moreover, besides control of drug impregnation, SCF processing will affect polymer
matrix morphology (porosity), crystallinity and consequently, water uptake, drug
release and degradation.
Electrospinning is another technique through which drug loaded polymer con-
structs can be obtained. This processing method allows control over construct
microstructure, which will produce special properties in comparison with other
polymer processing techniques. For example, crystallinity and hydrophilicity will
be very different when compared to other constructs obtained from the same poly-
mer. Selection of the drug and the polymer carrier has to be carefully considered
since drug solubility in polymer and drug loading will determine fiber morphology,
drug distribution and release kinetics. Loading and drug encapsulation in either
crystalline or amorphous form are interrelated and can control the release rate,
especially in the burst stage. Thus, in long term release applications where high
amounts of loaded drug are desirable, a compromise must be found in order to
balance the loading and release rate that seem to vary in opposite directions.
SCF and electrospinning techniques offer great flexibility in terms of drug
loading and polymer processing. We have seen in Chapter 2 and Chapter 3 that
various polymer morphologies can be easily obtained. Nevertheless, they are limited
in one aspect: the extent of drug loading. With SCF, maximum timolol loading
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of 1.8% and with electrospinning, maximum acetazolamide loading of 12.7% were
attained. Through SCF, the drug loaded amount will always be limited by the
drug solubility in the SCF. The same observation is valid for electrospinning. The
maximum amount of drug that can be loaded in the fibers can not be higher than
the drug solubility in the polymer, otherwise as we have seen in Section 3.3.4, burst
release will be produced.
Therapy with drug-eluting implants only makes sense if the benefits (such as
therapeutic efficiency, local delivery, patient compliance) are higher than the risks
(invasive method of introduction, complicated in vivo response). Sustained delivery
of drugs is feasible only if long term release (usually higher than 1 year) is achieved
in order to overcome the risks always involved with the surgical procedure of
insertion. For long term release, high amounts of drug are required which restrains
the use of SCF or electrospinning for the preparation of CDDS for the treatment
of chronic diseases such as glaucoma. Physical mixture of drugs and polymers
and subsequent processing into implants is a simple technique through which high
loadings can be achieved in a relatively small volume device.
The understanding of drug release mechanism is essential since control of drug
release can only be achieved when the effect of several factors (device morphology,
crystallinity, drug loading, drug distribution, just to name a few) is thoroughly
known. In this work, two types of CDDS were prepared and studied: monolithic
(Chapter 2, Chapter 3 and Chapter 5) and hybrid (Chapter 4).
Basically, in a monolithic device, drug diffusion through the polymer matrix
should be the controlling-phenomena. Nevertheless, when using a bulk degrading
polymer such as PCL, the system is more complicated and polymer degradation is
also an important step in the release process (as we have seen in Chapter 3 and
Chapter 5). This will have an important effect on the in vivo performance of the
device as total release will be achieved only after a prolonged time. Additionally,
the non-cumulative release rate will drop to zero in spite of significant amounts of
drug still present in the device. Thus, there is the need for constant drug release
rate device such as a reservoir system.
For a reservoir system, two controlling phenomena contribute to drug release:
partition of the drug from the core to the polymer membrane and drug diffusion
through the membrane. As long as membrane porosity is carefully controlled, drug
release will present a zero-order profile during the entire life time of the implant.
When reaching a low MW, the polymer membrane is expected to suddenly and
completely disintegrate. Nevertheless, this disintegration will not produce any
toxic effects, since by then, the drug load of the implant is expected to be almost
insignificant. That is why the polymer degradation period has to accurately match
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the intended release period of the implant. Thus, the degradation profile (MW
decrease, degradation rate) and the change in materials properties (such as porosity,
crystallinity) have to be completely understood (Chapter 6).
Unfortunately, a reservoir system presents a clear disadvantage with respect to
the monolithic one: the accidental release of the entire drug load in a very short
period of time due to defects in the polymer membrane. This could have a highly
dangerous effect in vivo. Thus, there is the need of a hybrid device (Chapter 4) that
combines the relatively safe release profile of the monolithic device with the constant
release rate of the reservoir device. In this system, release is controlled by the
diffusion through the polymer matrix, the partition of the drug from the polymer
matrix to the membrane and finally, by the diffusion through the membrane.
There is a long way from the in vitro tests to the actual in vivo performance of
the implant. Thus, in vivo experimentation is necessary if the implant is ever to be
arrive on the market. Animal experimentation is currently in dispute regarding its
usefulness and ethics, but all the phenomena involved in the foreign body reaction
triggered by the implant are so complex that it is very hard to simulate such a
system in the laboratory. For implants, the wound healing in and around the
device can determine how well the host can heal and accept the implanted material.
Moreover, the fibrous capsule formation can often have a direct effect on the device
performance. Thus, as long as the animal tests are carefully planned, the smallest
number of animals can be used, the benefits obtained from understanding the
changes in implant properties and in tissue response and subsequently in vivo drug
release can largely overcome the mentioned issues.
We have seen that there is no direct way to forecast in vivo drug release from
in vitro drug release data (Chapter 5). In vivo, the fibrous capsule formation
around the implant controlled the drug release, working as a barrier membrane.
Thus, the release kinetics changed from a t0.5 profile to a t0 profile. Nevertheless,
all the prepared devices had an effect on the decrease of IOP, which proves the
feasibility of the subconjunctival transport route to the cilliary body. Still, without
pharmacokinetic data it is difficult to understand exactly how this transport occurs.
In vivo, the drug-eluting implants were able to reduce IOP in an animal model
of glaucoma. Unfortunately, the maximum duration of the in vivo tests was 2
months. More prolonged in vivo tests are necessary in order to determine the
performance of the CDDS during periods of time closer to the real situation. We
have seen in Chapter 5 that small amounts of drug are sufficient to produce a
pharmacologic response in vivo. Thus, small devices will be able to decrease IOP
during long periods of time (and only limited by polymer degradation) as necessary
in the treatment of glaucoma, a life long condition.
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This work has revealed some insights in possible polymer processing and drug
loading techniques for the preparation of CDDS for intraocular delivery. It also
presented some results regarding the preliminary pre-clinical evaluation of PCL-
based implants. Nevertheless, two other extremely important issues have to be
addressed: cost estimation of implant manufacturing and patient compliance.
Patience compliance is of extreme importance especially in the therapy of chronic
diseases because patients have to keep up constantly with their pharmacological
regimen. The superiority of CDDS relative to conventional therapy has to be
proven in long term compliance studies because this is one of the main reasons of
developing CDDS therapy in the first place. Most of the studies present in the
literature fail to present compliance data, including this work.
Sensible cost evaluation of implant production is necessary in order to estimate
the final product price. CDDS are expected to present higher costs than conventional
therapy (eyedrops, in the case of glaucoma). Anyway, due to their improved
performance, a higher price can be justified. But how much higher? This is an
important question to be answered and can make the difference between another
purely academical study and actual commercialization of the product and usefulness
for the society.
Finally, efforts have to be made to the miniaturization of the device or the
development of simple insertion surgical procedures. If an implant requires a
complicated procedure to be placed in the eye, ophthalmologists may look to simpler
therapies. A simple office-based procedure offers advantages to implantations that
must be performed in the operating room.
